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Abstract 
Interferon (IFN) is activated in response to virus infections and upregulates 
interferon-stimulated genes (ISGs) resulting in the expression of hundreds 
of proteins, many of which have direct or indirect antiviral activity. 
Parainfluenza virus 5 (PIV5) of the Paramyxoviridae family is a non-
segmented negative sense single-stranded RNA virus with seven genes 
encoding eight proteins. Here we present that IFN induces alterations in 
the pattern of both virus transcription and translation and that ISG56 is 
primarily responsible for these effects. We report that when cells were 
treated with IFN post-infection, virus protein synthesis was inhibited while 
virus transcription levels were increased. These results suggest that 
ISG56 selectively inhibits the translation of viral mRNAs.  
In addition, the relationship of various PIV5 isolates was analysed by next 
generation sequencing. Four areas with a high degree of single nucleotide 
polymorphisms (SNPs) were identified and mapped to the intergenic 
regions of NP-V/P, M-F and HN-L, as well as the entire SH gene. Three of 
the isolates, the porcine strain SER and the canine strains CPI+ and CPI-, 
did not express an SH protein due to the lack of a start codon. A low 
degree of variation was found in the amino acid sequence of the HN 
glycoprotein suggesting that PIV5 may be less pressured to evolve in 
order to evade immune responses, such as neutralising antibodies.  
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 1 
1 Introduction 
 
THE PARAMYXOVIRIDAE 
The Paramyxoviridae infect a diverse range of hosts, including mammals, 
poultry and fish. Some of the human pathogens include measles virus 
(MeV), mumps virus (MuV), and metapneumoviruses (MPV), which can 
cause severe respiratory infections in children and infants (Williams et al., 
2004). Measles virus is considered one of the most infectious viruses, 
causing an estimated 2.6 million deaths each year before a widespread 
vaccination program was available. It has since been targeted by the 
World Health Organization for eradication, but the World Health 
Organization estimates that there were 139,300 deaths globally in 2010 
(www.who.int). Mumps virus is usually perceived as a childhood disease 
that only caused a mild infection, but prior to the MMR (measles, mumps 
and rubella) vaccine, mumps was the main cause of deafness and aseptic 
meningitis (Carbone & Rubin, 2007). 
 
There are also important animal pathogens such as rinderpest virus, 
bovine respiratory syncytial virus (bRSV) and Newcastle disease virus 
(NDV), which cause serious economic impact on farmers. The prototypic 
parainfluenza virus 5 (PIV5) was originally isolated in rhesus monkey 
kidney cells and was therefore named simian virus 5 (Choppin, 1964; Hull 
et al., 1956). It has since been recovered from several species, such as 
dogs and humans (Goswami et al., 1984; McCandlish et al., 1978) and it 
was therefore suggested that it should be re-named parainfluenza virus 5 
(Chatziandreou et al., 2004).  
 
In the 1990s, two new zoonotic paramyxoviruses emerged, Nipah (NiV) 
and Hendra (HeV) viruses, with high mortality in humans and animals. 
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Recently, paramyxoviruses have been identified in various types of bat, 
not just across Africa, Australia, Asia and South America, but also in 
European fruit bats. Paramyxoviruses usually have a narrow host range 
with no cross species transmission, but alarmingly, these new findings 
suggest a potential risk of emerging zoonotic paramyxoviruses (Chua et 
al., 2000; Drexler et al., 2012; Halpin et al., 2000; Kurth et al., 2012).  
 
Classification 
The word paramyxo derives from the Greek word para meaning ‘beyond’, 
and myxo meaning ‘mucus’. The Paramyxoviridae family is divided into 
two subfamilies: the Paramyxovirinae and the Pneumovirinae. The 
Paramyxovirinae contains seven genera:  Avulaviruses, Henipaviruses, 
Morbilliviruses, Respiroviruses, Rubulaviruses, Aquaparamyxoviruses and 
Ferlaviruses. The Pneumovirinae contains two genera: 
Metapneumoviruses and Pneumoviruses. There is also a group of recently 
discovered paramyxoviruses, including J virus, Beilong virus, Salem virus, 
Menangle virus, Mossman virus, and Tioman virus that have not yet been 
classified by the International Committee on the Taxonomy of Viruses 
(www.ictvonline.org, 2011). Paramyxoviridae classification is based on 
morphology, genome organisation, sequence relationship of the encoded 
proteins, and the biological activity of the proteins. The distinguishing 
feature of Paramyxovirinae is the nucleocapsid, which has a diameter of 
18 nm and is 1 µm in length. The Pneumovirinae differ morphologically as 
they have narrower nucleocapsids. Pneumovirinae also encode additional 
proteins (NS1, NS2 and M2) and their attachment protein does not have 
the same biological activity. The activity of the attachment protein is an 
important criterion for classification, as the attachment protein of 
Respiroviruses and Rubulaviruses has neuraminidase activity, while 
Morbilliviruses and Henipaviruses lack this activity (Lamb & Parks, 2006).  
Examples of viruses in each genus are found in Table 1.1. 
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PARAMYXOVIRIDAE 
Subfamily Paramyxovirinae 
Genus Rubulavirus 
Mumps virus (MuV) 
Parainfluenza virus 5 (PIV5) 
Human parainfluenza virus 2 (hPIV2) 
 
Genus Avulavirus 
Newcastle disease virus (NDV) 
 
Genus Respirovirus 
Sendai virus (SeV) 
Human parainfluenza virus 1 (hPIV1) 
Human parainfluenza virus 3 (hPIV3) 
 
Genus Henipavirus 
Hendra virus (HeV) 
Nipah virus (NiV) 
 
Genus Morbillivirus 
Measles virus (MeV) 
Rinderpest virus (RPV) 
Canine distemper virus (CDV) 
 
Genus Aquaparamyxovirus 
Atlantic salmon paramyxovirus 
 
Genus Ferlavirus 
Fer-de-Lance paramyxovirus 
 
Subfamily Pneumovirinae 
Genus Pneumovirus 
Human respiratory syncytial virus (hRSV) 
Bovine respiratory syncytial virus (bRSV) 
 
Genus Metapneumovirus 
Human metapneumovirus (hMPV) 
 
Table 1.1: Classification of the Paramyxoviridae family. Adapted from 
www.ictvonline.org, 2011.  
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Virion structure 
The Paramyxoviridae are enveloped, single stranded negative-sense RNA 
viruses with a non-segmented genome. The virions are spherical, 
approximately 150 to 350 nm in diameter, with a host-derived lipid layer 
(Fig. 1.1). Protruding 10 nm from the plasma membrane are the 
glycoproteins, the fusion (F) protein and the attachment protein (HN, H or 
G). The matrix (M) protein lines the inside of the membrane and plays a 
role in assembly and virus budding (Schmitt et al., 2005). The virus 
particle contains the negative-stranded genome of approximately 15,000 
to 19,000 nucleotides and the nucleocapsid (N), phospho- (P), and the 
large (L) proteins (Lamb & Parks, 2006).   
 
The genome is associated with the nucleocapsid protein and the P and L 
proteins are attached to the nucleocapsid:genome core. For 
Rubulaviruses, the V protein is also associated with the core complex. 
Certain differences exist amongst the Paramyxoviridae, in particular 
regarding the attachment proteins and the accessory proteins. 
Rubulaviruses and Respiroviruses both have an attachment protein with 
haemagglutinin and neuraminidase activities (HN protein), while the 
attachment protein of Morbilliviruses only has haemagglutinin activity (H 
protein). The Henipaviruses and Pneumoviruses have an attachment 
protein that has neither haemagglutinin or neuraminidase activities. 
Pneumoviruses also encode three additional proteins (NS1, NS2 and M2) 
(Lamb & Parks, 2006). 
A small hydrophobic (SH) protein is also found in the virion structure of 
certain Rubulaviruses. The role of the SH protein has been debated, but it 
has been reported that SH is not essential for virus growth (He et al., 
1998). 
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Figure 1.1: The parainfluenza virus 5 (PIV5) virion structure. The virion consists of a 
lipid bilayer derived from the host cell plasma membrane. Two glycoproteins are 
embedded in the lipid envelope: the haemagglutinin-neuraminidase (HN) protein and the 
fusion (F) protein. The matrix (M) protein lines the inside of the membrane. Inside the 
virion is the single-stranded negative-sense RNA genome encapsidated by the 
nucleocapsid (NP) protein and associated with the phosphoprotein (P) and the large (L) 
protein as well as the V protein. Embedded in the membrane is also the small 
hydrophobic (SH) protein. Figure courtesy of Dr. N. Chatziandreou.  
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Virus genome 
The genomes of paramyxoviruses are between 15 and 19 kb in size and 
contain six to ten tandemly linked genes that can encode one or several 
proteins due to overlapping open reading frames. For nonsegmented 
negative-strand (Mononegavirales) RNA viruses, the order of the genes 
are conserved. N, P and M are often located near the 3’ end and L is 
always near the 5’ terminus. The genes are flanked by a 3’ non-coding 
leader region consisting of approximately 50 nucleotides, and a 5’ non-
coding trailer region consisting of 31 to 161 nucleotides. These regions 
have a high A/U content, high sequence complementarity between each 
other and are multifunctional. Not only do they control transcription and 
replication, but they also contain signals for encapsidation and virus 
assembly (Whelan et al., 2004). 
The genes are separated by intergenic regions of various lengths. These 
regions are precisely three nucleotides long for Respiroviruses and 
Morbilliviruses, but are less conserved for Rubulaviruses (1-47 
nucleotides) and Pneumoviruses (1-56 nucleotides). Table 1.2 shows the 
sequences of the intergenic regions of PIV5.  
 
Genes Gene end Sequence (3’ to 5’) Gene start 
NP-P CCGAAAUUUCU7 A UCCGGGCCUG 
P-M UCCCAAAAUCU6 GCUAAUUGCUAUUUA UUCGGGCUUG 
M-F ACUAAGUUUCU4 GUUUAGUAUAAUUCUGAUAGGA UUCGUGCUUG 
F-SH UUAAAAAUUCU7 GCUA UCCUGGCUUG 
SH-HN AUAAAAUUUCU6 A UCCGGGCUUG 
HN-L ACCAAAAUUCU5 GGUUCUCUUGUUA UCCGGUCUUA 
L-trailer AAUCAAAUUCU6 AAUCAAAUUCU6  
 
Table 1.2: The nucleotide sequences of the gene end, intergenic regions, and gene 
start of PIV5. Adapted from Lamb and Parks (2006). 
 
These intergenic regions are divided into three different regions: gene end, 
intergenic region, and gene start, as described in Table 1.2. During 
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transcription, they control the polymerase activity, but are ignored during 
replication. 
 
PIV5 proteins 
Nucleocapsid protein 
NP is the first gene encoded in the PIV5 genome and is the most 
abundantly transcribed gene. It is an RNA-binding protein with an N-
terminal domain that is highly conserved in other paramyxoviruses, and is 
not only involved in NP-RNA interactions but also NP-NP interactions, as 
well as interactions with other viral proteins (Myers et al., 1997; Nishio et 
al., 1999; Parks et al., 1992; Schoehn et al., 2004). To prevent NP from 
self-aggregating, it has been proposed that both P and V bind to NP 
(Curran et al., 1993; Horikami et al., 1992; Randall & Bermingham, 1996).  
 
The C-terminus of NP is less conserved and appears to be dispensable for 
RNA binding, but nucleocapsids lacking the C-terminus are not functional 
as templates for the vRNP (Curran et al., 1993). The NP C-terminus is 
involved in several protein-protein interactions. Firstly, soluble NP binds P 
and tethers the P-L complex to the nucleocapsid, and it is thought that the 
association of P keeps NP in its soluble form for encapsidation (Precious 
et al., 1995). NP is also involved in budding through its interaction with the 
matrix protein (Bhella et al., 2002; Schmitt et al., 2002), and studies have 
shown that if NP lacks the C-terminus, then NP-M interactions are 
impaired and the production of virus-like particles is disrupted (Schmitt et 
al., 2010). In addition, soluble NP also binds the V protein and 
minigenome studies of PIV5 have suggested that this binding of V may 
inhibit PIV5 replication (Lin et al., 2005).  
 
Furthermore, NP also associates with the viral RNA in a stable 
nucleocapsid structure that consists of 14 NP subunits per helical turn. NP 
binds six nucleotides of the viral genome and encapsidates the viral RNA 
genome and antigenome. This is to protect the RNA from degradation but 
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it also forms the polymerase complex together with P and L. As described 
later in this Chapter, the concentration of NP is a determining factor in the 
switch from transcription to replication.  
 
The phosphoprotein 
The P protein is expressed by a mechanism of ‘RNA editing’ or non-
templated addition of two G nucleotides to the mRNA that derives from the 
V/P gene (Cattaneo et al., 1989; Hausmann et al., 1999b; Jacques & 
Kolakofsky, 1991; Vidal et al., 1990). It is believed that the mRNA template 
is expanded when the polymerase halts before the end of the C residue of 
the template. The nascent chain then slips backwards by two positions (for 
Rubulaviruses), which results in the two C residues being transcribed a 
second time. It was first discovered for PIV5, but was soon discovered for 
other paramyxoviruses as well (Thomas et al., 1988); the P/V/C gene of 
SeV being the most diverse with its seven encoded proteins (Lamb & 
Parks, 2006). In the case of PIV5, the unedited mRNA encodes the V 
protein while the P protein is encoded from the mRNA after the insertion of 
two additional G residues. Thus, V and P share the first 164 residues of 
the N-terminus but have different C-termini. Insertion of either one or four 
G residues results in the W protein (sometimes called the I protein). Only 
small amounts of W are detected in infected cells and the function in the 
PIV5 life cycle is not known (Thomas et al., 1988).  
 
The structure of P is important for RNA synthesis, since L binds to the 
nucleocapsid via P (Bowman et al., 1999; Hamaguchi et al., 1983; 
Smallwood et al., 1994). For SeV, two domains have been identified in the 
first 77 amino acids of the P N-terminus. This region is required for RNA 
synthesis and, additionally, amino acids 33-41 have been demonstrated 
as being required for binding unassembled NP (NP0) (Curran et al., 1994; 
1995).  
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Furthermore, it has been demonstrated by mutagenesis studies that P 
also functions in limiting host cell responses by reducing the synthesis of 
defective viral mRNAs, and may also limit the production of dsRNA (Dillon 
& Parks, 2007; Gainey et al., 2008). As the name suggests, P is heavily 
phosphorylated and the phosphorylation of a serine residue (Ser157) is of 
particular importance, as it has been linked to controlling viral gene 
expression, as virus replication but not transcription increased when the 
serine residue was mutated into a phenylalanine (Timani et al., 2008).  
 
V protein 
The PIV5 V protein is made from a faithful transcript of the V/P gene and 
shares its N-terminus with P but has a different C-terminus (Cattaneo et 
al., 1989; Hausmann et al., 1999a). The C-terminus of V is highly 
conserved and contains a cysteine-rich domain that binds two zinc 
molecules, that may be involved in interactions of other proteins with V 
(Fukuhara et al., 2002; Li et al., 2006c; Liston & Briedis, 1994; Paterson et 
al., 1995). PIV5 V is a structural component of the nucleocapsid of virions, 
which is unlike other paramyxoviruses such as MeV and SeV, where V is 
only a minor part of the virion structure (Paterson et al., 1995). 
Recombinant viruses with non-functional cysteine-rich domains of V 
showed increased gene expression and grew well in cell culture (Delenda 
et al., 1998; Kato et al., 1997; Schneider et al., 1997) but grew less 
efficiently in vivo (Kato et al., 1997; Valsamakis et al., 1998).   
 
For PIV5, the binding sites for NP map to the common N-terminus of V/P. 
It has been proposed that V functions as a negative regulator of viral RNA 
synthesis by competing with P for binding to soluble NP that is required for 
encapsidation. Once NP has been organised into nucleocapsids V cannot 
interact with NP (Randall & Bermingham, 1996), therefore it is likely that, 
although V has been shown to be able to bind RNA, V interacts indirectly 
with the viral RNA (Lin et al., 1997). 
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V is a multifunctional protein that plays an important role as an antagonist 
of host cell antiviral action (which will be discussed in further detail later). 
The zinc-binding domain in the C-terminus of V is believed to be involved 
in protein-protein interactions. V not only binds other viral proteins, but 
also cellular proteins, such as the UV damage-specific DNA binding 
protein 1 (DDB1). DDB1 is important for DNA repair and, in the case of 
PIV5, for the degradation of STAT1 (Andrejeva et al., 2002a, b; Lin et al., 
1998).  Deletions in the V protein C-terminus result in loss of the ability of 
V to bind DDB1 and also the ability to block IFN signalling (Andrejeva et 
al., 2002a). The interaction of V with DDB1 is suggested as being 
responsible for slowing down the cell cycle of infected cells. It has been 
proposed that slowing down the growth and the cell cycle would benefit 
virus growth. The PIV5 growth cycle is 18-24 hours, thus cell division 
would interfere with the viral growth cycle by preventing the viral 
glycoproteins from being transported to the cell surface (Lin & Lamb, 
2000).  
 
Large protein 
The large (L) protein is the most distal gene in the PIV5 genome and the 
largest of all the viral genes. It is an essential component of the viral 
polymerase together with P and NP. The N-terminus of L binds to P, which 
tethers L to the nucleocapsid. Since L is the most distal gene in the 
genome, it is also the least abundantly transcribed and only &50 copies of 
L are found in each virion. L is responsible for the replication of viral 
genomic and antigenomic RNA and is also responsible for 5’ capping and 
3’ end polyadenylation of viral mRNAs (Grdzelishvili et al., 2005; Hercyk et 
al., 1988; Ogino et al., 2005).  
 
There is generally little sequence homology between L proteins of different 
paramyxoviruses, but six conserved domains have been identified (Poch 
et al., 1990; Sidhu et al., 1993; Svenda et al., 1997). Domain II is highly 
positively charged and it has therefore been suggested that this domain 
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has RNA-binding activity (Chattopadhyay & Shaila, 2004). Domain III 
contains a QGDNQ motif and mutational analysis of this motif 
demonstrated that it is required for the polymerase activity of L (Malur et 
al., 2002), and domain VI has been linked to 5’ cap formation (Ferron et 
al., 2002; Poch et al., 1990). The functions of domains I, IV and V are still 
not clear, but SeV studies have reported that mutations in these domains 
result in defective viral replication (Chandrika et al., 1995; Feller et al., 
2000).  
 
L activity is dependent on protein-protein interactions and is involved in 
both self-assembly and interactions with viral and cellular proteins. For 
example, tubulin has been shown to interact with the L protein of SeV and 
MeV and promote L activity, and "-catenin increases hPIV2 transcription, 
but the exact role of these proteins in viral RNA synthesis is still not fully 
understood. However, one theory proposed that tubulin is a subunit of the 
polymerase as it was co-immunoprecipitated with the L protein of SeV and 
MeV (Moyer et al., 1986; 1990).  
 
Envelope glycoproteins 
All paramyxoviruses have two glycoproteins, but the properties of these 
proteins differ between viruses. The virus envelope is a lipid bilayer with 
the attachment protein (HN, H or G) and the fusion (F) protein embedded 
on its surface. The glycoproteins appear as spikes on the surface and 
these spikes are essential for adsorption, budding and assembly at the 
plasma membrane of the host cell. Schmitt et al. (2002) presented data 
where efficient budding required expression of NP, M and either HN or F 
(Schmitt et al., 2002).  
 
Fusion protein 
The fusion protein is a type I integral membrane protein with an 
extracellular N-terminus and is initially synthesised as an inactive 
precursor protein (F0). In order to promote fusion of the viral envelope with 
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the host cell plasma membrane, F0 needs to be cleaved. In the 
endoplasmic reticulum (ER), F0 is glycosylated and then transported as a 
homotrimer through the Golgi complex where a host-cell protease cleaves 
a sequence of five arginines (Paterson et al., 1984; 1985; Russell et al., 
1994). This cleavage process creates two subunits called F1 and F2 that 
are linked by disulfide bonds (Homma & Ouchi, 1973; Peluso et al., 1977), 
and results in a conformational change that is essential for obtaining 
fusion competence (Dutch et al., 2001).  
 
Sequence studies have revealed that there are a number of conserved 
residues in the fusion peptide among many paramyxoviruses. Substitution 
of glycine (Gly) to alanine (Ala) residues at positions 3, 7 and 12 resulted 
in substantial cell-cell fusion, correlating with a theory that glycine residues 
attenuate the alpha helical structure of the fusion protein and that 
substitution of Gly to Ala results in increased fusion (Horvath & Lamb, 
1992).  
 
Fusion between the viral envelope and the host cell plasma membrane 
occurs at neutral pH and by this process the viral nucleocapsid enters the 
host cell cytoplasm where virus replication takes place. Later in the 
infection fusion can also cause a cytopathic effect where cells form large 
syncytia, which enables the virus to spread from infected cells to 
neighbouring uninfected cells. These syncytia can be visualised by 
immunofluorescence and are typical for paramyxoviruses (Lamb & Parks, 
2006).  
The conformational change after cleavage of F0 results in the glycoprotein 
spikes being embedded in the lipid bilayer. It is not completely clear 
whether F requires binding of HN for fusion with the host cell. MeV, RSV 
and the PIV5 strain W3 did not require binding of HN, however W3 virus 
fusion was reduced. On the other hand, MuV, hPIV2 and hPIV3 all 
required co-expression of F and HN for fusion (Bissonnette et al., 2009; 
Cattaneo & Rose, 1993; Ebata et al., 1991; Horvath et al., 1992; Hu et al., 
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1992; Wild et al., 1991; Yao et al., 1997). It is not known why F would 
require binding of HN for efficient fusion but binding may cause a 
conformational change in HN that in turn would lead to the conformational 
change of F (Deng et al., 1999; Lamb, 1993).  
 
Haemagglutinin-neuraminidase protein 
For Rubulaviruses and Respiroviruses the attachment protein, 
haemagglutinin-neuraminidase (HN) protein, has both haemagglutinin and 
neuraminidase activity. The Morbilliviruses attachment protein has only 
haemagglutinin activity (H protein), and Henipaviruses and 
Pneumoviruses have neither activity (G protein). It is the haemagglutinin 
activity of PIV5 HN that mediates virus cell attachment to sialic acid 
residues on the host cell surface. PIV5 HN has only one sialic acid binding 
site, whereas NDV has two identified binding sites (Zaitsev et al., 2003). 
The neuraminidase activity mediates cleavage of sialic acid from the virion 
surface and from the surface of infected cells to prevent self-aggregation.  
 
The HN protein for PIV5 is a type II integral membrane protein that 
consists of a cytoplasmic tail, an uncleaved signal-anchor domain and an 
ectodomain. A type II membrane protein has a cytoplasmic N-terminus 
and the direction of the N-terminus towards the cytoplasm is determined 
by positively charged residues in the cytoplasmic tail (Parks & Lamb, 
1991; 1993). The signal anchor domain of the N-terminus of HN is 
hydrophobic and this domain is important for insertion into the membrane 
and transport to the cell surface (Parks, 1996; Parks & Pohlmann, 1995). 
In order to be transported from the ER, HN needs to oligomerise and fold 
correctly. HN is folded through a series of intermediates before transport 
from the ER to the Golgi apparatus. Once HN is transported to the plasma 
membrane it is internalised into endosomes (Ng et al., 1989). The function 
of the internalisation of HN is not clear but has been speculated to be 
involved in immune evasion.  
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Matrix protein 
The matrix (M) protein is the most abundant protein in the PIV5 virion. M is 
responsible for assembly by associating with viral nucleocapsids, viral 
glycoproteins, cellular proteins, and ligases, such as E3-ubiquitin ligase to 
initiate budding. Infectious particles can only be formed after all the 
structural components of the virion have assembled together (Schmitt & 
Lamb, 2004; Schmitt et al., 2005). Matrix proteins contain a domain that 
recruits cellular factors during budding and mutations in this domain tend 
to result in failed budding. PIV5 has a unique late domain motif with the 
sequence FPIV. Mutations in FPIV led to defective budding, but not to 
accumulation of virions that failed to pinch off. It was therefore suggested 
that the late domain of PIV5 functions prior to budding (Schmitt et al., 
2005).  
 
When budding fails, M is quite often inactivated. For example, M is 
sometimes absent in subacute sclerosing panencephalitis (SSPE), a fatal 
but rare measles virus infection. SSPE is a condition that causes 
neurological disease resulting from persistent measles virus infection. It 
frequently encodes unstable and mutated M proteins that are either 
completely absent or defective. When M is present, it is not able to bind to 
nucleocapsids, and therefore is not able to bud properly (Cattaneo et al., 
1988; Hirano et al., 1993). Recombinant measles virus lacking M have 
been engineered but these viruses released less infectious particles 
thereby indicating that M is indeed important for virus assembly 
(Cathomen et al., 1998).  
 
Small hydrophobic protein 
The small hydrophobic (SH) protein was first discovered in PIV5 (Hiebert 
et al., 1985) and has since been discovered in RSV, human MPV and 
avian MPV (Olmsted & Collins, 1989; van den Hoogen et al., 2002; Yunus 
et al., 2003), but not all paramyxoviruses. It is present in the MuV genome 
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and since MuV strains are so variable SH has been used as a marker to 
categorise MuV isolates (Takeuchi et al., 1991). The function of SH in a 
MuV infection or a PIV5 infection has not been established as it is not 
required for virus growth (Takeuchi et al., 1996). Although no clear role of 
SH has been found, it does appear to be involved in blocking apoptosis in 
infected cells by inhibiting the tumour necrosis factor ! (TNF-!) pathway 
(Lin et al., 2003). The role of SH in the TNF-! pathway is still unclear but 
SH may inhibit either production or signalling of TNF-!, or both. One 
model has been proposed for the role of SH in the PIV5 life cycle: virus 
infection activates nuclear factor % B (NF-%B) and that can lead to 
activation of TNF-! (Albrecht et al., 1995; Hohmann et al., 1990). Thus, 
infected cells have increased expression of TNF-!. SH may block TNF-! 
signalling through an interaction with the membrane-bound receptor called 
TNF-R1 and therefore prevents more TNF-! from being produced as TNF-
! works in an autocrine manner. The low levels of TNF-! already 
expressed in infected cells are too low to induce apoptosis (Wilson et al., 
2006).  
 
PIV5 replication cycle 
Primary transcription and translation 
The PIV5 virion attaches to sialic acid receptors on the cell surface and 
the virus is adsorbed by fusing the viral membrane with the cellular plasma 
membrane. After entry the encapsidated viral genome is delivered into the 
cytoplasm where replication takes place.   
 
Like other negative-strand RNA viruses, PIV5 must synthesise three 
different RNA products: negative-sense genomic RNA, positive-sense 
antigenomic RNA, and messenger RNA (mRNA).  
The active template for virus transcription and replication is the negative-
sense genome encapsidated with NP. Replication can only occur when 
sufficient amounts of NP have accumulated. Therefore, at an early stage 
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of the virus infection the viral ribonucleoprotein (RNP) complex consisting 
of NP, P and the viral polymerase L, only transcribe capped and 
polyadenylated mRNAs that are then translated into proteins. This stage of 
the infection is called primary transcription. Once enough NP has been 
translated genome replication can begin.  
 
 
Figure 1.2: Transcription and replication of PIV5. The negative genomic template is 
copied to produce the leader and capped and polyadenylated mRNAs. The mRNAs are 
then translated into viral proteins and once sufficient amount of NP has been produced 
genome replication can begin. During replication, full-length antigenomes and genomes 
are synthesised and encapsidated by NP together. Antigenomic RNA is used as template 
for negative sense progeny genomes, which can be used for the synthesis of viral 
mRNAs, genome replication or can be assembled into infectious virions. Adapted from 
(Whelan et al., 2004).  
 
The leader region of PIV5 is 55 bases long and located at the 3’ end of the 
genome. It is the leader that directs transcription initiation to produce 
mRNA as well as replication to produce complementary RNA called 
antigenomic RNA. The trailer region at the 5’ end consists of 31 
nucleotides. The antigenomic complement region to the trailer (termed tr’) 
only directs replication to produce full-length genomes. It is believed for 
paramyxoviruses that the polymerase can only attach to the template at a 
single site at the 3’ end of the genome. The first gene transcribed is NP, 
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followed by V/P, M, F, SH, HN and L. At the end of each gene there are 
cis-acting signals that direct the capping and polyadenylation of each 
mRNA. The gene end contains signals that are recognised by the viral 
polymerase to terminate transcription, followed by a sequence of several 
U residues that serve as the template for polyadenylation. The polymerase 
is believed to stay attached to the template while it reads along the 
intergenic region until it reaches the start of the downstream gene, which 
contains signals for reinitiation of transcription and adding of a methylated 
5’ guanine cap to the mRNA (Lamb & Parks, 2006; Whelan et al., 2004).  
Sometimes the polymerase fails to reinitiate transcription and disengages 
from the template. Measurement of the amount of virus mRNAs 
demonstrated that virus transcription of Mononegavirales occurs in a 
polarised manner with decreasing transcription of the genes the further 
away from the 3’ terminus they are located (Cattaneo et al., 1987a, b; 
Villarreal et al., 1976). It is generally believed that when the polymerase 
disengages it cannot reinitiate directly but, rather needs to re-attach at the 
3’ end of the genome resulting in higher amounts of NP and P and lower 
amounts of L (Fig. 1.2).  
 
PIV5 genome replication 
The viral RNP consisting of NP, P and L is required for genome 
replication. During replication, the virus RNA is bound to NP which also 
encapsidates the nascent RNA strand. Encapsidation causes the viral 
polymerase to ignore transcription signals, such as the intergenic regions, 
and instead the polymerase creates a full-length copy. 
There are several distinct features of PIV5 genome replication. For 
paramyxoviruses it is required that the genome is a multiple of six, the so 
called ‘rule of six’. It was first reported that SeV required a genome length 
that was divisible by six for efficient replication (Calain & Roux, 1993). 
Thus as the viral genome is encapsidated by NP during replication, the 
copied RNA strand associated with the RNP complex reaches the 3’ end 
of the nascent strand. A multiple of six is required for precise 
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encapsidation, thus if the genome was not divisible by six the remaining 
NP nucleotides would end up protruding from the 3’ terminus.  
The rule of six is not an absolute requirement for all paramyxoviruses. The 
PIV5 genome is a multiple of six (15,246 nucleotides) and replication is 
most efficient when the genome length is a multiple of six but it is not a 
strict requisite (Murphy & Parks, 1997). For SeV the rule of six is essential 
but for RSV the genome length is of no specific importance. The most 
likely explanation for the rule of six is not the number of nucleotides that 
are protruding from the 3’ end but rather the position of the cis-acting 
promoter sequences that will only be recognised if they are in the right 
location (Kolakofsky et al., 1998; Vulliémoz & Roux, 2001).  
 
A second requirement for genome replication is specific promoter 
elements in the genomic leader and antigenomic trailer. These elements 
are highly important in determining the efficiency of virus replication (Keller 
et al., 2001). Two sequences, termed promoter element I (PrE-I) and II 
(PrE-II), were identified within 90 nucleotides of the 3’ terminus of the 
antigenomic promoter. PrE-I consists of the last 18 nucleotides at the 3’ 
end of the genome and antigenome while PrE-II is located approximately 
100 bases from the 3’ end in the coding region of L for the antigenomic 
promoter and in the coding region of NP for the genomic promoter (Fig. 
1.3) (Murphy et al., 1998; Murphy & Parks, 1999).  
 
 
Figure 1.3: PIV5 genome structure and genomic promoter. The nucleotide sequence 
of two elements termed PrE-I and PrE-II in the promoter region is denoted by boxes. 
These elements are key for efficient virus replication. The two nucleotides highlighted by 
asterisks are known to enhance transcription (Manuse & Parks, 2009). Modified from 
(Parks et al., 2011).  
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These regions are highly conserved for Rubulaviruses but the exact 
sequence of PrE-II is different for PIV5 compared to SeV (Murphy et al., 
1998; Tapparel et al., 1998). For PIV5, the sequence of PrE-II contains 
CG motifs in the first two positions of three hexamers whereas PrE-II for 
SeV contains a C in the last position of three hexamers. The motifs are not 
a strict requisite for PIV5 as it has been demonstrated that PIV5 was less 
sensitive to mutations in the CG motifs. SeV, on the other hand, could not 
accept any mutations. The location of PrE-II in the genome also differs 
between SeV and PIV5. In the case of PIV5, it is located 73-90 bases from 
the 3’ terminus but for SeV it is located 79-96 bases from the 3’ terminus 
(Murphy et al., 1998; Tapparel et al., 1998).  
A third sequence discovered by Keller and Parks was termed Region III 
(RIII) and is located 51-66 bases from the 3’ end of the antigenome. 
Changing the location of RIII did not affect replication suggesting that RIII 
is not essential but enhances replication (Keller & Parks, 2003).  
 
The third requirement for genome replication is the spacing of PrE-I and 
PrE-II relative to each other. Deletions in the RNA between the two 
elements reduced replication but when the deleted sequences were 
substituted with non-viral RNA, the replication was restored. This would 
indicate that the reduction of replication was not due to the deletions of 
important cis-acting signals. When six nucleotides were inserted or 
deleted from the genome, replication again was reduced. Therefore it was 
unlikely due to the rule of six and more likely that PIV5 is sensitive to the 
position of the two elements. Further, it may be important that the 
sequences need to align correctly in the nucleocapsid template (Murphy et 
al., 1998).  
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Figure 1.4: Life cycle of PIV5. The HN glycoprotein facilitates the attachment of virions 
to the host cell surface and the viral envelope fuses with the plasma membrane of the 
infected cell. The virus is then uncoated and the nucleocapsid is released into the 
cytoplasm, where virus replication takes place. Negative sense genomes are first 
transcribed into capped and polyadenylated mRNAs, which are translated into viral 
proteins. Correctly folded viral proteins are then transported to the Golgi apparatus, 
where proteins are packaged and then assembled at the cell membrane where the matrix 
protein directs the assembly and budding of virions.  When levels of NP have increased, 
the viral polymerase switches from transcription to replication to produce full-length 
antigenomes (positive sense). These antigenomes are used to synthesise further viral 
progeny genomes and together, the antigenomes and genomes are encapsidated by the 
nucleocapsid protein.   
 
PIV5 termini 
The function of PrE-I and PrE-II is still unknown, but there are currently 
two hypotheses. Firstly, that they are sites for encapsidation of the 
nascent RNA strand by NP. However, it is currently believed that binding 
of NP to the genome provides an anti-termination signal to the viral 
polymerase, which is located approximately 55 nucleotides from the 3’ 
terminus of the genome. It would therefore be unlikely that the decision for 
encapsidation during replication or continuing with transcription would be 
made as late as 73-96 nucleotides from the 3’ terminus. Secondly, PrE-I 
and PrE-II have been proposed to be sites for polymerase binding. This 
theory has been supported by reverse genetics studies on SeV where the 
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polymerase is able to recognise PrE-I and II when it is positioned in an 
internal site (Vulliémoz & Roux, 2001). 
 
Intergenic regions 
Although the PIV5 polymerase stays attached to the template through the 
intergenic regions it occasionally fails to reinitiate at the downstream gene 
start as described previously, resulting in a gradient of transcription (Kuo 
et al., 1996; Villarreal et al., 1976). Additionally, sometimes the 
polymerase remains bound to the genome to produce a bicistronic mRNA.  
Generally, only 10-15% of read-through product can be found for PIV5 but 
with one exception, namely the M-F region which can generate 40% read-
through (Rassa & Parks, 1998). Mutational studies of the M-F junction, 
where the M-F intergenic region was replaced by a non-viral sequence, 
reported that this mutant virus grew to lower titres than wild-type (wt) virus 
and L protein was also overexpressed. It was suggested that read-through 
increases access of the polymerase to the more distal genes and that this 
was a mechanism to control transcription (Parks et al., 2001).  
 
The PIV5 intergenic regions are diverse and many studies have 
investigated the effect of these regions. The regions differ in length and 
sequence with variable U tracts and gene start sequences. The length of 
the U tracts do not correlate with the length of the poly(A) tail, as the 
length of the poly(A) tails were the same for M, NP and SH mRNAs 
despite having U tracts of different lengths (Rassa et al., 2000). The U 
tracts direct the termination and reinitiation at the downstream gene during 
transcription and the length of the tract has proven to be of importance. 
When the U tract consisted of four residues, the next residue needed to be 
a G for efficient termination of transcription to take place. Longer tracts did 
not have this specific requirement (Rassa & Parks, 1999). It has been 
implied that the U tracts play a role as a spacer region, important for 
reinitiation. Rassa et al. (2000) showed that the HN region needed at least 
six residues between the start of HN and the end of SH. If the region 
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consisted of less than six residues, transcription termination still occurred 
but reinitiation at SH was significantly inhibited (Rassa et al., 2000). Taken 
together, the intergenic regions appear to have an important function in 
transcriptional control.  
 
Virus assembly and budding 
Like other enveloped viruses, PIV5 virions assemble and bud from cellular 
membranes. Particle formation takes place when all viral components, 
including the viral RNPs and viral glycoproteins, have assembled at the 
cellular plasma membrane. Membrane proteins are essential for the 
budding process as they interact with both viral nucleocapsids and 
cytoplasmic tails of the glycoproteins. For many paramyxoviruses M is 
sufficient for releasing virus-like particles from transfected cells in the 
absence of any other viral component. In the case of PIV5, not only M is 
required but also NP and at least one of the two glycoproteins (F or HN) 
(Harrison et al., 2010; Schmitt et al., 2002). In addition, the cytoplasmic 
tails of the glycoproteins also play an important function (Waning et al., 
2002) as they are essential for efficient assembly and budding.  
 
Minireplicon systems of negative-strand RNA viruses 
Reverse genetics is a powerful tool to introduce genome manipulation in 
order to study viral pathogenesis and function. It allows for the introduction 
of specific mutations into the genetic background of a virus and for 
subsequent study of the changes in the virus phenotype that are 
attributable to those specific mutations. A minireplicon system is the first 
step towards a reverse genetics system and is used to create recombinant 
viral nucleocapsids containing artificial genome-like RNA, called a 
minireplicon. If full-length viral cDNA constructs are used, infectious virions 
can be rescued and analysed (Fig. 1.5). The first RNA virus that was 
generated from cloned DNA was the bacteriophage Q" (Taniguchi et al., 
1978), quickly followed by the successful transfection of mammalian cells 
with poliovirus (PV) cDNA which led to the production of infectious 
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particles (Racaniello & Baltimore, 1981). The advantage of positive-strand 
RNA viruses is the fact that the viral genome already is in the mRNA 
sense, and thus can both synthesise viral proteins and serve as a 
template for genome replication. Minireplicon systems of negative-strand 
RNA viruses proved to be more difficult as neither the genome nor the 
antigenome is sufficient to initiate viral replication; instead, the minimal 
infectious unit is an RNP (Palese et al., 1996). This discovery has resulted 
in the development of minireplicon systems for viruses such as MeV 
(Zhang et al., 2002),  RSV (Fearns et al., 2000) and NDV (Benfield et al., 
2010).  
The first minireplicon systems for PIV5 involved a vaccinia virus (VV) T7 
polymerase system (Murphy & Parks, 1997; Pattnaik & Wertz, 1990; 
Rassa & Parks, 1998), but the system based on vaccinia virus was later 
replaced by using the BHK-derived cell line BSRT7/5 that constitutively 
expresses the T7 RNA polymerase (Buchholz et al., 1999; Tompkins et 
al., 2007). Numerous PIV5 mutants and vectors expressing foreign 
proteins have now been generated using reverse genetics (Arimilli et al., 
2008; He et al., 2002; Lin et al., 2005; Manuse & Parks, 2010; Parks et al., 
2002).  
 
Schnell et al. (1994) successfully rescued rabies virus (RABV), the first 
non-segmented negative-strand RNA virus. In this study, the viral 
antigenome was cloned under the control of the T7 RNA polymerase 
promoter and transfected into cells together with plasmids expressing N, P 
and L. Infection with a recombinant vaccinia virus encoding the T7 RNA 
polymerase produced infectious rabies particles. 
This approach was successful because of the use of the positive 
antigenome rather than the negative genome. It is generally believed that 
the negative sense genome may hybridise with the positive sense mRNA 
of the transfected expression plasmids for N, P and L, which would 
interfere with virus replication. An authentic 3’ terminus has been shown to 
be required for successful virus rescue, while modifications of the 5’ 
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terminus are tolerated (Collins et al., 1995; De & Banerjee, 1993). Due to 
this requirement, the hepatitis delta ribozyme is often preferred for use in 
reverse genetics systems. The hepatitis delta ribozyme has an 
autocatalytic activity that after cleavage will create an exact 3’ terminus 
(Perrotta & Been, 1991).  
With the successful minireplicon systems for non-segmented negative-
strand RNA viruses, systems for segmented negative-strand RNA viruses 
followed, and now there are reverse genetics systems for many 
segmented viruses (Blakqori et al., 2003; Bridgen & Elliott, 1996; Fodor et 
al., 1999; Kohl et al., 2004; Lowen et al., 2004; Mühlberger et al., 1999; 
Neumann et al., 1999a).  
 
 
Figure 1.5: Non-segmented negative-strand RNA virus rescue. The system is based 
on transfection of plasmids encoding the viral proteins present in the viral RNP (NP, P 
and L for PIV5) together with the virus genome, all under the control of the T7 RNA 
polymerase promoter. The T7 RNA polymerase is provided by infection of recombinant 
vaccinia virus that express the T7 RNA polymerase (VV-T7) or by transfecting into cell 
lines that express the protein. Adapted from (Pekosz et al., 1999).
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THE INTERFERON RESPONSE 
Introduction 
Interferons (IFNs) were discovered by Isaacs and Lindenmann over 50 
years ago (Isaacs & Lindenmann, 1957). They are a group of secreted 
antiviral cytokines that are divided into three classes called type I, II and III 
IFNs. Type I IFNs are the largest group and contains IFN-!, IFN-", IFN-', 
IFN-% and IFN-(. In humans, there are 13 subtypes of IFN-! and one of 
IFN-". Type II IFNs comprise only one member: IFN-#, whereas the IFN-$s 
(or type III IFNs) comprise three subtypes, IFN-$1 (also called IL-29), IFN-
$2 (also called IL-28A), and IFN-$3 (also called IL-28B) (Pestka et al., 
2004; Stark et al., 1998). The induction of IFN-" in fibroblasts has been 
extensively studied and large amounts of IFN-! are produced in pDC cells. 
IFN-$ is produced by T-lymphocytes and natural killer (NK) cells (Pestka 
et al., 2004; Prakash et al., 2005).  
The IFN system is activated within hours of detecting a virus and 
upregulates the gene expression of hundreds of proteins, many of which 
have antiviral activity, resulting in an inhospitable environment for virus 
replication. Additionally, the IFN response elicits an antiviral state in 
neighbouring cells, thus restricting virus spread to uninfected cells 
(Randall & Goodbourn, 2008).  
 
Detection of virus infection 
Pattern recognition receptors 
Cells of the innate immune response detect microbes mainly through 
pattern recognition receptors (PRRs) present on the cell surface or in 
intracellular compartments. PRRs identify pathogens displaying pathogen-
associated molecular patterns (PAMPs) that are normally not found in host 
cells (Kumar et al., 2011). There are several families of PRRs and they are 
able to detect both intracellular and extracellular PAMPs. Some of the 
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most studied PRRs are the Toll-like receptors (TLRs) and the RIG-I-like 
receptors (RLRs) (Jensen & Thomsen, 2012).  
 
Toll-like receptors 
The TLRs are transmembrane glycoproteins with an ectodomain of 
multiple leucine-rich repeats (LRRs) that are required for PAMP 
recognition, and an intracellular Toll/interleukin-1 resistance (TIR) domain 
required for signal transduction (Akira & Takeda, 2004; Bowie & O'Neill, 
2000). PAMP binding to the LRR induces dimerisation of the receptor, 
which then recruits adaptor proteins to start signalling (Akira et al., 2006; 
O'Neill, 2006). The human TLR family comprises 10 members of which 
three are of importance in recognising components of RNA viruses, such 
as viral double stranded RNA (dsRNA) and single stranded RNA (ssRNA) 
(Akira et al., 2006). 
 
TLR3 detects endosomal and extracellular dsRNA 
A decade ago TLR3 was identified as being responsible for the detection 
of dsRNA (Alexopoulou et al., 2001). TLR3 is found in a variety of cells, 
but is expressed at high levels in myeloid dendritic cells (mDCs), bone 
marrow-derived macrophages and fibroblasts (de Bouteiller et al., 2005; 
Johnsen et al., 2006; Matsumoto et al., 2002). TLR3 is also expressed 
strongly in the brain as well, and in epithelial cells in areas such as the 
intestine, airway and cornea (Akira et al., 2006). Through its expression in 
endosomes and on the membrane of cells, TLR3 can detect extracellular 
dsRNA and intracellular dsRNA through endosomal virion uncoating. 
Knockout studies have reported that mice were insensitive to infection of 
certain viruses, such as lymphocytic choriomeningitis virus (LCMV), 
reovirus and vesicular stomatitis virus (VSV), (Edelmann et al., 2004), 
although these viruses are detected by different PRRs.  
 
Binding of dsRNA to TLR3 results in receptor dimerisation, tyrosine 
phosphorylation and the subsequent recruitment of the TRIF (Toll-
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interleukin (IL)-1-resistance (TIR) domain-containing adaptor inducing IFN-
") adaptor protein, and phosphatidylinositol 3 (PI3) kinase (Hoebe et al., 
2003; Sarkar et al., 2004; Yamamoto et al., 2003). The activation of TRIF 
ultimately leads to activation of NF-%B and interferon regulatory factor 3 
(IRF3) (Fig. 1.6). For NF-%B activation, tumour necrosis factor (TNF) 
receptor-associated factor 6 (TRAF6) is recruited by TRIF together with 
receptor-interacting protein 1 (RIP1) (Cusson-Hermance et al., 2005; 
Jiang et al., 2004; Meylan et al., 2004; Sato et al., 2003). This recruitment 
leads to oligomerisation and subsequent Lys63-linked polyubiquitination of 
TRAF6 and RIP1 (Chen, 2005). The transforming growth factor "-
associated kinase 1 (TAK1), along with TAK1-binding proteins 2 and 3 
(TAB2 and TAB3), interact with TRAF6 and RIP1 through binding of the 
polyubiquitin chains (Kanayama et al., 2004; Rothenfusser et al., 2005). 
This protein complex mediates the recruitment of the inhibitor of NF-%B 
(I%B) kinase (IKK) complex (Ea et al., 2006; Li et al., 2006a; Wang et al., 
2001; Wu et al., 2006; Yoneyama et al., 2005). IKK is made up of the 
catalytic subunits IKK! and IKK", and the regulatory subunit IKK# (also 
known as NF-%B essential modifier (NEMO)). IKK# recognises the 
polyubiquitinated RIP1 and as a result of this interaction IKK" is 
phosphorylated directly by TAK1 (DiDonato et al., 1997; Mercurio et al., 
1997; Rothwarf et al., 1998; Wang et al., 2001; Zandi et al., 1998). This 
leads to the downstream phosphorylation of I%B, which is then 
polyubiquitinated and degraded. With the degradation of I%B, NF-%B is 
free to translocate to the nucleus through a process that is regulated by 
the de-ubiquitination enzyme A20, which removes ubiquitin from TRAF6 
(Boone et al., 2004).  
 
For IRF3 activation TRIF needs to interact with TRAF3 (Häcker et al., 
2006; Oganesyan et al., 2006). This association leads to the formation of a 
complex comprising TRAF-associated NF-%B activator (TANK) (Li et al., 
2002), TANK-binding kinase 1 (TBK1), and IKK' (Fitzgerald et al., 2003; 
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Hemmi et al., 2004; Sharma et al., 2003). IRF3 is phosphorylated by TBK1 
and IKK' and is subsequently translocated to the nucleus (Hemmi et al., 
2004) (Fig. 1.6). In addition, TBK1 and IKK' can also phosphorylate IRF7 
(Sharma et al., 2003). 
 
 
Figure 1.6: TLR3-dependent signalling in response to dsRNA. TLR3 detects dsRNA 
and recruits the adaptor protein TRIF that in turn leads to activation via the IRF3 or NF-
%B pathways. IRF3, NF-%B and AP-1 bind to the IFN-" promoter, and recruits the co-
factors CBP/p300 and RNA polymerase II. This ultimately leads to IFN-" transcription. 
Adapted from (Randall & Goodbourn, 2008). 
  
TLR7 and TLR9 detect endosomal ssRNA and DNA 
Plasmacytoid dendritic cells (pDCs) produce large amounts of IFN in 
response to a virus infection but they do not express TLR3 (Kadowaki et 
al., 2001). Instead, they express TLR7 and TLR9 in the endosomes 
(Diebold et al., 2004; Jarrossay et al., 2001; Kadowaki et al., 2001). TLR7 
has been revealed to detect ssRNA, either synthetic RNA or derived from 
viruses (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004). In 
contrast, TLR9 detects unmethylated CpG motifs from viral DNAs (Abe et 
al., 2005; Hemmi et al., 2000; Rutz et al., 2004). A requirement for both 
TLR7 and TLR9 is that viruses must be internalised before detection as 
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TLR7/9 are not expressed on the cell surface of pDCs (Lund et al., 2003; 
2004).  
The TLR7 signalling pathway is activated when TLR7 binds to ssRNA. 
This recruits an adaptor protein called myeloid differentiation factor 88 
(MyD88) (Lund et al., 2004). In turn, MyD88 recruits a complex comprising 
interleukin-1 receptor-associated kinase 4 (IRAK4), IRAK1 and TRAF6, 
which also involves TRAF3 (Häcker et al., 2006). Similarly to TLR3 
signalling, TRAF6 activates IKK by TAB2/3 and TAK1, followed by 
activation of NF-%B. The complex consisting of 
MyD88/IRAK1/IRAK4/TRAF6 binds to IRF7, a process that is also 
dependent on polyubiquitinated RIP1 (Huye et al., 2007; Uematsu et al., 
2005). Subsequently, IRAK1 phosphorylates IRF7 which allows IRF7 to 
translocate to the nucleus (Uematsu et al., 2005) (Fig. 1.7).  
 
TLR9 exists in the endosomal compartment of both mDCs and pDCs, 
however these cells use different signalling pathways. In pDCs, 
endosomal retention of the unmethylated CpG ligand is required and TLR9 
activates IRF7 and NF-%B through a MyD88-dependent signalling pathway 
(Honda et al., 2005). In contrast, mDCs can not retain the CpG ligand in 
the endosome and instead promote antiviral signalling driven by IRF1 
(Schmitz et al., 2007) (Fig. 1.7). 
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Figure 1.7: TLR7- and TLR9-dependent signalling. TLR7 and TLR9 detect ssRNA and 
CpG DNA, respectively. Activated TLRs recruit MyD88, which recruits IRAK4 and IRAK1. 
This complex recruits components for IRF7 or NF-%B, which leads to nuclear 
translocation and IFN-" induction. Adapted from (Randall & Goodbourn, 2008). 
 
RIG-I and MDA5 RNA helicases detect cytoplasmic RNA 
In addition to the TLRs, the RIG-I-like receptors (RLRs) detect intracellular 
RNA (Edelmann et al., 2004; Yoneyama & Fujita, 2010). The RLRs 
comprise three proteins, the retinoic acid-inducible gene 1 protein (RIG-I), 
melanoma differentiation-associated protein 5 protein (MDA5) and 
laboratory of genetics and physiology 2 (LGP2) protein. RIG-1 binds to 
poly I:C (Yoneyama et al., 2005) while MDA5 was first reported to bind to 
the PIV5 V protein (Andrejeva et al., 2004) and shares similar properties to 
RIG-I (Yoneyama et al., 2005).  Both RIG-I and MDA5 have two caspase 
activation and recruitment domains (CARDs) at the N-terminus, and a C-
terminus containing a helicase domain with RNA binding properties (Li et 
al., 2009a; Lu et al., 2010; Takahasi et al., 2009; Wang et al., 2010). 
Binding of viral RNA to the RNA binding domain results in a 
conformational change of RIG-I and MDA5 that exposes the CARD 
domains for binding with the IFN-" promoter stimulator protein 1 (IPS-1) 
(also called mitochondrial antiviral signalling protein [MAVS]/CARD 
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adaptor inducing IFN-" [CARDif]/virus-induced signalling adaptor [VISA]) 
(Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). 
RIG-I, but not MDA5, needs to be ubiquitinated by tripartite motif 
containing 25 (TRIM25) (Gack et al., 2007; 2008). The polyubiquitinated 
CARD complex then recruits IPS-1 (Zeng et al., 2010), which associates 
with tumour necrosis factor receptor 1 (TNFR1)-associated death domain 
protein (TRADD). This association organises the assembly of the 
TRAF3/TRAF6/TANK/RIP-1/FADD (Fas associated death domain 
containing protein) complex (Michallet et al., 2008) which then leads to 
activation of the IFN response through the NF-%B and IRF3 pathways 
(described earlier) (Zhao et al., 2007) (Fig. 1.8).  
 
 
 
Figure 1.8: RIG-1 and MDA5-dependent signalling. RIG-I and MDA5 both detect viral 
dsRNA, and RIG-I also detects 5’ triphosphate RNA. The CARD domains of RIG-I and 
MDA5 recruit the adaptor protein IPS-1 that recruits components that either associate 
with the IRF3 or NF-%B pathways. This results in assembly on the IFN-" promoter and 
transcription induction. Adapted from (Randall & Goodbourn, 2008). 
 
 
             1  Introduction: the interferon response
  
 
 32 
RIG-I and MDA5 are negatively regulated by their interaction with 
Atg5/Atg12 components, which inhibit signalling downstream of IPS-1 
(Jounai et al., 2007). MDA5, but not RIG-I, also interacts with 
dihydroxyacetone kinase (DAK) which leads to negative regulation of 
MDA5 (Diao et al., 2007).  
 
In addition, LGP2 was identified as a negative regulator of RIG-I 
(Rothenfusser et al., 2005). LGP2 lacks the CARD domain that mediates 
downstream signalling and it was therefore suggested that LGP2 inhibits 
IFN induction by sequestering viral RNA (Komuro & Horvath, 2006; 
Rothenfusser et al., 2005; Yoneyama et al., 2005). In contrast, LGP2 is 
also involved in promoting RNA recognition by RIG-I and MDA5 via its 
ATPase domain (Komuro & Horvath, 2006; Komuro et al., 2008; Satoh et 
al., 2010; Wilkins & Gale, 2010; Yoneyama & Fujita, 2010). However, 
LGP2 knockout studies showed that mice deficient in LGP2 were more 
sensitive to viruses that activated MDA5 signalling than those activating 
RIG-I signalling. It was also proposed that LGP2 was not the main 
negative regulator of IFN induction (Venkataraman et al., 2007). Further, a 
recent study demonstrated that the V protein of PIV5 forms a complex with 
RIG-I and LGP2 and this interaction inhibits IFN induction via the RIG-I 
pathway (Childs et al., 2012).  
 
RIG-I and MDA5 are both activated by the synthetic dsRNA polyI:C 
(Andrejeva et al., 2004; Yoneyama et al., 2004) but they recognise 
different ligands. RIG-I recognises viral ssRNA with uncapped 5’-
triphosphates and also short dsRNA which is produced during virus 
replication (Hornung et al., 2006; Marq et al., 2011; Pichlmair et al., 2006), 
while MDA5 recognises longer dsRNA which does not contain uncapped 
5’-triphosphates (Hornung et al., 2006; Kato et al., 2008; Pichlmair et al., 
2006; 2009; Schlee et al., 2009; Schmidt et al., 2009). The different 
binding ligands for RIG-I and MDA5 are supported by how the detection of 
viruses is mediated. For example, IAV and many paramyxoviruses 
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activate RIG-I signalling but not MDA5, while MDA5 but not RIG-I detects 
picornaviruses, as picornaviruses do not produce 5’-triphosphates as the 
RNA is bound to the VPg protein (Berghäll et al., 2006; Gitlin et al., 2006; 
Kato et al., 2006; Lee et al., 1977; Loo et al., 2008; Pichlmair et al., 2006).  
However, although many paramyxoviruses have been reported to activate 
RIG-I there are studies showing that numerous paramyxoviruses in fact 
bind to MDA5 and not RIG-I but rather indirectly inhibit RIG-I activation by 
interacting with LGP2 (Andrejeva et al., 2004; Childs et al., 2007; 2012; 
2009). Certain flaviviruses, including Dengue virus (DENV) and West Nile 
virus (WNV), and reoviruses activate both RIG-I and MDA5 (Loo et al., 
2008).   
 
Detection of cytosolic DNA 
Recently, numerous sensors of cytosolic DNA have been identified. 
However, it is unlikely that these sensors have different selectivity for 
different types of dsDNA but instead detect DNA in different cell types 
(Keating et al., 2011). 
One of these sensors of cytosolic DNA that activates IFN expression 
independently of TLR9 is called DNA-dependent activator of IFN 
regulatory factors (DAI) (also known as DLM1 and ZBP1) (Fu et al., 1999; 
Stetson & Medzhitov, 2006; Takaoka et al., 2007). DAI has been shown to 
bind directly with DNA and full activation requires three domains (Wang et 
al., 2008). DAI also recruits TBK1 and IRF3, both of which are critical in 
type I IFN induction (Takaoka et al., 2007). Furthermore, when DAI was 
suppressed in L929 mouse cells and mouse embryonic fibroblast (MEF) 
cells IFN was significantly inhibited in the MEF cells but not the L929 cells. 
This suggests there is an additional cytosolic DNA sensor molecule that 
contributes to IFN induction and that it may be cell-type dependent 
(Takaoka et al., 2007; Wang et al., 2008).  
Additionally, two TLR9-independent but MyD88-dependent DNA detection 
pathways have been suggested in pDCs called DHX9 and DHX36. It has 
been demonstrated that DHX36 is required for the IFN-! response to 
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herpes simplex virus 1 (HSV-1) in pDCs, while DHX9 is required for TNF-! 
induction following HSV-1 infection (Kim et al., 2010).  
The Ku70 protein is involved in DNA repair and has also been described 
as an inducer of IFN-$1 and a binding protein of dsDNA. Induction of IFN-
$1 mediated by Ku70 requires DNA of more than 500 bases suggesting 
that Ku70 may need to bind multiple DNA sites to trigger induction (Zhang 
et al., 2011).   
 
STING 
The stimulator of interferon genes (STING) plays a significant role in 
inducing IFN by detecting non-CpG motifs. STING is located in the ER and 
has five transmembrane domains (Ishikawa & Barber, 2008). IFN-" is 
induced by STING through the IRF3 and NF-%B signalling pathways. 
Recently, it was demonstrated that STING was involved in the 
phosphorylation of IRF3 by TBK1. A region in the C-terminus of STING 
was identified that is necessary to activate TBK1 and stimulate IRF3 
phosphorylation. STING was also found to interact with TBK1 and IRF3, 
suggesting that STING functions as a scaffold to support IRF3 
phosphorylation by TBK1 (Tanaka & Chen, 2012). 
 
Induction of IFN-! 
IFN-! can be divided into two groups, one immediate-early gene called 
IFN-!4, which is induced quickly, and one group of delayed genes 
comprising IFN-!2, 5, 6 and 8. IFN-! induction in leukocytes occurs 
independently of IFN-" induction, unlike in fibroblasts where induction of 
IFN-" is required for IFN-! induction. The IFN-! promoter lacks a binding 
site for NF-%B (Erlandsson et al., 1998). In most cells other than pDCs, 
expression of IRF7 is undetectable so induction of the primary IFN gene 
IFN-" is triggered via the IRF3 pathway. IFN-" stimulates IRF7 expression 
which is required for transcription of secondary IFN-! (Erlandsson et al., 
1998; Levy et al., 2002; Marié et al., 1998). However, pDCs constitutively 
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express IRF7, therefore IFN-! is produced much earlier in the virus 
infection (Prakash et al., 2005).  
 
Induction of IFN-" 
After activation, IRF3 and NF-%B translocate to the nucleus and assemble 
on the IFN-" promoter to form a complex called the enhanceasome 
together with a c-jun/ATF-2 heterodimer. To provide further stability to the 
enhanceasome, the non-histone high mobility group (HMG)-I/Y chromatin 
protein binds to the complex. The assembled enhanceasome then recruits 
CREB-binding protein (CBP)/p300 and RNA polymerase II to complete the 
transcription machinery (Randall & Goodbourn, 2008). For optimal 
induction, cooperation between each transcription factor is needed, 
although IRF3 and/or IRF7 are indispensible for induction.  
 
Induction of IFN-#  
IFN-# is produced by NK cells, CD4+ T helper cells and CD8+ cells. NK 
cells are capable of producing IFN-# without the need of antigen 
presentation by antigen presenting cells (APC). In contrast, CD4+ and 
CD8+ cells require antigen presentation (Takaoka & Yanai, 2006). The IFN 
promoter differs between NK cells and CD4+ cells. In CD4+ cells, the 
promoter comprises two elements, a distal element that is activated by 
binding of GATA binding protein 3 (GATA3), and a proximal element 
activated by binding of a transcription complex. NK cells, on the other 
hand, only require the distal domain. APCs secrete the IL12 and IL18 
cytokines which enhance IFN activation (Goodbourn & Randall, 2009; 
Singh et al., 2000; Young, 1996). 
 
Induction of IFN-$ 
IFN-$ induction occurs in a similar manner as type I IFN induction. 
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IFN signalling pathways 
The STAT proteins 
Seven signal transducers and activators of transcription (STAT) proteins 
have been identified in humans, termed STAT1-4, STAT5a, STAT5b, and 
STAT6. The STAT proteins consist of seven structural domains: an amino 
terminal domain, a coiled-coil domain, a DNA binding domain, a linker 
domain, a Scr-homology 2 (SH2) domain, a tyrosine activation motif, and a 
transcriptional activation domain (TAD). The amino terminal domain 
promotes unphosphorylated STATs to form dimers (Braunstein et al., 
2003; Zhong et al., 2005) which aids the delivery and activation of STAT 
dimers at the receptor. The coiled-coil domain has been suggested to be 
involved in controlling nuclear import and export. The DNA-binding domain 
allows binding to GAS elements and all but one (STAT2) STAT 
homodimers bind GAS (McBride & Reich, 2003; Schindler & Plumlee, 
2008; Xu et al., 2005). The linker domain induces dimerisation to the DNA 
binding domain while the SH2 domain mediates receptor recruitment and 
activation of STAT dimers (Bhattacharya & Schindler, 2003; Gupta et al., 
1998; Schindler et al., 2007; Shuai et al., 1994). The TAD is located at the 
C-terminus of STAT and regulates protein stability, as particularly STAT4, 
STAT5 and STAT6 are sensitive for ubiquitination, while STAT1, STAT2 
and STAT3 are more stable (Tanaka et al., 2005; Wang et al., 2000).  
 
The Janus kinase (JAK) family comprise four members called JAK1, 
JAK2, JAK3 and Tyk2. Together they have seven JAK homology domains 
named JH1-7. The JH1 domain has tyrosine kinase activity but JH2 does 
not appear to have enzymatic activity and negatively regulates JH1 (Luo et 
al., 1997; Saharinen et al., 2000). JH3 and JH4 have SH2-like domains, 
while JH6 and JH7 have a Band 4.1, ezrin, radixin, moesin (FERM) 
domain, that is involved in promoting interactions with cytokine receptors 
(Huang et al., 2001; Velazquez et al., 1992; Yamaoka et al., 2004).  
The JAK family is involved in signalling stimulated by cytokines. Tyk2 
binds the interferon !/" receptor IFNAR1, JAK1 binds IFNAR2 and 
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IFNAR1, and JAK3 binds IFNAR2 (Schindler & Plumlee, 2008). Following 
ligand-binding the JAKs are activated through auto- or trans-
phosphorylation. This leads to phosphorylation of the receptors at specific 
tyrosine residues, and in turn, results in recruitment of downstream SH2 
domain-containing signalling molecules, such as STATs and PI3K (Rane 
& Reddy, 2000).  
 
Type I IFN signalling 
The well characterised Jak/STAT pathway is activated in response to type 
I IFNs. IFN-!/" binds to the heterodimeric receptor (comprising IFNAR1 
and IFNAR2) leading to oligomerisation and a conformational change. In 
the inactivated state, IFNAR1 is associated with Tyk2 and IFNAR2 is 
associated with JAK1, but can also be bound to STAT2 (Abramovich et al., 
1994; Tang et al., 2007). The conformational change induced from ligand-
binding results in Tyk2 phosphorylation of Tyr466 on IFNAR1, which 
creates a docking site for STAT2. This promotes the phosphorylation of 
Tyr690 on STAT2 by Tyk2, and STAT1 is then phosphorylated by JAK1 on 
Tyr701, forming a stable STAT1/STAT2 heterodimer which reveals a 
nuclear localisation signal (NLS) for translocation to the nucleus 
(Banninger & Reich, 2004). It remains in the nucleus until the dimer is 
dephosphorylated and the nuclear export signal (NES) is exposed for 
transport back to the cytoplasm (Banninger & Reich, 2004; Fagerlund et 
al., 2002; Gack et al., 2007; McBride et al., 2000; Mélen et al., 2003). The 
STAT1/STAT2 dimer associates with IRF9 to form a heterotrimer that is 
also called IFN stimulated gene factor 3 (ISGF3), which translocates to the 
nucleus and binds to the interferon-stimulated response element (ISRE) in 
the promoter of interferon-responsive genes. This activates the 
transcription of interferon-stimulated genes (ISGs) (Gack et al., 2008; 
Kessler et al., 1990; Levy et al., 1989; Tang et al., 2007).  
 
Other STAT heterodimers are also involved in the IFN response, such as 
STAT1/3, STAT1/4, STAT1/5, STAT2/3 and STAT5/6 (Farrar et al., 2000; 
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Platanias, 2005; Torpey et al., 2004). These different STAT dimers bind to 
ISRE/GAS elements in the promoters of ISGs, and it is believed that these 
combinations of STAT dimers may regulate the upregulation of ISGs as 
some STAT dimers bind to ISRE or to GAS, or alternatively to both. The 
diversity in STAT dimer formation is thought to promote optimal 
expression of ISGs (Platanias, 2005).  
 
 
 
Figure 1.9: IFN signalling. The type I, II and III IFNs bind to their respective receptor 
thus triggering the JAK/STAT pathway, resulting in ISGF3 complex or GAF formation. 
These complexes migrate to the nucleus to induce IFN-stimulated genes from IFN-
stimulated response elements for types I and III IFNs, or GAS elements for type II IFNs. 
Adapted from (Sadler & Williams, 2008). 
 
Type II IFN signalling 
Type II IFN binds to the type II IFN receptor, which comprise IFNGR1 and 
IFNGR2. Like the receptor for type I IFNs, IFNGR1/2 are associated with 
members of the JAK family. IFNGR1 associates with JAK1 and IFNGR2 
associates with JAK2 (Chen et al., 2004; Stark et al., 1998). Similarly to 
the type I IFNs, activation of IFNGR results in receptor dimerisation and 
activation of JAK1 and JAK2. The JAKs phosphorylate IFNGR1 which 
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results in a conformational change that exposes two binding sites for 
STAT1. This recruits two STAT1s through the SH2 domains and STAT1 is 
then phosphorylated at Tyr701. This allows STAT1 to dissociate from the 
receptor. SH2 domains then promote the homodimerisation of STAT1 and 
the translocation of the STAT1/STAT1 homodimer (also called gamma-
activated factor, GAF) to the nucleus. Transcription is then activated from 
GAS elements in the promoter (Decker et al., 1991; Nguyen et al., 2002). 
 
Type III IFN signalling 
The signalling of type III IFNs is similar to that of type I IFNs, as they use 
the JAK/STAT signalling pathway. Following binding to the heterodimeric 
receptor, consisting of the interleukin 10 receptor 2 (IL-10R2) and the IFN-
$R1 subunits, phosphorylation of tyrosine residues of the receptor results 
in STAT activation. Type III IFN receptor complexes result in the formation 
of the ISGF3 transcription complex (same as for type I IFN signalling) and 
subsequent translocation to the nucleus. STAT proteins involved in type III 
IFN signalling are STAT1 and STAT2 but studies have reported that IFN-
$1 also induces phosphorylation of STAT3, 4, and 5 (Donnelly & Kotenko, 
2010; Dumoutier, 2004). The similarities in signalling pathways of IFN-!/" 
and IFN-$ also give them similar biological activities, as they are both 
induced by dsRNA, and both upregulate antiviral proteins and the antigen 
expressing class I major histocompatibility complex (MHC) (Kotenko et al., 
2003). However, type I and III IFNs differ with regard to the responsive cell 
types. Type I is present in most cell types, whereas type III IFNs seem to 
be expressed mainly in epithelial cells (Meager et al., 2005; Pott et al., 
2011; Sommereyns et al., 2008).  
 
Negative regulation of IFN 
In order to control the IFN response there are several IFN-inducible 
proteins that act negatively on the IFN system. One of these proteins is 
the protein inhibitor of activated STATs 1 (PIAS1) that blocks the DNA 
binding activity of STAT1, thus inhibiting gene activation mediated by 
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STAT1 in response to IFN (Liu et al., 1998). The suppressor of cytokine 
signalling (SOCS) family of proteins either inhibit the activity of JAK 
proteins and/or target them for proteasomal degradation (Rui et al., 2002; 
Sasaki et al., 1999). Furthermore, the virus-induced ISG56 has been 
found associated with the adaptor protein STING, which subsequently 
disrupts the interaction of STING with MAVS or TBK1. This inhibits the 
activation of IRF3 and the subsequent IFN-" expression and cellular 
antiviral responses (Li et al., 2009b).  
In addition, Cullin-based ubiquitin ligases have been reported as being 
involved in proteasomal degradation of IRF3 (Bibeau-Poirier et al., 2006; 
Ye & Maniatis, 2011).  
 
Additional signalling pathways 
The classical JAK/STAT pathway is not the only signalling pathway that 
results in the upregulation of antiviral proteins. Additional pathways have 
been identified that produce signalling cascades that aid in optimising the 
IFN response. Such pathways are the mitogen associated protein kinase 
(MAPK) p38 cascade (Platanias, 2005), the CRK proteins (Ahmad et al., 
1997; Feller, 2001), and the PI3K proteins (Hawkins et al., 2006; 
Platanias, 2005). The CRK proteins interact with Tyk2 and the PI3K 
proteins negatively regulate the JAK/STAT signalling pathway.  
 
The IFN-induced antiviral state 
Production and secretion of IFN promotes the upregulation of over 300 
ISGs. These ISGs mediate an antiviral response in infected cells and are 
also involved in numerous other processes in the infected cell, such as 
immunomodulation and antiproliferation (de Veer et al., 2001). The effect 
of the induced antiviral state creates an inhospitable environment and 
causes the virus to replicate inefficiently. The ISGs also include proteins 
that regulate apoptosis and the cell cycle, as well as proteins regulating 
transcription and translation. The best characterised ISGs are the protein 
kinase R (PKR), 2’-5’ oligoadenylate synthetases (OAS/endoribonuclease 
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L (RNaseL), Mx GTPases and ISG15. Other ISGs, such as viperin and 
ISG56 have been implicated in antiviral actions and are quickly becoming 
the focus of many studies.   
 
Interferon-stimulated genes 
Mx GTPases 
The class of guanine hydrolysing proteins comprise four proteins: the p65  
GBPs (guanylate-binding proteins), the large inducible GTPases, the p47 
GBPs and the Mx proteins. In humans two Mx proteins have been 
identified, MxA and MxB (Haller et al., 1979; Lindenmann, 1962; 1964). 
These are cytoplasmic proteins and of the two proteins MxA is the only 
one with antiviral activity (Haller et al., 1995). However, MxA is able to 
translocate to the nucleus once it has been equipped with a nuclear 
localisation signal. The Mx proteins consist of a large N-terminus GTPase 
domain, a central interacting domain (CID) and a C-terminus leucine 
zipper. The CID and the leucine zipper domain are needed for viral 
recognition. Mx proteins are located at the smooth endoplasmic reticulum 
where they target viral nucleocapsid-like particles and trap viral 
components, thus preventing secondary transcription and virus replication 
(Accola et al., 2002; Kochs & Haller, 1999; Pavlovic et al., 1992).  
 
Studies on influenza demonstrated that avian influenza virus was more 
sensitive to MxA than human IAV (Dittmann et al., 2008). When avian and 
human strains were compared in minireplicon studies it was shown that 
MxA targeted the viral nucleoprotein. These findings would suggest that 
MxA confers a barrier to prevent transmission between birds and humans 
(Dittmann et al., 2008; Haller & Kochs, 2011). 
 
Human MxA also inhibits Coxsackie virus, Hepatitis B virus (HBV), and 
members of the Bunyaviridae (Andersson et al., 2004; Chieux et al., 2001; 
Gordien et al., 2001). It has also been demonstrated that MxA 
polymorphism can result in higher susceptibility to Hepatitis C virus (HCV) 
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and HBV. It was also true for MeV, where polymorphism in MxA resulted 
in higher rates of SSPE (Hijikata et al., 2000; Suzuki et al., 2004; Torisu et 
al., 2004).  
 
OAS/RNaseL 
The 2’-5’-oligoadenylate synthase (OAS) proteins are present in the 
cytoplasm where they act as sensors of viral dsRNA (Sadler & Williams, 
2008). Double stranded RNA activates OAS which then synthesises 2’-5’-
oligoadenylate oligomers from ATP. Subsequently, the 2’-5’-
oligoadenylate oligomers activate the constitutively expressed but inactive 
RNaseL that is expressed in most tissues (Zhou et al., 2005). RNaseL 
consists of two kinase-like domains and eight ankyrin repeats (Silverman, 
2007). Ankyrin binding of the 2’-5’-oligomers causes homodimerisation 
and activation occurs (Nakanishi et al., 2005). Activated RNaseL cleaves 
both cellular and viral RNAs and causes damage to the cell machinery of 
the host cell, particularly the ribosome, as well as inducing apoptosis 
(Castelli et al., 1997; 1998; Silverman, 2007; Silverman et al., 1983; 
Wreschner et al., 1981). The short RNA fragments produced by RNaseL 
can bind to RIG-I and MDA5 and induce IFN (Malathi et al., 2007; 
Silverman, 2007).  
 
Studies with RNaseL-deficient mice showed a higher susceptibility to RNA 
viruses, such as members of the Picornaviridae, Paramyxoviridae, 
Reoviridae, Orthomyxoviridae, Togaviridae, Flaviviridae and Retroviridae 
families (Silverman, 2007). However, poliovirus and other group C 
enteroviruses contain a region known as RNaseL ciRNA that inhibits 
RNaseL (Townsend et al., 2008a, b).  
 
PKR 
PKR is constitutively expressed at low levels in all tissues and is induced 
by type I and III IFNs (Ank et al., 2006). PKR is kept in an inactive state 
but by binding to ligands, such as viral RNA, PKR is released from the 
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hindrance of its N-terminus (Gelev et al., 2006; Nanduri et al., 2000). 
Activation requires homodimerisation and autophosphorylation at several 
residues (Dey et al., 2005; Romano et al., 1998; Taylor et al., 1996). The 
N-terminus of PKR contains two RNA-binding motifs (RBMs) and dsRNA 
longer than 30 bp activates PKR most effectively. PKR phosphorylates the 
translation initiation factor eIF2! which ultimately results in translation 
inhibition (Dar et al., 2005).  
 
PML 
Promyelocytic leukaemia (PML) protein localises in nuclear bodies that 
contain many other proteins which are IFN-inducible. Both type I and II 
IFNs lead to enhanced transcription and increases of the size and number 
of PML nuclear bodies (Chelbi-Alix et al., 1995). PML nuclear bodies are 
involved in apoptosis, DNA damage, viral infection and IFN responses 
(Everett & Chelbi-Alix, 2007; Geoffroy & Chelbi-Alix, 2011). Many viruses, 
including HSV-1, adenovirus, HIV-1 and IAV, encode proteins that 
colocalise with PML and alter the nuclear bodies (Iki et al., 2005; Maul et 
al., 1993; Perfettini et al., 2009; Puvion-Dutilleul et al., 1995). This 
suggests that PML nuclear body alterations might be a viral defense 
strategy to evade cellular antiviral mechanisms (Everett & Chelbi-Alix, 
2007; Tavalai & Stamminger, 2008).   
 
ISG15 
ISG15 is an IFN-inducible ubiquitin homologue that is bound to 
intracellular proteins in a process that is called ISGylation (Loeb & Haas, 
1992). Like ubiquitination, ISGylation requires an E1 activating enzyme, an 
E2 conjugating enzyme and an E3 ligase. Unlike ubiquitination, which 
generally leads to degradation of proteins by proteasomes, ISGylation 
results in protein translocation, protein stabilisation and modulation of 
enzyme functions (Sadler & Williams, 2008). Furthermore, ISG15 prevents 
virus-mediated degradation of IRF3, which ultimately results in 
enhancement of IFN induction. Many proteins involved in the IFN 
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response undergo conjugation by ISG15, such as STAT1, JAK1, RIG-I, 
and MxA (Zhao et al., 2005). In addition, ISG15 acts as a cytokine and is 
secreted in large amounts during a virus infection. The antiviral properties 
of ISG15 have been described for several viruses, including HSV-1, 
Sindbis virus (SV), IAV and influenza B virus (IBV) (Lenschow et al., 2005; 
Sadler & Williams, 2008). Protein conjunction by ISG15 may also serve as 
a negative regulator of the IFN response, as RIG-I ISGylation has been 
implicated in inhibiting the stimulation of the IFN-" promoter during NDV 
infection (Kim et al., 2008).  
 
ISG56 
ISG56 (also known as IFIT1) was discovered early on as a protein induced 
by viruses and type I IFNs (Chebath et al., 1983; Kusari & Sen, 1986). 
Four members have been identified in humans, ISG56/IFIT1, ISG54/IFIT2, 
ISG60/IFIT3, and ISG58/IFIT4 (Bluyssen et al., 1994; de Veer et al., 2002; 
Lee et al., 1994; Levy et al., 1986; Niikura et al., 1997; Smith & 
Herschman, 1996; Yu et al., 1997; Zhu et al., 1997).  
ISG56 is characterised by having only two exons, the first of which 
encodes only the 5’ UTR and the ATG start codon, and the second 
encodes the rest of the mRNA. Two ISREs are located in the promoter 
region of ISG56 and are recognised by activated IRFs which induce 
transcription (Bluyssen et al., 1994; Darnell et al., 1994; de Veer et al., 
2002; Levy et al., 1986; Tamura et al., 2008; Yu et al., 1997).  
 
PAMPs of both bacterial and viral origin can, independently of IFN, induce 
the transcription of ISG56 via IRF3 (Bandyopadhyay et al., 1995; Elco et 
al., 2005) and therefore ISG56 is termed a viral stress-inducible gene 
(VSIG) (Sarkar et al., 2004). IRF3 activated by dsRNA via RIG-I or MDA5 
strongly induces ISG56 and is therefore often used as a control of IRF3 
transcriptional activity (Chattopadhyay et al., 2010). ISG56 is a 
cytoplasmic protein without enzymatic activity but with tetratricopeptide 
repeats (TPR) which allow protein-protein interactions (D'Andrea & Regan, 
             1  Introduction: the interferon response
  
 
 45 
2003) (Fig. 1.10). The best characterised function of ISG56 is inhibition of 
translation. Human ISG56 can inhibit cellular translation by as much as 
40% by binding subunits of the eIF3 protein complex (Guo et al., 2000). 
Both ISG54 and ISG56 bind eIF3e (also called p48) thereby inhibiting 
complex formation (Guo et al., 2000; Hui et al., 2003; Terenzi et al., 2006).  
 
 
Figure 1.10: Functions of the ISG56 gene family. Human ISG56 is involved in 
translation inhibition by binding the eIF3 complex and inhibition of HPV DNA replication. 
Furthermore, ISG56 functions as a negative regulator of IFN-" induction by disrupting the 
STING/IPS-1 and STING/TBK-1 complexes. Adapted from (Fensterl & Sen, 2011).  
 
However, ISG56 also exhibits antiviral functions, as studies have 
demonstrated that ISG56 inhibits HCV translation through its binding to 
eIF3. HCV is a positive strand RNA virus that instead of a cap structure 
has an IRES that requires eIF3 (Lukavsky, 2009). ISG56 has been 
discovered in ribosomal complexes with eIF3 and HCV RNA (Wang et al., 
2003). Furthermore, ISG56 can induce complete inhibition of human 
papillomavirus (HPV) DNA replication by binding to the HPV E1 helicase 
and it also sequesters E1 in the cytoplasm, thus separating E1 from the 
rest of the viral genome in the nucleus (Terenzi et al., 2008). In contrast, 
ISG56 does not appear to have an antiviral effect on bunyamwera virus 
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(Carlton-Smith & Elliott, 2012). Recently, ISG56 has been suggested to 
bind the cap structure of some viral mRNAs. Most cellular eukaryotic cap 
structures are methylated both at the N-7 position and at the 2’-O site. 
Viruses that replicate in the cytoplasm utilise methyltransferases that 
facilitate capping of viral mRNAs or, alternatively, they “cap snatch” 
cellular caps (Decroly et al., 2012). N-7 methylation is important for 
translation and RNA stability, but the role of the 2’-O methylation has 
remained unknown (Figure 1.11). Recently, mutational studies with viruses 
lacking a methylated 2’-O site suggested that ISG56 recognises this 
unmethylated 2’-O and this is how ISG56 can distinguish cellular mRNAs 
from viral mRNAs (Daffis et al., 2010; Szretter et al., 2012; Zust et al., 
2011). 
 
 
 
Figure 1.11: cap structure of eukaryotic mRNA. Sites for N-7 methylation is shaded 
green and 2’-O methylation sites are shaded red (Decroly et al., 2011).  
 
ISG56 is also a negative regulator of antiviral responses. IFN-" induction 
is initiated by RIG-I and MDA5, resulting in recruitment of IPS-1 and 
STING (Ishikawa & Barber, 2008; Takeuchi & Akira, 2010; Zhong et al., 
2008). During infection with SeV, ISG56 binds STING which dismantles 
the STING/MAVS and STING/TBK-1 complexes (Li et al., 2009b). 
Consequently, this results in inhibition of IRF3- and NF-%B-dependent 
activation of the IFN-" gene.  
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Other ISGs 
Several other ISGs have been implicated in the IFN response, for example 
TRIM proteins, ISG20, the restriction factors apolipoprotein B mRNA-
editing enzyme-catalytic polypeptide-like (APOBEC) 3F and 3G, and 
adenosine deaminases. Members of the TRIM family play a role in 
apoptosis and innate immunity (Carthagena et al., 2009; Ozato et al., 
2008) with 16 and 8 members upregulated  by type I and type II IFN, 
respectively. TRIM5!, TRIM19/PML and TRIM25 all have ISREs in their 
promoter region, thus are directly induced by IFN (Carthagena et al., 
2009). TRIM22 acts as a suppressor of HBV transcription and targets the 
viral 3C protease of encephalomyocarditis virus (Eldin et al., 2009; Gao et 
al., 2009). Furthermore, TRIM25 is essential for ubiquitylation of RIG-I and 
for the RIG-I-mediated IFN response to RNA virus infection (Gack et al., 
2007). ISG20 is a 3’-5’ exonuclease that degrades ssRNA (Degols et al., 
2007). Adenosine deaminase mutates dsRNA by converting adenosine to 
inosine (Zahn et al., 2007). The APOBEC enzymes mutate the viral 
template and inhibit the reverse transcription of retroviruses (Ying et al., 
2007). 
 
Interferon and apoptosis 
Establishing a pro-apoptotic state in infected cells is advantageous for the 
host organism, as it ensures that virus spread is limited. PKR and RNaseL 
are both involved in apoptosis and are activated by virus dsRNA (Castelli 
et al., 1998; García et al., 2006). Several viruses induce apoptosis through 
PKR but sometimes apoptosis is mediated via eIF2! pathways 
(Balachandran et al., 2000; Gaddy & Lyles, 2007; Gil et al., 1999; 
Scheuner et al., 2006; Srivastava et al., 1998; Zhang & Samuel, 2007). 
Furthermore, the apoptosis-activating gene p53 is induced by IFN and can 
either be activated by a virus infection or by dsRNA (Takaoka et al., 2003).  
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Virus antagonism 
As the IFN system is such a powerful antiviral response it is not surprising 
that viruses have developed countermeasures to circumvent the IFN 
response (Bonjardim et al., 2009; Randall & Goodbourn, 2008). These 
countermeasures include inhibition of IFN induction, signalling and the 
function of interferon-stimulated genes. In addition, viruses can also 
induce a general inhibition of transcription and translation. Inhibition of 
cellular transcription and protein synthesis is advantageous for the virus as 
it inhibits IFN and the expression of antiviral ISGs. However, induction of 
host cell protein shut-off prevents the virus from using the cellular 
transcription and translation machinery. Bunyamwera virus encodes the 
NSs protein that targets human polymerase II, thereby blocking host cell 
transcription and subsequently translation (Thomas et al., 2004). Similarly, 
foot and mouth disease virus (FMDV) induces cellular protein shut-off 
(Chinsangaram et al., 1999), while the 3A protein of picornaviruses inhibits 
protein secretion (Choe et al., 2005). In most cases viruses use several 
mechanisms to promote more efficient IFN evasion, such as encoding a 
multifunctional viral protein that targets the IFN response in several 
different ways, such as the NS1 protein of influenza virus and the V 
protein of many paramyxoviruses (Andrejeva et al., 2004; Didcock et al., 
1999a, b; Hale et al., 2008; Poole et al., 2002).  
 
Inhibition of IFN induction 
Many viruses target cellular recognition of PAMPs, such as by encoding 
proteins that bind and sequester dsRNA. VACV protein E3L (Deng et al., 
2008; Xiang et al., 2002) and Ebola virus VP35 (Cárdenas et al., 2006; 
Hartman et al., 2006) bind intracellular dsRNA to block the IFN response. 
Instead of binding dsRNA, the BVDV Erns glycoprotein degrades dsRNA 
through its RNase activity (Iqbal et al., 2004). Another method employed 
by viruses is to interfere with RIG-I/MDA5 signalling and TLR signalling. 
The NS1 protein of IAV inhibits RIG-I activity while the V protein of many 
paramyxoviruses binds to and inhibits MDA5, and indirectly inhibits RIG-I 
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(Andrejeva et al., 2004; Childs et al., 2012; Hale et al., 2008). The HCV 
protease NS3/4A cleaves TRIF thus inhibiting downstream TLR signalling. 
NS3/4A also cleaves IPS-1 and prevents its activation of TBK-1 and IKK' 
(Cheng et al., 2006; Kaukinen et al., 2006; Li et al., 2005; Lin et al., 2006a; 
Loo et al., 2006; Meylan et al., 2005). Furthermore, the HPV E7 protein 
and the E3 protein of adenovirus (Friedman & Horwitz, 2002; Spitkovsky 
et al., 2002) inhibit NF-%B activation by associating with the IKK complex 
thereby preventing NF-%B from migrating to the nucleus.  Moreover, 
another viral strategy is to block IRF3 activation. HPV encodes the E6 
protein that binds and sequesters IRF3 (Ronco et al., 1998) while bovine 
viral diarrhoea virus (BVDV) and classical swine fever virus (through their 
Npro proteases) target IRF3 for proteasomal degradation (Bauhofer et al., 
2007; Graff et al., 2007; Hilton et al., 2006; Ruggli et al., 2005).  
 
Inhibition of IFN signalling 
As with inhibition of IFN induction, viruses target IFN signalling in many 
different ways. Many viruses, such as poxviruses, encode soluble proteins 
that bind IFN-! and IFN-# and sequester extracellular IFNs thus 
preventing receptor activation (Alcamí & Smith, 1995; Colamonici et al., 
1995; Mossman et al., 1995; Symons et al., 1995; Upton et al., 1992). 
These soluble proteins are also capable of binding to the surface of 
uninfected and infected cells and prevent the induction of an antiviral state 
(Alcamí et al., 2000). A common target of viral IFN antagonists is the 
Jak/STAT pathway, either by degradation, inhibition or inactivation of the 
components. The HPV E6 protein, the Japanese encephalitis virus (JEV) 
NS5 protein and Dengue virus block the activation of Tyk2 (Ho et al., 
2005; Li et al., 1999; Lin et al., 2004; 2006b). The human cytomegalovirus 
(CMV) degrades JAK1 and murine polyoma virus inactivates signalling 
through binding to JAK1, whereas HSV-1 decreases JAK1 expression 
(Chee & Roizman, 2004; Miller et al., 1998; 1999; Weihua et al., 1998). 
This is a particularly advantageous viral strategy as JAK1 is involved in 
both type I and II IFN signalling and therefore both pathways are inhibited.  
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The V proteins of paramyxoviruses have an important function in viral 
countermeasures and target many members of the STAT family. STAT1 
and STAT3 are targeted by MuV while STAT2 is targeted by human PIV2. 
A range of Rubulaviruses target only STAT1, including PIV5 and simian 
virus 41 (SV41), but also the Avulavirus NDV (Andrejeva et al., 2002b; 
Didcock et al., 1999b; Huang et al., 2003; Kubota et al., 2001; Nishio et 
al., 2001; Parisien et al., 2001; Precious et al., 2005b; Ulane et al., 2003; 
Young et al., 2000). In an SeV infection, the C protein targets STAT1 for 
ubiquitination and also inhibits phosphorylation of STAT1 (Garcin et al., 
1999; 2002; 2003; Young et al., 2000). The HCV core protein prevents the 
association of STAT1 with STAT2 and the subsequent formation of ISGF3 
(Lin et al., 2006c). VACV encodes the VH1 phosphatase that 
dephosphorylates STAT1 (Najarro et al., 2001). Another method of IFN 
antagonism is to sequester STAT proteins and prevent the STAT1/STAT2 
complex from translocating to the nucleus. The V proteins of RPV, HeV, 
NiV and MeV all sequester STAT1 (Nanda & Baron, 2006; Palosaari et al., 
2003; Rodriguez et al., 2002; 2003) whereas the human CMV IE1 protein 
binds STAT1/STAT2 and prevents ISGF3 association with the ISRE 
(Paulus et al., 2006). Additionally, IRF9 is targeted by viruses, such as the 
E7 oncoprotein of HPV16, which subsequently blocks ISGF3 formation 
(Barnard & McMillan, 1999).  
 
Inhibition of ISGs 
Several viruses sequester dsRNA to minimise activation of PKR and OAS, 
but sequestration does not block PKR activation by PACT (PKR-
associated activator) and therefore viruses such as influenza specifically 
target PKR (Li et al., 2006b; Tan & Katze, 1998). Furthermore, viral 
strategies include preventing PKR dimerisation by the VA-RNA of 
adenovirus, or by inhibiting the activity of PKR, which is done by the NS1 
protein of influenza virus, the NS5A and E2 of HCV, and PK2 of 
baculovirus (Langland et al., 2006). Additionally, viral proteins can 
degrade PKR, for example the poliovirus protease, or induce expression of 
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cellular inhibitors of PKR, such as NS1 of influenza that induces the 
expression of p58IPK (Langland et al., 2006). Some of the mechanisms of 
the ubiquitin-like ISG15 are still unknown, but since many viruses interfere 
with the activity of ISG15, it has been suggested to be of importance in the 
antiviral response. The NS1 protein of influenza B virus binds ISG15 and 
blocks the interaction of NS1 with the E1 ligase of ISG15 (Yuan & Krug, 
2001). The cytidine deaminases APOBEC3F and 3G are targeted by HIV 
and other lentiviruses by encoding a protein called vif, which forms a 
complex with cellular E3 ligases and this results in ubiquitination and 
degradation of APOBEC3 proteins (Malim, 2006; Soros & Greene, 2007). 
Viruses also have several mechanisms for indirect inhibition of the antiviral 
response, such as inhibiting apoptosis and controlling the cell cycle. 
 
Antiviral functions of PIV5 V protein 
PIV5 is a poor inducer of IFN and efficiently evades the IFN response 
through limiting IFN production and signalling. This important function is 
credited to the multifunctional V protein (Andrejeva et al., 2004; Didcock et 
al., 1999a, b; Poole et al., 2002). The V protein inhibits IFN signalling (both 
type I and II IFNs) by targeting STAT1 for proteasomal degradation 
(Andrejeva et al., 2002b; Didcock et al., 1999a, b; Young et al., 2000). As 
mentioned above, V interacts with DDB1 that forms E3 ligase complexes 
together with Cullin 4a. The interaction of V with DDB1 is critical for 
STAT1 degradation, and, in addition, STAT2 is essential in STAT1 
degradation by V (Andrejeva et al., 2002a; Lin et al., 1998; Parisien et al., 
2002; Shiyanov et al., 1999). It has been suggested that STAT1 
degradation requires the V, STAT1, STAT2, DDB1 and Cullin 4a 
multiprotein complex (Precious et al., 2005a; Ulane & Horvath, 2002). It 
has also been demonstrated that V is unable to bind STAT1 directly but is 
able to bind STAT2 and DDB1. It is believed that V acts as an adaptor that 
recruits STAT1 via its interaction with STAT2 (Precious et al., 2005a; 
2007). Strains of PIV5 with naturally occurring differences in their ability to 
block IFN signalling have been discovered. The CPI- strain was isolated 
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from a dog infected with the PIV5 strain CPI+ (Baumgärtner et al., 1981). 
CPI+ is capable of inhibiting IFN signalling, but in CPI-, three amino acid 
substitutions in the N-terminus of V rendered this strain unable to degrade 
STAT1 (Chatziandreou et al., 2002).  
 
V also binds to and inhibits MDA5 thus inhibiting IFN induction (Andrejeva 
et al., 2004; He et al., 2002; Poole et al., 2002). This interaction is specific 
to MDA5 as RIG-I is unaffected by V (Childs et al., 2007; Komatsu et al., 
2007; Yoneyama et al., 2005). It is believed that V competes with dsRNA 
for MDA5 binding to inhibit MDA5 activation (Childs et al., 2007; 2009).  
 
V has RNA-binding activity and inhibits replication and translation of viral 
RNA. It has been proposed that this is to prevent production of defective 
RNAs that may activate IFN (Dillon & Parks, 2007; Gainey et al., 2008; Lin 
et al., 1997; 2005). Thus, it appears that V limits antiviral induction by 
limiting viral RNA production.  
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Aims 
 
To further investigate the effect of IFN on PIV5 transcription and 
translation, in particular the effect of the interferon-stimulated gene ISG56, 
which has been identified to be primarily responsible for inhibiting PIV5.  
 
To define the relationships between various PIV5 isolates, analysed by 
next generation sequencing and identify areas of nucleotide variation.  
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2 Materials and methods 
 
Cell and virus culture 
Table 2.1: Cell lines 
Cell line Description 
BSRT7/5 Baby hamster kidney cells constitutively 
expressing the T7 RNA polymerase. Supplied 
by Prof. R. M. Elliott. 
Hep2 Human cervical epithelial cells. 
Hep2/sh56 Hep2 cells expressing shRNA that knocks 
down ISG56. Supplied by Lena Andrejeva. 
Hep2/BVDV/Npro Hep2 cells expressing the Npro protein of 
BVDV. 
Hep2/BVDV/Npro/sh56 Hep2 cells expressing the Npro protein of 
BVDV and shRNA that knocks down ISG56. 
Supplied by Lena Andrejeva. 
Hep2/BVDV/Npro/T7 Hep2 cells expressing the Npro protein of 
BVDV and expresses the T7 RNA polymerase. 
Generated in this study. 
Vero Fibroblast-like African Green Monkey kidney 
cells. 
 
Cell maintenance 
Cryogenically frozen cells were resuscitated by thawing at 37°C, followed 
by centrifugation at 1000 rpm and resuspension in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen) supplemented with 10% foetal calf 
serum (FCS; Biowest). Cell monolayers were maintained in 25 cm2 or 75 
cm2 tissue culture flasks (Greiner, UK). Cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2. When confluent, cells were 
passaged using Trypsin/EDTA. 
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To freeze cell stocks, the cells were first trypsinised and then centrifuged 
at 1000 rpm for 5 minutes. The pelleted cells were resuspended in DMEM 
containing 20% FCS and 10% DMSO, then aliquoted into cryovials, and 
frozen at -70°C before storage in liquid nitrogen.  
 
Treatment of cells 
IFN treatment 
Cells were treated for 10-16 hours with DMEM/2% FCS supplemented 
with recombinant human IFN!-2a (Roferon-A, Roche Diagnostics) at a 
concentration of 1000 units/ml. 
 
CHX treatment 
Cycloheximide (CHX) at a concentration of 20 µg/ml (unless otherwise 
stated) was added to the cell medium and left overnight at 37°C/5% CO2. 
 
Table 2.2: Viruses 
Virus strains Description 
W3A wild-type of PIV5. 
V)CvM2 PIV5 strain with a deleted C-terminus of the V protein that 
has been passaged twice. 
CPI+ Canine strain of PIV5 isolated in Germany. 
CPI- Canine strain of PIV5 isolated in Germany. 
SER Porcine isolate of PIV5. 
DEN Human isolate of PIV5 from multiple sclerosis patient. 
MEL Human isolate of PIV5 from multiple sclerosis patient. 
MIL Human isolate of PIV5 from multiple sclerosis patient. 
LN Human isolate of PIV5 from multiple sclerosis patient. 
RQ Human isolate of PIV5 from multiple sclerosis patient. 
78524 Canine strain of PIV5 isolated in Scotland 
H221 Canine strain of PIV5 isolated in Scotland. 
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Preparation of virus stocks 
Stocks of PIV5-V)CvM2 were maintained and kindly provided by Dan 
Young (University of St Andrews, UK). 
 
Vero cells at 90% confluency were infected with the virus master stock 
(prepared by Dan Young) and incubated at 37°C and 5% CO2 until 
cytopathic effect was visible in the monolayer. Subsequently, the 
supernatant was harvested and centrifuged at 2000 rpm for 5 minutes to 
remove cellular debris. The supernatant was then used to infect larger 
monolayers grown in roller bottles. Cells were incubated with the virus 
inoculum on a rolling platform for 1-2 hours at 37°C before it was replaced 
with fresh DMEM supplemented with 2% FCS. When fusion could be 
detected in the cell monolayer (approximately two days later), the 
supernatant was harvested and centrifuged to precipitate cell debris, 
aliquoted into cryovials and stored at -70°C. Virus titers were determined 
as described below. 
 
Virus infection 
Cell monolayers were infected at a multiplicity of infection (MOI) of 10 
pfu/cell. The inoculum containing virus stocks diluted in DMEM with 2% 
FCS (200 µl per well of a 6-well plate) was added to the cell monolayer. 
The cells were incubated with the inoculum (with DMEM/2% FCS) on a 
rocking platform at 37°C. The inoculum was replaced with fresh DMEM 
containing 2% FCS at 1h post-infection. 
 
Virus titration 
Vero cells were grown in 6-well plates (Greiner, UK) until 80-90% 
confluent. Cells were incubated with 10-fold dilutions of virus and DMEM 
containing 2% FCS (1 ml/well). After 1 hour on a rocking platform at 37°C 
the inoculum was removed and 5-7 ml of medium overlay (0.5% Methocel; 
Sigma-Aldrich) was added to each well. Cells were incubated at 37°C and 
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5% CO2 for 10-12 days until plaques had formed in the monolayer. The 
overlay was then aspirated and plaques were fixed with 5% formaldehyde 
in PBS for 10-15 minutes. Plaques were stained with crystal violet (0.1% 
crystal violet, 3.6% formaldehyde, 1% methanol, 20% ethanol in H2O). 
Virus titres were then estimated in pfu/ml, taking into account the original 
dilutions made.  
 
Lentivirus infection 
Hep2/BVDV/Npro cells at 30% confluency were infected with lentivirus in 
the presence of polybrene (8 µg/ml). Cells were selected by resistance to 
blasticidin (10 µg/ml) 48h post-infection and were kept under blasticidin 
selection until the naïve control cells were dead.  
 
 
Table 2.3: Plasmids 
Plasmid Description 
pCAGGS Parental vector used in 
transfections. 
pCAGGS-FFLuc Plasmid expressing the firefly 
luciferase gene. 
pCAGGS-HN Plasmid expressing the full-length 
HN gene. 
pCAGGS-L Plasmid expressing full-length L 
gene. 
pCAGGS-M Plasmid expressing full-length M 
gene. 
pCAGGS-NP Plasmid expressing full-length NP 
gene. 
pCAGGS-P Plasmid expressing full-length P 
gene. 
pGEM-Teasy Linear vector with T overhangs 
(Promega). 
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pGEM-P Plasmid expressing the full-length P 
gene. 
pGEM-PIV5le Plasmid expressing leader of PIV5. 
pGEM-PIV5tr Plasmid expressing trailer of PIV5. 
pMG-RLUC Plasmid expressing the Renilla 
luciferase gene flanked by the 
UTRs of PIV5. 
pSPT19 Parental vector used to determine 
primer efficiency. 
pSPT19-Actin Plasmid expressing the human "-
actin gene. 
pSPT19-L Plasmid expressing the PIV5 L 
gene. 
pSPT19-NP Plasmid expressing the PIV5 NP 
gene. 
phRL-CMV Plasmid expressing human Renilla 
luciferase under the control of a 
CMV promoter. 
pT7BUNMREN(-) Plasmid expressing the Renilla 
luciferase gene flanked by the 
UTRs of BUNV M segment 
pTM1-FFLuc Plasmid under the control of the T7 
RNA polymerase expressing firefly 
luciferase gene. 
pTM1-L Plasmid under the control of the T7 
RNA polymerase expressing BUNV 
L segment. 
pTM1-S Plasmid under the control of the T7 
RNA polymerase expressing BUNV 
S segment. 
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Prof. Biao He (University of Georgia, USA) kindly provided the following 
plasmids: pCAGGS-FFLuc, pCAGGS-NP, pCAGGS-P, pCAGGS-L and 
pMG-RLuc. 
Prof. Richard Elliott (University of St Andrews, UK) kindly provided pTM1-
S, pTM1-L, pTM1-FFLuc, phRL-CMV and pT7BUNMREN(-) plasmids.  
 
Preparation of competent cells 
JM109 E. coli bacteria were grown in 50 ml of Luria-Bertani (LB) medium 
in a shaker incubator at 37°C until the OD600nm was in the range of 0.4-0.6.  
The competent cells were then prepared with the Z-Competent* E. coli 
Transformation Kit (ZYMO RESEARCH) according to the manufacturer’s 
instructions.  
 
Transformation of competent cells 
Plasmid DNA (1 µl) was mixed with 50-100 µl of competent cells and 
incubated for 20 minutes on ice. The suspension was plated on pre-
warmed LB-agar plates supplemented with ampicillin (90 mm-diameter 
Petri dishes; Scientific Laboratory Supplies). Plates were inverted and 
incubated at 37°C overnight. Bacterial colonies were picked for 
preparation of plasmid DNA. 
 
Preparation of plasmid DNA 
For small-scale preparations, colonies were grown in 10 ml of LB 
supplemented with ampicillin (100 µg/ml) overnight in an incubator at 37°C 
and with shaking at 200 rpm. DNA was extracted and purified using the 
QIAprep Spin Mini-prep kit (QIAGEN) according to the manufacturer’s 
instructions. For large-scale preparations, colonies were grown in 50 ml of 
LB with ampicillin overnight at 37°C with shaking at 200 rpm. DNA was 
extracted and purified using the QIAfilter Plasmid maxi-prep kit (QIAGEN). 
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Determination of DNA concentration 
The plasmid DNA concentration was quantified by measuring the Abs260 
using a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific). The 
purity of the DNA was estimated by calculating the Abs260/Abs280 ratio. 
Ratios between 1.8 and 2.0 were considered acceptable. 
 
Protein analysis 
SDS-polyacrylamide gel electrophoresis 
Mammalian cells were lysed by adding disruption buffer (6M Urea, 4% 
(w/v) SDS, 2M "-mercaptoethanol coloured with bromophenol blue). 
Lysates were sonicated (15 seconds) to reduce viscosity and proteins 
were separated on 4-12% NuPAGE polyacrylamide gradient gels 
(Invitrogen) by electrophoresis at 170V, 1 hour in MOPS [3-(N-morpholino) 
propanesulphonic acid] buffer (Invitrogen). 
 
Immunoblotting 
Proteins were separated by SDS-PAGE as described above and 
transferred to a polyvinylidene difluoride (PVDF) membrane using the 
XCell II Blot Module according to the manufacturer’s instructions 
(Invitrogen). The membranes were then incubated for 1 hour in blocking 
buffer (0.1% Tween 20 in PBS), followed by a further incubation for 1 hour 
to overnight with primary antibody diluted in blocking buffer. After multiple 
washes with 0.1% Tween 20 in PBS, membranes were incubated with 
secondary antibody conjugated with horseradish peroxidase (HRP) for 1 to 
3 hours. This was followed by washing again with 0.1% Tween 20 in PBS 
before proteins were detected using ECL Plus Western Blotting Detection 
Reagents (GE Healthcare). Membranes were then exposed to Kodak X-
Omat film.  
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Table 2.4: Antibodies 
Target protein Manufacturer 
PIV5-NP-a (monoclonal) (Randall et al., 1987) 
PIV5-P-e (monoclonal) (Randall et al., 1987) 
PIV5-M-f (monoclonal) (Randall et al., 1987) 
PIV5-M-h (monoclonal) (Randall et al., 1987) 
PIV5-HN-4a (monoclonal) (Randall et al., 1987) 
PIV5-SH (polyclonal) Kindly given by Prof. Biao He 
(University of Georgia, USA) 
"-actin (monoclonal) Sigma-Aldrich 
ISG56 (polyclonal) Santa Cruz 
 
 
[35S]-methionine radiolabelling 
Cells were metabolically labelled with [35S]-methionine (30 µCi/25 cm2 
flask) together in methionine-free DMEM (Sigma) supplemented with 
glutamine (2 µM) for 1 hour at 37°C. The cells were then lysed with 
immunoprecipitation buffer (20mM Tris-HCl [pH 7.8], 1 mM EDTA, 0.65M 
NaCl, 0.3% NP-40) containing protease inhibitor (Complete, Roche). The 
cells were then centrifuged at 13,000 rpm for 30 min and the pellet was 
removed. The cell lysates were then sonicated for 15 seconds and 
incubated with Protein G-Sepharose beads (Sigma) pre-coupled with 
antibodies in a rotating machine at 4°C for 1.5 hours with constant 
rotation. The beads were then spun down briefly and the supernatant was 
aspirated. The beads were washed with immunoprecipitation (1 ml) 
multiple times before dissociation of protein-antibody complex by heating 
in SDS-PAGE loading buffer at 99°C for 5 min. Proteins were then 
analysed by SDS-PAGE. 
 
 
                                                                              2  Materials and methods 
 
 62 
DNA analysis 
All PCR reactions were performed with the GoTaq DNA polymerase 
(Promega). The reactions were prepared using 0.5 ml thin-walled tubes 
and analysed with a thermo cycler, according to the parameters described 
below.  
 
Standard PCR protocol using GoTaq DNA polymerase: 
5x reaction buffer   10 µl 
dNTPs (10 mM each)  1 µl 
DNA template   x µl 
Forward primer (2 µM)  1 µl 
Reverse primer (2 µM)  1 µl 
GoTaq polymerase (5U/ml) 0.25 µl 
dH2O (up to 50 µl)   y µl 
 
PCR programme for GoTaq DNA polymerase: 
Polymerase activation 95°C  2 min 
Denaturation   95°C  30 sec        
Annealing   55°C  30 sec            25 cycles         
Elongation   72°C  1 min 
Final extension  72°C  10 min 
 
Cloning into the pGEM-Teasy vector 
Single adenine residues were added during the PCR reaction by the 
GoTaq DNA polymerase. The DNA fragment was then ligated into the 
pGEM-Teasy vector (Promega) according to the manufacturer’s 
instructions. 
 
Restriction endonuclease digestion 
Restriction digests were performed in 15 or 20 µl reactions according to 
the instructions of each respective enzyme. Enzymes were either from 
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Promega or New England Biolabs. Two µl of 10x reaction buffer, 1 unit of 
enzyme and dH2O to a total volume of 20 µl was incubated either at room 
temperature or 37°C (or other temperature if so required by the 
manufacturer’s instructions). 
 
Agarose gel electrophoresis 
DNA was separated using 1% (w/v) agarose/TAE buffer. Four µg/ml of 
ethidium bromide was added to the agarose before the gels were covered 
in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA). Samples were mixed 
together with loading dye and separated by electrophoresis at 100V. The 
gels were analysed by UV light. 
 
Purification of DNA gel fragments 
DNA fragments were excised with a scalpel under UV light. The gel 
fragments were purified using the Qiaquick Gel Extraction kit (QIAGEN) 
according to the manufacturer’s instructions.  
 
DNA ligation 
For ligation of DNA fragments a 3:1 insert:vector ratio was used. 
 
10x ligation buffer  2 µl 
vector (50 ng)  X µl 
insert (150 ng)  Y µl 
T4 DNA ligase (5U/µl) 1 µl 
H2O    up to 10 or 15 µl 
 
The reaction was incubated at 16°C overnight. 
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RNA analysis 
Total cellular RNA extraction 
Infected cells were lysed using TRIzol (Invitrogen) with either 2 ml (25 cm2 
flask) or 5 ml (75 cm2 flask) of TRIzol. Cell lysates were incubated at room 
temperature for approximately 30 min before being transferred to 1 ml 
Eppendorf tubes and RNA was extracted according to the manufacturer’s 
instructions. 
 
Determination of RNA concentration 
RNA concentration was determined using the same method as for DNA 
concentration as previously described. 
 
RNA reverse transcription 
Complementary DNA was generated in a two-step reaction using reagents 
from Promega, as described below. 
 
RNA (1-2 µg)   X µl 
Reverse primer (5 µM)  1 µl 
H2O     up to 10 µl 
Incubate for 10 min at 72°C in a thermo cycler. 
 
Add the following: 
dNTPs (10 mM each)  2 µl 
DTT (0.1 mM)   2 µl 
5x M-MLV buffer   4 µl 
M-MLV (reverse transcriptase) 1 µl 
RNasin    1 µl 
Incubate for 1 hour at 42°C in a thermo cycler. 
 
Preparation of RNP 
Vero cells were grown in roller bottles and infected when confluent. When 
sufficient CPE was observed, the cells were detached by swirling glass 
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beads together with PBS and centrifuged at 2000 rpm for 10 min. The 
pelleted cells were lysed in ice-cold lysis buffer (150 mM NaCl, 50 mM 
Tris-HCl pH7.5, 0.6% NP-40 and one protease inhibitor [Complete, 
Roche]). Approximately 800 µl of lysis buffer was used per roller bottle. 
The lysed cells were incubated on ice for 5 min followed by a 2 min vortex 
step and then centrifuged for 2 min at 8000 rpm at 4°C. The supernatant 
was then transferred to a fresh tube and re-centrifuged. The supernatant 
was reserved and EDTA was added to bring the final concentration to 6 
mM. A CsCl gradient was then made by adding 2 ml of 25% w/w CsCl (25 
mM Tris-HCl pH 7.5, 2 mM EDTA; 25 g CsCl in 100 g total) and 1.5 ml of 
35% w/w CsCl (25 mM Tris-HCl pH 7.5, 2 mM EDTA; 35 g CsCl in 100 g 
total). The cell extract was added on top of the gradient and centrifuged at 
40,000 rpm overnight. The nucleocapsid band was harvested with a 
syringe and transferred to a fresh Eppendorf tube. The viral RNA was 
purified by TRIzol as previously described. 
 
Real-time quantitative PCR 
Total cellular RNA was extracted using TRIzol as described above and 2 
µg of RNA was then used in a reverse transcription PCR reaction (total 
volume 20 µl). The cDNA produced was subsequently used in the real-
time quantitative PCR reaction, which was performed using a SYBR 
Green-based master mix (MESA Blue MasterMix Plus with ROX, 
Eurogentec). The real-time quantitative PCR reaction is described below. 
 
cDNA      0.5 µl 
Forward primer (5 nM or 25 nM)  0.2 µl 
Reverse primer (5 nM or 25 nM)  0.2 µl 
MESA Blue MasterMix Plus, ROX 10 µl 
RNase free H2O (up to 20 µl)  X µl 
 
Primer concentrations were optimised for each primer pair (see Chapter 3 
for more details). Reactions were prepared in 96-well real-time quantitative 
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PCR plates (Eurogentec). The wells were sealed with a plastic seal 
followed by centrifugation of the plate at 1000 rpm for 2 minutes.  
 
Real-time quantitative PCR program: 
 
Step PCR program Number of 
cycles 
Description 
1 2 min, 60 °C 1 Activates master-
mix 
2 10 min, 95 °C 1 Activates 
polymerase 
3 0.15 min, 95 °C 
1 min, 60 °C 
40 Melt curve step 
Annealing/extension 
 
Real-time quantitative PCR was analysed using a 7300 Applied Biosystem 
Real-Time PCR Systems thermo cycler.  
 
Miscellaneous assays 
Luciferase assay 
These assays were performed using the Dual-Luciferase Reporter Assay 
System (Promega). 24-well plates of confluent cells were transfected with 
plasmid DNA. The total concentration of DNA transfected was kept equal 
by adding different amounts of pCAGGS vector. Transfections were 
performed using Lipofectamine 2000 according to the manufacturer’s 
instructions. The luciferase assay was done 24 hours post-transfection. 
Firefly luciferase plasmid DNA plasmid was used as a transfection control. 
Light emitted was measured with a luminometer (Turner Design) and 
calculated as relative light units (RLU).  
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3 The effect of IFN on PIV5 transcription and 
translation 
 
Introduction 
PIV5 has developed methods of blocking the IFN response in a variety of 
ways. The main viral antagonist is the V protein, that blocks IFN induction 
through its C-terminal cysteine-rich domain (Poole et al., 2002) which 
binds MDA5 (Andrejeva et al., 2004). In addition, it was recently reported 
that V indirectly inhibits RIG-I by forming a complex with LGP2 and RIG-I, 
thus inhibiting RIG-I-mediated IFN induction (Childs et al., 2012). The V 
protein also blocks IFN signalling by targeting STAT1 for proteasome-
mediated degradation (Didcock et al., 1999b). Despite the effective way in 
which PIV5 circumvents the IFN response, much can still be learned about 
the mechanisms of the viral interactions with antiviral effector molecules 
because the ability of PIV5 to block the IFN response is not absolute. 
Some virus infected cells can still secrete small amounts of IFN that will 
induce an antiviral state in the surrounding uninfected cells, which limits 
further spread of the virus (Andrejeva et al., 2002b; Chatziandreou et al., 
2004; Didcock et al., 1999a).  
A gradient effect during virus transcription has been observed for 
paramyxoviruses, as discussed in Chapter 1. PIV5 gene junctions contain 
a gene end, an intergenic region, and a gene start, that control and direct 
transcription. Each gene end contains a signal that is recognised by the 
polymerase to terminate transcription and each gene start contains a 
signal to reinitiate transcription. It is believed the polymerase stays 
attached to the genome through the intergenic regions, but the 
transcription reinitiation occasionally fails and the polymerase can 
disengage from the template. The polymerase can only gain access to the 
genome at a site near the 3’ end. When the polymerase disengages from 
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the genome it cannot reinitiate and instead it needs to re-attach at the 3’ 
end, thus NP mRNA is found most abundantly and L mRNA is the least 
abundant, resulting in a transcriptional gradient (Cattaneo et al., 1987a; 
Villarreal et al., 1976; Whelan et al., 2004).  
 
In order to study the effects of IFN on the replication cycle of PIV5, one 
needs to take into account that wild-type PIV5 blocks the IFN response 
and that cells usually produce IFN when they are infected. To avoid this 
problem, the following experiments have been performed using cell lines 
that have been engineered to express the Npro protein of BVDV that 
targets IRF3 for degradation (Gil et al., 2006; Hilton et al., 2006), therefore 
they cannot produce IFN, only respond to it. By infecting these cells with 
CPI-, a strain that cannot block IFN signalling (Baumgärtner et al., 1987; 
1981; 1982; Chatziandreou et al., 2002; Evermann et al., 1980) it is 
possible to investigate the effects of IFN on PIV5. Another cell line used 
extensively in the model system described above is Vero cells. These cells 
are kidney fibroblast cells from African green monkeys and they are 
incapable of producing IFN due to spontaneous gene deletions (Desmyter 
et al., 1968; Mosca & Pitha, 1986), but can respond to exogenous IFN that 
has been added to the culture medium. In addition to using Vero cells, the 
use of a strain like CPI- enables us to study the effect of IFN on PIV5 
replication without interference of virus countermeasures to IFN signalling.  
 
 
The effect of IFN on PIV5 protein synthesis 
Protein analysis using Vero cells 
Previous data by Carlos et al. (2005) showed that IFN treatment alters the 
pattern of PIV5 protein synthesis, which we wanted to investigate further. 
Vero cells were infected with CPI+ or CPI- at a multiplicity of infection 
(MOI) of 10 pfu/cell. Eight hours post-infection, cells were either treated 
with IFN-! (Roferon, Roche) at a concentration of 1000 U/ml or left 
untreated. Mock infected cells served as a control. Twenty hours post-
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infection the cells were metabolically labelled with [35S]-methionine for 1 
hour, followed by immunoprecipitation of viral proteins. Antibodies specific 
for NP, P, HN and M were used, while L was precipitated as part of a 
complex together with NP and P. The precipitated viral proteins and total 
cellular proteins were separated by electrophoresis and the resolved 
bands were visualised by autoradiography. "-actin was used as a cellular 
loading control, analysed by Western blot.  
As seen in Figure 3.1 lanes 2 and 3, when cells were infected with CPI+ 
there was no apparent difference in the levels of viral protein synthesis 
between the IFN-treated and untreated cells. However, for CPI- there was 
a significant reduction in the levels of viral protein synthesis following IFN 
treatment, especially for M, HN and L (lanes 4 and 5). The levels of total 
cell protein synthesis showed no apparent decrease with or without IFN 
(lanes 7 to 10), suggesting that IFN has a selective effect on virus protein 
synthesis.  
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Figure 3.1: Analysis of protein levels of Vero cells infected with CPI+ or CPI- 
viruses. Vero cells were either treated with 1000 U/ml of IFN-! at 8 hours p.i. or 
left untreated. Mock infected served as a control. Twenty hours p.i., the cells were 
metabolically labelled with [35S]-methionine for 1 hour and viral proteins were 
precipitated with a pool of antibodies to NP, P, M and HN. L was precipitated as 
part of a complex with NP and P. Total cellular and precipitated viral proteins 
were separated by electrophoresis and visualised by autoradiography. Actin 
served as a loading control, analysed by Western blot.  
p.i. = post-infection, m = mock.  
 
Protein analysis of CPI- infected human cells 
From Figure 3.1 it was clear that IFN has an effect on PIV5 protein 
synthesis. It was of interest to see whether this effect could be seen in 
other cell lines as well. The effect of IFN was therefore also investigated in 
the human epithelial cell lines Hep2 and Hep2/BVDV/Npro. Hep2 are IFN 
competent cells, able to produce and respond to IFN following infection, 
while Hep2/BVDV/Npro are IFN deficient due to expression of the Npro 
protein of BVDV and they can, therefore, respond to but not produce IFN. 
The cells were infected with CPI- at an MOI of 10 pfu/cell and treated with 
1000 U/ml of IFN 8 hours post-infection or left untreated. Twenty hours 
post-infection (12 hours post-treatment), the cells were metabolically 
labelled with [35S]-methionine for 1 hour. Viral proteins were then 
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immunoprecipitated with a pool of antibodies as described above. Both 
viral proteins and total cellular proteins were separated on a 
polyacrylamide gel and labelled proteins were visualised by 
autoradiography. "-actin was used as a cellular loading control, analysed 
by Western blot. 
 
Infected Hep2/BVDV/Npro cells resulted in high levels of viral proteins in 
the untreated cells. IFN treatment had a marked effect on viral protein 
synthesis for Hep2/BVDV/Npro cells, specifically for M, HN and L, but not 
so much for NP and P (compare lanes 5 and 6, Fig. 3.2A). Treatment with 
IFN did not reduce levels of total cellular protein synthesis (Fig. 3.2B), 
suggesting that the selective inhibitory effect of IFN seen for Vero cells in 
Figure 3.1 is also true for Hep2/BVDV/Npro cells. As expected, the IFN 
competent Hep2 cells showed reduced levels of viral protein synthesis 
(Fig. 3.2A, lanes 2 and 3), especially for M and HN proteins. However, 
there was no significant difference in the levels of NP and P proteins 
between untreated and IFN-treated cells (compare lanes 2 and 3, Fig. 
3.2A).  
Figure 3.2 illustrates the importance of looking at the levels of total cell 
protein synthesis and not only the levels of immunoprecipitated viral 
proteins. Precipitation makes it easier to detect the viral proteins, 
especially HN, P and L proteins in the case of PIV5, but it is also important 
to stress that immunoprecipitation does not always give a complete picture 
of viral protein synthesis. For example, the levels of precipitated NP in the 
IFN-treated and untreated Hep2/BVDV/Npro cells appeared to be similar, 
but the levels of total cell protein synthesis revealed that there were in fact 
reduced levels of NP in the presence of IFN (compare lanes 5 and 6, Fig. 
3.2B). Therefore, protein synthesis levels of immunoprecipitated virus 
proteins will always be shown together with the levels of total cell protein 
synthesis throughout this thesis. To further confirm the reduction of viral 
protein synthesis in the presence of IFN the protein bands can be 
quantified by phosphorimager analysis. By measuring the intensity of the 
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various bands it is possible to compare the expression of the labelled viral 
proteins in the presence and absence of IFN and determine whether the 
reduction of viral proteins is statistically significant. Protein quantitation of 
CPI- infected Vero cells treated with IFN in a similar manner as in Fig. 3.2 
supports the conclusions drawn from these experiments that IFN 
treatment following infection with CPI- causes a specific reduction of M, 
HN and L proteins (Carlos et al., 2005).  
 
 
Figure 3.2: Protein analysis of CPI- infected Hep2 and Hep2/BVDV/Npro cells. Hep2 
and Hep2/BVDV/Npro cells were infected with CPI- or mock infected (m). The cells were 
IFN-treated 8 hours p.i. (+IFN) or left untreated (-IFN). Twenty-four hours p.i., the cells 
were metabolically labelled with [35S]-methionine for 1 hour and proteins were 
precipitated with viral protein-specific antibodies. Precipitated viral (A) and total cellular 
(B) proteins were separated by SDS-PAGE and visualised by autoradiography. Actin 
served as a loading control, analysed by Western blot. p.i. = post-infection. 
 
Optimisation of real-time quantitative PCR 
There are two methods to quantify RNA: Northern blot analysis and real-
time quantitative PCR. In Northern blotting, RNA is separated by gel 
electrophoresis and hybridised to a labelled probe that is complementary 
to the target sequence. The advantage with Northern blotting is that it is 
possible to distinguish between RNA products, but the method requires 
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large amounts of RNA and is only semi-quantitative as the amount of RNA 
is measured by the intensity of the band. Real-time quantitative PCR, on 
the other hand, is extremely sensitive requiring only small amounts of 
RNA. The real-time quantitative PCR begins with a reverse transcription 
PCR step, where cDNA is synthesised from the total RNA and then used 
as a template for the real-time quantitative PCR reaction.  As the name 
suggests, the levels of RNA are measured in real-time as it is amplified. 
The RNA is then quantified either by relative quantification or by absolute 
quantification. Absolute quantification requires a standard curve to plot the 
cycle threshold (Ct) values obtained from the PCR against known amounts 
of template. Whereas relative quantification does not need a standard 
curve and instead shows the RNA levels of the gene of interest relative to 
a reference gene or untreated samples. Previously, Northern blot analysis 
has suggested that IFN treatment results in an alteration in the 
transcription of PIV5 (Carlos et al., 2005), and we wanted to investigate 
the effects of IFN treatment on virus transcription further by real-time 
relative quantitative PCR.  
 
For this study, SYBR Green I (Eurogentec) was used, which is a double-
stranded intercalating dye that fluoresces when it binds DNA. SYBR 
Green I binds to any double-stranded DNA, including non-specific DNA 
and primer-dimer products. It is therefore important to include a 
dissociation curve (melt curve) in the PCR program that enables one to 
control the specificity of the amplified product. If the amplified product is 
valid, it shows a single, sharp peak. Also included in the SYBR Green I 
master-mix is ROX, a reference dye used as an internal control that 
normalises against any fluctuations in the volume or concentration of the 
master-mix. This gives a higher reproducibility of the PCR assay.  
 
To measure the amount of PIV5 mRNA in IFN-treated and untreated cells, 
primers for NP, P, M, HN, L and "-actin were used. Figure 3.3 is a 
schematic representation of the PIV5 genome and where the primers 
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anneal to the template. The concentration of the primers was optimised by 
serial dilutions and determined at 5 nM per reaction. The primer efficiency 
was calculated by using plasmid DNA with a starting template amount of 
0.001 picomoles followed by 10-fold serial dilutions done in triplicate. 
Table 3.1 shows the primer sequences used to detect mRNA in the real-
time quantitative PCR assay.  
 
Name 5’ + 3’ Description 
1 AGGGTAGAGATCGATGGCT NP forward 
2 GTCTGACCACCATTCCCTT NP reverse 
3 AATACCACCAGGGGTCACAG P forward 
4 CGAGCACCCAAACTGTGCTT P reverse 
5 TCATGAGCCACTGGTGACAT M forward 
6 TGGAATTCCCTCAGTTGTCC M reverse 
7 AACTCTGCAGTCGCTCTACC HN forward 
8 GCAATCTGACACTTGGCCCA HN reverse 
9 TCCAAGTGATGACTTTGAATT L forward 
10 CCATACTCATTACTCGTGTGCC L reverse 
15 ACCAACTGGGACGACATGGAG "-actin forward 
16 TAGCACAGCCTGGATAGCAAC "-actin reverse 
 
Table 3.1: List of primers used for real-time quantitative PCR to quantify viral mRNA. 
 
 
 
Figure 3.3: Schematic figure of primers, and where they bind to the template, used in this 
study for real-time quantitative PCR.  
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The Ct values for each primer pair from the real-time quantitative PCR 
assay were plotted as a standard curve. The slope of this curve gives the 
efficiency of the PCR reaction by the following equation (Pfaffl, 2001): 
 
Efficiency = 10(-1/slope) – 1 
 
When the slope of the standard curve is -3.32, the primer efficiency is 
100%. Acceptable PCR efficiency is 100% ±10%. The slopes obtained 
from the machine software were as follows: 
 
Primer  Slope Efficiency 
NP -3.43 96% 
P -3.17 104% 
M -3.56 90% 
HN -3.38 95% 
L -3.37 95% 
"-actin -3.36 95% 
 
Table 3.2: The 7300 Applied Biosystems Real-Time PCR System software determined 
the slope of the curves. The primer efficiencies were calculated by Pfaffl’s equation 
(Pfaffl, 2001). 
 
 
Figure 3.4: Standard curves obtained for each primer. To calculate the efficiency, the 
formula Efficiency = 10(-1/slope) – 1 was used. 
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Figure 3.5: Melt curves obtained from the PCR assay. 
 
The plotted standard curves in Figure 3.4 determined the slope of the 
curves, which was used in the calculations of the primer efficiency. All 
primers turned out to have a primer efficiency within the range of what is 
acceptable for real-time quantitative PCR. They also gave rise to a single 
peak, which indicated that no primer dimers were made during the 
reaction and that the primers did not bind non-specifically (Fig. 3.5). 
 
Analysis of viral mRNA expression by real-time 
quantitative PCR 
Analysis of viral mRNA levels over a 24 hour time-course 
To determine the optimal time-point in the virus infection to measure levels 
of viral mRNA, a time-course was performed. Hep2/BVDV/Npro cells were 
infected with CPI- at an MOI of 10 pfu/cell. At 6, 12, 18 and 24 hours post-
infection, total RNA was extracted using TRIzol (Invitrogen), followed by 
reverse transcription PCR with oligo d(T) primers to transcribe the RNA to 
cDNA. The cDNA was then used in real-time quantitative PCR using a 
7300 Real-Time PCR System (Applied Biosystems) with primers for NP, 
P, M, HN and L. "-actin was used as an internal control. Annealing and 
extension were both performed at 60 °C during a step consisting of 40 
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cycles, during which amplification data and the melt curve were collected 
(Table 3.3). 
 
Step PCR program Number of 
cycles 
Description 
1 2 min, 60 °C 1 Activates master-
mix 
2 10 min, 95 °C 1 Activates 
polymerase 
3 0.15 min, 95 °C 
1 min, 60 °C 
40 Melt curve step 
Annealing/extension 
 
Table 1.3: Table showing the real-time quantitative PCR program. Amplification data and 
dissociation curve were collected from step 3. 
 
The relative mRNA values were quantified using the comparative Ct 
method: 2-(Ct(gene of interest) – Ct(reference)) (Cikos et al., 2007; Livak & 
Schmittgen, 2001), mRNA values were expressed as the quantity of the 
gene of interest relative to the quantity of "-actin. The samples were 
analysed in triplicate. Non-template sample and non-reverse transcriptase 
sample were analysed routinely as controls. The plotted values in Figure 
3.6 show the quantity of target mRNA relative to the quantity of "-actin 
mRNA over the 24 hour time-course. 
 
The length of a single virus cycle varies between different 
paramyxoviruses but they generally range between 14 to 30 hours (Lamb 
& Parks, 2006). As shown in Figure 3.6, the levels of viral mRNA were low 
at 6 hours post-infection, but increased significantly by 12 and 18 hours 
post-infection. The overall levels of viral mRNA peaked at 18 hours post-
infection, before decreasing by approximately 50% at 24 hours post-
infection. As mentioned, during PIV5 transcription a gradient effect can be 
seen, with higher levels of viral mRNA transcribed by genes closest to the 
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3’ terminus followed by decreasing levels of the subsequent genes. 
Throughout the time-course the same pattern of viral mRNA levels was 
observed, with highest mRNA levels of NP and lowest levels of L mRNA. 
Unexpectedly, at all time-points we saw less M mRNA than HN mRNA, 
which is inconsistent with the transcriptional gradient (discussed later).  
 
 
Figure 3.6: Analysis of mRNA levels of PIV5 genes at different times post-infection. 
Hep2/BVDV/Npro cells were infected with CPI- at an MOI of 10 pfu/cell. Total RNA was 
extracted using TRIzol at the indicated time-points post-infection and the RNA was 
transcribed to cDNA by reverse transcription PCR. Subsequently, the cDNA was used in 
real-time quantitative PCR with primers for NP, P, M, HN, L and "-actin. The levels of 
mRNA were quantified as gene expression of target gene relative to gene expression of 
"-actin. Error bars denote standard error of the mean value of triplicate samples. 
 
Viral mRNA analysis of CPI- infected cells treated with IFN 
Virus mRNA was measured when Hep2/BVDV/Npro and Hep2 cells were 
left untreated or treated with 1000 U/ml of IFN either post-infection or prior 
to infection. With pre-treatment, the cells were IFN-treated 8 hours before 
infection. Cells that were post-treated were first infected and at 8 hours 
post-infection were treated with IFN for a total of 12 hours, i.e. 20h post-
infection. Because the highest levels of viral mRNA from the time-course 
(Fig. 3.6) were detected between 18 and 24 hours post-infection, the 
mRNA levels in the following experiments were measured at 20 hours 
post-infection. The cells were lysed and total RNA was extracted using 
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TRIzol. Two µg of RNA was used to make cDNA with oligo d(T) primers in 
a reverse transcription PCR. Subsequently, the cDNA was used for real-
time quantitative PCR with primers for NP, P, M, HN and L, with "-actin 
used as a reference gene. The levels of mRNA were quantified using the 
comparative Ct method as described above (Cikos et al., 2007; Livak & 
Schmittgen, 2001).  
 
The viral mRNA levels of untreated Hep2/BVDV/Npro cells showed higher 
abundance of NP and P mRNA, the two genes which are transcribed 
closest to the 3’ end (Fig. 3.7). As in Figure 3.6, a decrease in M mRNA 
compared to HN mRNA was observed. As real-time quantitative PCR 
assay was optimised and calibrated for the primers used in this study, it is 
unlikely there is a technical reason for the decreased levels of M mRNA. 
Moreover, the Ct values for "-actin, which were used for normalisation, 
were consistent. However, when the Hep2/BVDV/Npro cells were treated 
with IFN post-infection, the transcription pattern changed and the levels of 
M mRNA were now higher than HN. Further, in the presence of IFN the 
levels of P mRNA were higher than NP mRNA.  
 
Surprisingly, all the viral genes (except for HN) showed increased 
amounts of viral mRNA in the IFN post-treated Hep2/BVDV/Npro cells 
(Fig. 3.7). A 2-fold increase in mRNA levels was noted for L, suggesting 
that the polymerase is less likely to disengage from the template when 
cells had been treated with IFN post-infection. Unlike untreated 
Hep2/BVDV/Npro cells, the untreated Hep2 cells showed a similar mRNA 
pattern to the IFN post-treated cells. Hep2 cells both produce and respond 
to IFN and therefore IFN is present in the infected untreated cells, which 
might explain why the pattern resembles that for the cells treated with IFN 
post-infection. As expected, pre-treatment with IFN severely inhibited viral 
transcription for both Hep2/BVDV/Npro and Hep2 cells. The increase in 
transcription levels in the post-treated cells was not reflected in the levels 
of virus protein synthesis observed in the previous experiment (Fig. 3.2), 
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where analysis of virus protein synthesis showed a clear reduction in the 
levels of viral protein synthesis for cells that had been treated with IFN 
post-infection. Taken together, this shows that IFN changes the 
transcriptional pattern of PIV5. It also suggests that IFN affects the levels 
of viral mRNA.  
 
 
Figure 3.7: Analysis of viral mRNA from Hep2 and Hep2/BVDV/Npro cells infected 
with CPI-. The cells were either pre-treated with IFN for 8 hours prior to infection (pre-), 
IFN-treated 8 hours p.i. (+IFN) or left untreated (-IFN). IFN was added at a concentration 
of 1000 U/ml. Twenty hours p.i. total RNA was extracted and 2 µg was analysed by 
reverse transcription PCR followed by real-time quantitative PCR. Reverse transcription 
PCR was performed by oligo d(T) primer and Table 3.1 shows primer sequences used for 
the real-time quantitative PCR. mRNA values were expressed as the quantity of the gene 
of interest relative to the quantity of "-actin. Error bars denote standard error of the mean 
value of duplicate samples in two separate experiments. p.i. = post-infection.  
 
The effect of ISG56 on PIV5 
The effect of ISG56 on virus protein synthesis 
As described in the Introduction, the induction of IFN results in an antiviral 
state in cells through the induction of more than 300 ISGs that have 
multiple functions. It has been demonstrated that ISGs regulate both viral 
transcription and translation, inhibit viral replication and are important for 
apoptosis and immune modulation (de Veer et al., 2001). It was therefore 
of interest to identify ISGs of specific importance for IFN-induced inhibition 
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of PIV5, which was investigated by Dr. Lena Andrejeva in our lab. Of the 
tested ISGs, ISG56 was identified (Andrejeva et al., 2012), and therefore 
several ISG56 knockdown cell lines (termed sh56) were generated by Dr. 
Andrejeva and used extensively in this study. The lentivirus vector pLKO-
blast used for expression of ISG56 shRNA sequence was based on the 
pLKO.1puro vector as described in (Everett et al., 2007). Double stranded 
oligonucleotides were used to clone into pLKO.blast with the following 
sequences: GGATAAAGCTCTTGAGTTA (target 1 of human ISG56) and 
CTACAAATTGGAAGGAAAT (target 2 of human ISG56) (Li et al., 2009b). 
Lentivirus infected cells were selected with blasticidin (10 µg/ml) for four 
weeks. Cells were then tested for ISG56 expression by Western blot.  
 
ISG56 is a member of the interferon-induced proteins with 
tetratricopeptide repeats (IFIT) family. New insights into the different 
functions of ISG56 are constantly emerging. Its role in inhibiting protein 
translation has been known for several years (Guo et al., 2000) but 
recently antiviral functions of ISG56 have also been described. Both 
Terenzi et al. (2008) and Saikia et al. (2010) have described how ISG56 
inhibits human papillomavirus replication and Raychoudhuri et al. (2011) 
described the implications of ISG56 in inhibiting hepatitis C replication.  
 
Hep2/BVDV/Npro cells and Hep2/BVDV/Npro/sh56 cells were infected 
with CPI- and were either untreated or treated with 1000 U/ml of IFN 8h 
prior to infection (pre-treatment) or 8h post-infection (post-treatment). 
Twenty hours post-infection, the cells were metabolically labelled with 
[35S]-methionine for 1 hour and proteins were precipitated with anti-PIV5 
antibodies, as described above.  
In Figure 3.8A, the untreated Hep2/BVDV/Npro cells showed the normal 
virus protein pattern of CPI- with L, HN, NP, P and M proteins expressed. 
When the cells were treated with IFN post-infection, the levels of virus 
protein synthesis dropped significantly, especially for HN, M and L proteins 
(compare lanes 1 and 2, Fig 3.8A). IFN pre-treatment resulted in further 
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inhibition of virus protein synthesis and only low levels of NP and P were 
detected. When ISG56 was knocked down, the normal protein pattern of 
CPI- was restored in the cells treated with IFN post-infection (lanes 4 and 
5, Fig. 3.8A). Pre-treatment had a slight inhibitory effect on viral protein 
synthesis, but the effect was less obvious compared to the control 
Hep2/BVDV/Npro cells (compare lanes 3 and 6, Fig. 3.8A). Strikingly, the 
effect of IFN on the levels of precipitated viral proteins was not reflected in 
the levels of total cell protein synthesis, as there was no general reduction 
of total cellular protein synthesis. This would suggest that IFN treatment 
selectively inhibits virus protein synthesis and that by knocking down 
ISG56 normal viral protein synthesis is restored (Fig. 3.8B).  
 
 
Figure 3.8: Protein analysis of CPI- infected Hep2/BVDV/Npro and 
Hep2/BVDV/Npro/sh56 cells. Cells were either treated with 1000 U/ml of IFN 8 hours 
p.i. (+IFN), pre-treated with IFN for 8 hours prior to infection (pre-) or left untreated (-IFN). 
Twenty-four hours p.i., the cells were metabolically labelled with [35S]-methionine and 
viral proteins were precipitated with anti-PIV5 antibodies. Precipitated viral (A) proteins 
and total cellular (B) proteins were separated by electrophoresis and the resolved bands 
were visualised by autoradiography. Mock infected (C) served as a control. Anti-ISG56 
and anti-actin were used as control for the knockdown and loading control, analysed by 
Western blot. p.i. = post-infection. 
 
Infected IFN competent Hep2 and Hep2/sh56 cells showed similar findings 
as the Hep2/BVDV/Npro cells. In the naïve Hep2 cells the levels of viral 
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protein synthesis were significantly reduced compared to the normal 
protein pattern for CPI-. The reduction was more obvious for M and L 
proteins, and no HN could be detected at all (lanes 1 to 3, Fig. 3.9A). 
However, when ISG56 was knocked down, the virus was able to fully 
replicate in the cells (lanes 4 to 6, Fig. 3.9A).  
Taken together, these two experiments showed that of the hundreds of 
ISGs that are induced by PIV5 infection, ISG56 is of great importance for 
the inhibition of CPI- protein synthesis.  
 
 
Figure 3.9: Analysis of protein levels of Hep2 and Hep2/sh56 cells infected with 
CPI- virus. Cells were either treated with 1000 U/ml of IFN 8 hours p.i. (+IFN), pre-
treated with IFN for 8 hours prior to infection (pre-) or left untreated (-IFN). Twenty hours 
p.i., the cells were metabolically labelled with [35S]-methionine for 1 hour and viral 
proteins were precipitated with a mix of antibodies to NP, P, M and HN. L was 
precipitated with NP and P. Precipitated viral (A) proteins and total cellular (B) proteins 
were separated on a polyacrylamide gel and the resolved bands were visualised by 
autoradiography. Mock infected (C) served as a control. Anti-ISG56 and anti-actin were 
used as control for the knockdown and loading control, analysed by Western blot. p.i. = 
post-infection. 
 
Effect of IFN on CPI+ infected cells 
In order to confirm that the observed effect of ISG56 on CPI- was due to 
the inability of CPI- to block IFN signalling, the experiment was repeated 
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using CPI+, which can antagonise the IFN response. Hep2, Hep2/sh56, 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were infected with 
CPI+ at an MOI of 10 pfu/cell and either left untreated or treated with 1000 
U/ml 8h post-infection or prior to infection. The proteins were radiolabelled, 
viral proteins were precipitated and visualised together with cellular 
proteins, as described earlier. Unlike the major inhibitory effect IFN had on 
viral protein synthesis levels in CPI- infected Hep2/BVDV/Npro cells, IFN 
treatment post-infection had no apparent effect on the levels of viral 
protein synthesis in Hep2/BVDV/Npro cells that were infected with CPI+ 
(Fig. 3.10), which was expected since CPI+ can block IFN signalling. Only 
cells that were treated with IFN prior to infection showed a reduction in 
viral protein synthesis levels, particularly in M and L protein levels. 
Knockdown of ISG56 restored the normal viral protein synthesis pattern in 
both Hep2 and Hep2/BVDV/Npro cells.  
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Figure 3.10: Protein analysis of CPI+ infected Hep2, Hep2/sh56, Hep2/BVDV/Npro 
and Hep2/BVDV/Npro/sh56 cells. Cells were infected with CPI+ at an MOI of 10 pfu/cell 
and either treated with 1000 U/ml of IFN 8 hours p.i. (+IFN), pre-treated with IFN for 8 
hours prior to infection (pre-) or left untreated (-IFN). Twenty hours p.i., the cells were 
metabolically labelled and viral proteins were precipitated with anti-PIV5 antibodies. 
Precipitated viral (A and C) and total cellular (B and D) proteins were separated by SDS-
PAGE and the resolved bands were visualised by autoradiography. "-actin was used as a 
cellular loading control, analysed by Western blot. p.i. = post-infection. 
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The effect of ISG56 on virus transcription 
Since the results in Figures 3.8 and 3.9 showed that ISG56 had such a 
striking effect on CPI- virus protein synthesis, it raised the question 
whether ISG56 also had an effect on virus transcription. This was 
assessed by real-time quantitative PCR. 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were infected with 
CPI- (MOI 10 pfu/cell) and subjected to IFN treatment 8h prior to infection 
or 8 hours post-infection, and one set was also left untreated. cDNA was 
made with oligo d(T) primers in a reverse transcription PCR and this cDNA 
was used in real-time quantitative PCR as described above. The 
experiment was performed in duplicate in two separate experiments. 
Figure 3.11 shows the mRNA levels of the infected Hep2/BVDV/Npro and 
Hep2/BVDV/Npro/sh56 relative to the mRNA levels of "-actin.  
 
The viral mRNAs are transcribed in a decreasing manner, with higher 
levels of the genes closest to the 3’ terminus and lower levels of the genes 
located further to the 5’ end (Fig. 3.11). IFN treatment post-infection 
resulted in increased levels of viral mRNAs, which was also observed in 
Figure 3.7. Again, this was in stark contrast to the observations that IFN 
treatment significantly inhibited virus protein synthesis (Fig. 3.8A). 
Although viral mRNA levels were still slightly increased in the ISG56 
knockdown cells, the difference between untreated, post-treated and pre-
treated cells was less marked than for the control Hep2/BVDV/Npro cells.  
This correlates with the findings that ISG56 knockdown restored the virus 
protein synthesis pattern of CPI- (Fig. 3.8A) and suggests that ISG56 
knockdown also restores a normal pattern of virus transcription (Fig. 3.11).  
 
The untreated control cells showed the same pattern as that seen in 
Figure 3.7, with high levels of NP and P mRNAs but much lower levels of 
M mRNA than HN mRNA, despite M having a more proximal position in 
the genome than the HN gene.  However, when the cells were treated with 
IFN post-infection, M mRNA levels increased to higher than those of HN 
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mRNA. As expected, pre-treatment of IFN caused a significant reduction 
in viral mRNAs. IFN did not appear to change the virus transcription 
pattern in the ISG56 knockdown cells, as the mRNA pattern was more 
similar to that of the untreated control cells, with reduced levels of M 
mRNA.  
 
 
Figure 3.11: Analysis of viral transcription in CPI- infected Hep2/BVDV/Npro and 
Hep2/BVDV/Npro/sh56 cells. Cells were infected with CPI- at an MOI of 10 pfu/cell and 
were either untreated (-IFN) or treated with 1000 U/ml of IFN 8h pre- or post-infection 
(pre- and +IFN, respectively). Twenty hours p.i., total RNA was extracted using TRIzol 
and then cDNA was made with 2 µg of RNA using oligo d(T) primers in a reverse 
transcription PCR. Subsequently, the cDNA was used in real-time quantitative PCR with 
primers for NP, P, M, HN and L, as well as "-actin as a reference control. Messenger 
RNA values were expressed as the quantity of the gene of interest relative to the quantity 
of "-actin. Error bars denote standard error of the mean value of duplicate samples in two 
separate experiments. p.i. = post-infection. 
 
These data demonstrate that IFN has an effect on both virus protein 
synthesis and virus transcription. Viral protein synthesis levels were 
significantly reduced when cells had been treated with IFN post-infection, 
and were even more reduced when cells had been pre-treated with IFN. 
Viral mRNA levels were surprisingly increased in the presence of IFN 
(post-infection), and IFN also changed the transcriptional pattern. It was 
also clear that ISG56 has an important function in the IFN response for 
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CPI-, as both protein synthesis levels and transcription levels were 
restored in ISG56 knockdown cells.  
 
in vitro translation on cells treated with IFN post-infection 
The increased levels of virus mRNA that were observed raised the 
question of whether the mRNAs were functional, as non-functional mRNAs 
would explain why there was a reduction in virus protein levels but an 
increase in virus mRNA levels. To investigate this, an in vitro translation 
was performed in collaboration with Dr. Lena Andrejeva. Hep2/BVDV/Npro 
cells were infected with CPI- at an MOI of 10 pfu/cell, followed by IFN-
treatment 8 hours post-infection or left untreated. Total RNA was extracted 
using TRIzol and mRNA was isolated using an oligo d(T) column 
(QIAGEN). Each in vitro translation reaction was mixed with 30 µl of rabbit 
reticulocytes, 20 µCi of [35S]-methionine, 40U of RNasin (Promega), 1 µl of 
amino acid mixture and 1.5 µg of mRNA to the final volume of 50 µl. 
Following the in vitro translation reaction according to the manufacturer’s 
protocol, the in vitro translated products were immunoprecipitated, as 
described previously, analysed by gel electrophoresis and the resolved 
bands were visualised by autoradiography. Mock infected cells and rabbit 
reticulocytes served as negative controls.  
An increase in viral proteins made by in vitro translation from the mRNA 
was observed (Fig. 3.12, lanes 3 and 4), confirming that the viral mRNA is 
functional which is consistent with the real-time quantitative PCR data 
(Fig. 3.11). This confirms that IFN does indeed increase the levels of viral 
mRNAs and shows that there must be another explanation as to why IFN-
treatment causes an increase in virus transcription.  
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Figure 3.12: in vitro translation of CPI- infected Hep2/BVDV/Npro cells. In vitro 
translation was performed using Nuclease Treated Rabbit Reticulocyte System 
(Promega). Hep2/BVDV/Npro cells were infected with CPI- at an MOI of 10 pfu/cell and 
treated or not treated with IFN 8 hours post-infection. Mock infected cells and rabbit 
reticulocytes served as controls. 12 hours post IFN treatment, total RNA was extracted 
using TRIzol, followed by mRNA isolation. For each reaction, rabbit reticulocytes were 
mixed together with [35S]-methionine, RNasin, amino acid mixture and 1.5 $g of mRNA to 
a final volume of 50 $l. The assembled reactions were incubated at 65°C for 3 minutes to 
allow denaturing of template mRNA and were then immediately cooled on ice, followed 
by incubation at 30°C for 90 min.  The products of in vitro translated viral proteins were 
immunoprecipitated with anti-PIV5 antibodies, separated by gel electrophoresis and the 
resolved bands were visualised by autoradiography. retic. = reticulocytes; IP = 
immunoprecipitation; tot = total cell. 
 
Effects of inhibiting protein synthesis on the pattern of 
virus transcription and translation 
One of the best characterised functions of ISG56 is to inhibit total protein 
translation by binding to specific subunits of the eIF3 complex. Therefore, 
it was of interest to ascertain whether the change in viral protein synthesis 
and viral transcription patterns was a specific effect of ISG56 on the virus 
or an effect on both virus and host cell translation and transcription. One 
way to investigate this was to use the protein inhibitor cycloheximide 
(CHX) to study the effect on the pattern of viral and cellular transcription 
and protein synthesis.  
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CPI- infected Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were 
treated with either IFN (1000 U/ml) or CHX at a concentration of 50 µg/ml 
8 hours post-infection, or left untreated. Twenty hours post-infection, the 
cells were metabolically labelled with [35S]-methionine for 1 hour, followed 
by immunoprecipitation of viral proteins. The resolved bands were then 
visualised by autoradiography (Fig. 3.13). Removing CHX from the culture 
medium can easily reverse the inhibition of protein synthesis so the cells 
that were treated with CHX were also labelled in the presence of CHX. At 
the time of lysis, the cells were examined by microscopy to ascertain that 
no wide-spread cell death had occurred due to the CHX treatment.  
 
CHX treatment resulted in a significant inhibition of HN, M and L protein 
synthesis (Fig. 3.13A, lanes 1 and 4). The untreated and IFN-treated 
Hep2/BVDV/Npro cells showed the expected protein pattern of CPI- with 
strong levels of all virus proteins in untreated cells but reduced levels of M, 
HN and L in the presence of IFN. Knockdown of ISG56 reversed this 
reduction of virus protein synthesis and there was no difference in viral 
protein levels between untreated and IFN-treated Hep2/BVDV/Npro/sh56 
cells (compare lanes 5 and 6, Fig. 3.13A). Levels of total cellular protein 
synthesis showed no apparent difference between untreated and IFN-
treated cells for both Hep2/BVDV/Npro cells (Fig 3.13B lanes 2 and 3) and 
Hep2/BVDV/Npro/sh56 cells (lanes 5 and 6). CHX treatment, on the other 
hand, almost completely inhibited cellular protein synthesis (lanes 1 and 
4). 
 
                             3  The effect of IFN on PIV5 transcription and translation                                                                                            
                                       
 
 91 
 
Figure 3.13: The effect of CHX treatment on protein synthesis. Hep2/BVDV/Npro and 
Hep2/BVDV/Npro cells were infected with CPI- at an MOI of 10 pfu/cell. 8h post-infection, 
cells were either treated with 50 µg/ml of CHX or 1000 U/ml of IFN or left untreated (-). 
Twenty hours post-infection, the cells were metabolically labelled with [35S]-methionine for 
1 hour and viral proteins were precipitated with anti-PIV5 antibodies. The cells that were 
treated with CHX were labelled in the presence of CHX. Precipitated viral (A) proteins 
and total cellular (B) proteins were analysed by SDS-PAGE and the resolved bands were 
visualised by autoradiography. Actin served as a loading control, analysed by Western 
blot. 
 
The viral protein pattern in the presence of CHX resembled that of IFN 
pre-treatment (compare lanes 1 and 4, Fig. 3.13A and lane 3, Fig. 3.9A), 
therefore a CHX titration was performed to investigate whether it was 
possible to mimic the pattern of IFN treatment, i.e. with no effect on host 
cell protein synthesis but reduced viral protein synthesis. 
Hep2/BVDV/Npro cells were infected with 10 pfu/cell of CPI- and CHX, 
with decreasing concentrations as indicated, was added 8 hours post-
infection. However, it was not possible to mimic the pattern on virus and 
cellular protein synthesis observed with IFN treatment, because when a 
reduction in viral protein synthesis was observed, for example at a 
                             3  The effect of IFN on PIV5 transcription and translation                                                                                            
                                       
 
 92 
concentration of 20 µg/ml, a reduction was also observed in cellular 
protein synthesis (Fig. 3.14).  
 
 
Figure 3.14: Levels of protein synthesis following CHX treatment. Hep2/BVDV/Npro 
cells were infected by CPI- at an MOI of 10 pfu/cell. 8h post-infection, the cells were 
treated with CHX at the concentrations indicated. Twenty hours post-infection, the cells 
were metabolically labelled with [35S]-methionine together with CHX for 1 hour. Viral 
proteins were precipitated with anti-PIV5 antibodies. Precipitated viral (A) proteins and 
total cellular (B) proteins were analysed by SDS-PAGE and the resolved bands were 
visualised by autoradiography.  
 
Next, it was of interest to see whether CHX treatment affected the pattern 
of virus transcription. Eight hours post-infection with CPI-, 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were treated with CHX 
(20 µg/ml) or left untreated. Twenty hours post-infection, total RNA was 
extracted and cDNA was made with oligo d(T) primers in a reverse 
transcription PCR assay. This cDNA was then used in real-time 
quantitative PCR as described previously. Messenger RNA values were 
expressed as the quantity of the gene of interest relative to the quantity of 
"-actin.  
 
CHX treatment did not decrease transcription levels significantly. 
However, because CHX was added at 8 hours post-infection, viral proteins 
required for transcription most likely had time to accumulate during this 
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time before CHX induced a block in translation, thus allowing transcription 
to occur. The relative mRNA levels showed the characteristic pattern seen 
previously, with a transcriptional gradient and significantly reduced M 
mRNA levels (Fig. 3.15). CHX treatment did not alter the pattern of virus 
transcription as IFN treatment did suggesting that the effect observed with 
IFN treatment post-infection was a virus-specific effect of ISG56. It was 
also clear that it was not possible to mimic the effect of IFN on the patterns 
of virus transcription and translation by using a general inhibitor of protein 
translation. 
 
 
Figure 3.15: Transcription levels for CPI- infected cells treated with CHX. 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 were infected with 10 pfu/cell of CPI-. 
Eight hours post-infection, the cells were treated with 20 µg/ml of CHX. Twenty hours 
post-infection, total RNA was extracted using TRIzol and 2 µg was used to make cDNA in 
reverse transcription PCR. Subsequently, the cDNA was used in real-time quantitative 
PCR with primers for NP, P, M, HN and L, as well as "-actin as a reference control. 
Messenger RNA values were expressed as the quantity of the gene of interest relative to 
the quantity of "-actin. Error bars denote standard error of the mean value of duplicate 
samples in two separate experiments.  
 
Analysis of genomic and antigenomic RNA levels 
As ISG56 affects PIV5 transcription and translation it was also of interest 
to investigate whether ISG56 also affects PIV5 replication. It has been 
reported that ISG56 affects replication for certain viruses, such as HPV 
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and HCV (Raychoudhuri et al., 2011; Saikia et al., 2010; Terenzi et al., 
2008). Primers were designed to anneal to the leader and trailer of 
genomic and antigenomic RNA (Fig. 3.16). The leader of PIV5 is 55 
nucleotides long and the trailer is only 32 nucleotides long. In order to 
enable us to visualize a product on a gel, the primers were designed to 
amplify a product of approximately 200-250 bp. It was therefore necessary 
to extend the amplicon into the NP (for leader) and L (for trailer) genes. 
The concentration of the primers was optimised by serial dilutions and 
determined at 25 nM per reaction. The PCR amplicons were each cloned 
into the pGEM-Teasy vector to be used in the determination of the primer 
efficiency (Fig. 3.17). These primer efficiencies were determined as 
described earlier.  
 
 
Figure 3.16: Schematic figure of primers, and where they bind to the template, used to 
measure the levels of viral genomic and antigenomic RNA.  
 
 
For detection of genomic RNA, cDNA was generated by oligos 11 (leader 
end) or 12 (trailer end).  
For detection of antigenomic RNA, cDNA was generated by oligos 14 
(trailer end) or 12 (leader end). 
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A) 
Name 5’ + 3’ 
11 GACTCAAATCATCGAAGACCCT 
12 GGCAGAATAGAAGAAGCCGGG 
13 GCTACATTAGGAAATTGATTGAGGGGG 
14 CCAAGGGGAAAACCAAGATTAATCCTC 
 
    
 B) 
 
 
C)                                                       D)      
 
Figure 3.17: Optimisation of leader and trailer primers. Shown are: primer sequences 
(A); standard curves obtained from serial dilutions of plasmid DNA (B); melt curves 
showing specific binding of the primers (C); and primer efficiencies calculated by Pfaffl’s 
equation using the slopes obtained from the standard curve (D). 
 
 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were infected and 
treated with IFN either 8h prior to infection, 8h post-infection or left 
untreated. Twenty hours post-infection, total RNA was extracted using 
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TRIzol. In order to separate the antigenomic and genomic RNA from 
mRNA, the total RNA was centrifuged through an oligo d(T) column. The 
separated mRNA was saved and later used as a control in the real-time 
quantitative PCR, while 2 µg of the mRNA depleted RNA was used to 
make cDNA using specific primers to the leader and trailer regions. The 
control mRNA was used to make cDNA using oligo d(T) primers. The 
samples were analysed in triplicate in two separate experiments with "-
actin mRNA as a reference gene. In the control Hep2/BVDV/NPro cells the 
genomic (termed leader and trailer) and antigenomic (termed leader’ and 
trailer’) RNA levels remained mainly unaffected by IFN treatment post-
infection compared to the untreated cells but pre-treatment caused a 
reduction, particularly in the levels of antigenomic RNA (Fig. 3.18). These 
data suggest that the polymerase may not be able to produce a full-length 
transcript, as the levels of trailer RNA were lower than leader RNA as 
observed in the control cells subjected to IFN post- or pre-treatment. The 
overall levels of antigenomic RNA suggest that the polymerase also falls 
off the template when moving back across the template back from the 
antigenomic trailer end (trailer’) since the levels of leader’ RNA were lower 
than trailer’. Although ISG56 appeared to affect the RNA levels in cells 
pre-treated with IFN, the difference between leader and trailer levels was 
observed in the ISG56 knockdown cells as well.  
 
Another observation was the ratio of genome to antigenome. In this 
experiment, the ratio of genome to antigenome was 1:1 which contradicts 
that which has been reported in the literature (Le Mercier et al., 2002; 
Tapparel et al., 1998). The ratio of genomic to antigenomic RNA is 
determined by the strengths of the leader and trailer promoters (Le 
Mercier et al., 2002). The antigenomic promoter is considered to be a 
stronger promoter than the genomic promoter because it only needs to 
synthesise genomic RNA, while the genomic promoter directs the 
synthesis of both mRNA and antigenomic RNA. One explanation for this 
could be that the oligo d(T) column did not properly separate the 
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antigenomic and genomic RNA from the mRNA. However, the positive and 
negative controls used in this study suggested that the separation had 
been successful, because  cDNA made from mRNA only amplified a PCR 
product when made with oligo d(T) primers, and not the specific leader 
and trailer primers. cDNA made from genomic and antigenomic RNA only 
amplified a PCR product when specific primers were used in the reverse 
transcription PCR, and not when oligo d(T) primers were used (data not 
shown).  
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A) 
 
 
     B) 
 
Figure 3.18: Levels of genomic (A) and antigenomic (B) leader and trailer RNA. 
Hep2/BVDV/Npro and Hep2/BVDV/Npro/sh56 cells were infected with CPI- at an MOI of 
10 pfu/cell. They were then either treated with IFN 8 hours post-infection (+IFN) or 8 
hours prior to infection (pre-) or left mock treated (-IFN). Twenty hours post-infection, the 
cells were lysed and total RNA was extracted using TRIzol. The RNA was then 
centrifuged through an oligo d(T) column to separate the genomic and antigenomic RNA 
from mRNA. cDNA was made using 2 µg of RNA and specific primers in reverse 
transcription PCR. Subsequently, the cDNA was used in real-time quantitative PCR with 
primers for antigenomic and genomic leader and trailer, as well as "-actin mRNA as a 
reference control. Error bars denote standard error of the mean value of triplicate 
samples in two separate experiments.  
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Figure 3.18 showed the ratio at 20 hours post-infection, but it was also of 
interest to establish whether the ratio changed during the course of 
infection. The experiment was therefore repeated with Hep2/BVDV/Npro 
cells at 6 and 12 hours post-infection (Fig. 3.19). Samples were analysed 
in triplicate with "-actin mRNA as a reference gene. At both time-points, 
the ratio of genome to antigenome RNA was still approximately 1:1.  
 
 
Figure 3.19: Levels of genomic (leader and trailer) and antigenomic (leader’ and 
trailer’) RNA for CPI- infected Hep2/BVDV/Npro cells. Cells were infected at an MOI of 
10 pfu/cell of CPI-. Total RNA was extracted using TRIzol at the time-points indicated. 
Messenger RNA was separated from the total RNA in an oligo d(T) column and later 
used as a control of successful separation. Two µg of antigenomic/genomic RNA was 
used with specific primers to make cDNA in a reverse transcription PCR. Subsequently, 
this cDNA was used in real-time quantitative PCR with primers for genomic leader and 
trailer and antigenomic leader’ and trailer’, as well as "-actin mRNA as a reference 
control. Error bars denote standard error of the mean value of triplicate samples. 
 
As the real-time PCR data showed a 1:1 ratio of viral genomic:antigenomic 
RNA levels it needed to be confirmed that there was not a problem with 
the real-time PCR methodology. Although the controls indicated that the 
RNA used in the real-time PCR was completely depleted of mRNA, 
another way to confirm the ratio of viral RNA was to use purified viral RNP 
to measure the levels of genomic and antigenomic viral RNA, as RNPs 
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only contain viral antigenomic and genomic RNA together with NP, P and 
L proteins. The RNP was purified from CPI- infected Vero cells and 
centrifuged through a CsCl gradient. The RNA was purified using TRIzol 
and cDNA was made using primers for genomic and antigenomic leader 
and trailer regions and then used for real-time quantitative PCR. The Ct 
values from the real-time quantitative PCR were similar, thus suggesting 
that the ratio was indeed 1:1 in the RNP as well.  
 
Discussion 
The aim of this Chapter was to look at how IFN affects PIV5 virus 
transcription and translation and to follow up on previous results by Carlos 
et al. (2005) that have shown that cells treated with IFN induce a change 
in both virus protein synthesis and transcription. The mechanism by which 
PIV5 evades the IFN response has been reported previously. The V 
protein is involved with inhibiting cellular antiviral responses by blocking 
IFN signalling through targeting STAT1 for degradation (Didcock et al., 
1999b) and also IFN induction by binding MDA5 (Andrejeva et al., 2004). 
The recently discovered complex of V, LGP2 and RIG-I has also been 
shown to play a role in IFN inhibition (Childs et al., 2012). Although IFN 
induces an antiviral state in uninfected cells they cannot maintain this 
antiviral state once STAT1 has been degraded as continuous IFN 
signalling is required to keep the cells in the antiviral state (Precious et al., 
2007).  
In this work we have used the PIV5 strain CPI- as it cannot block IFN 
signalling. CPI- was used to infect Vero cells or Hep2/BVDV/Npro cells 
which cannot produce IFN, although they can respond to IFN, thus 
enabling us to add IFN exogenously and investigate the effects of IFN 
under controlled conditions. The data presented here show that when 
Vero cells were infected with CPI+, IFN treatment 8 hours post-infection 
did not have an effect on viral protein synthesis. CPI- infected Vero and 
Hep2/BVDV/Npro cells treated with IFN 8 hours post-infection, on the 
other hand, showed a significant reduction of HN, M, and L protein 
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synthesis (Fig. 3.1 and Fig. 3.2A), although the levels of NP and P 
proteins were similar between IFN post-treated and untreated cells. In 
contrast, levels of total cellular protein synthesis did not show the same 
reduction, suggesting that IFN has a selective inhibitory effect on viral 
protein synthesis (Fig. 3.1 and Fig. 3.2B). This data proves that IFN 
induces an antiviral response in cells and that this affects the synthesis of 
viral proteins.  
 
During these studies, Dr. Lena Andrejeva identified ISG56 to be of 
importance for PIV5, and we therefore decided to investigate the effect of 
ISG56 on viral protein synthesis by using an ISG56 knockdown cell line 
termed Hep2/BVDV/Npro/sh56. It was demonstrated that by knocking 
down ISG56, a normal pattern of virus protein synthesis was restored 
following IFN treatment post-infection (Fig. 3.8 and 3.9), suggesting that 
ISG56 is primarily responsible for selective inhibition of translation of virus 
mRNAs.  
 
In this study we also demonstrate that ISG56 affects virus transcription 
levels (Fig. 3.11). IFN treatment post-infection resulted in increased levels 
of virus mRNA in the control Hep2/BVDV/Npro cells, while transcription 
levels were similar in untreated, post-treated and pre-treated ISG56 
knockdown cells. The mechanism by which ISG56 affects virus 
transcription remains to be established but it is possible that the inhibition 
of virus protein synthesis (particularly of the levels of HN, M and L) causes 
a change in the pattern of virus transcription due to a change in the ratio of 
the different viral proteins. Inhibition of viral proteins, such as the V protein 
that acts as a negative regulator of viral RNA synthesis, may result in 
increased levels of virus mRNA. Alternatively, ISG56 may affect the 
activity or the processivity of the polymerase complex. Our data would 
suggest the latter, as virus protein synthesis and virus transcription 
patterns were also analysed after treatment with the protein translation 
inhibitor (cycloheximide). Although host cell protein shut-off was observed 
                             3  The effect of IFN on PIV5 transcription and translation                                                                                            
                                       
 
 102 
in the presence of cycloheximide, NP and P proteins could still be 
detected but, in contrast to IFN treatment post-infection, the virus mRNA 
pattern did not change in the presence of cycloheximide (Figs. 3.13 and 
3.15). These results indicate that the effect of IFN on virus translation and 
transcription patterns was not due to a general mechanism affecting both 
virus and host cell translation and transcription but rather due to an ISG56-
specific effect on the virus, as it was impossible to mimic the effects 
observed with IFN treatment post-infection by inducing a general inhibition 
of host and virus translation. Since only gene fragments of approximately 
250 bp were measured instead of the full-length gene it is impossible to 
determine at which stage the block in viral translation occurs. However, 
the decision to measure only PCR fragments was based on the 
importance of using fragments of similar sizes in the real-time quantitative 
PCR. Our hypothesis that the translation block is induced at the stage of 
initiation instead of for example elongation therefore makes it unlikely that 
amplification of full-length products would give a different result. 
 
Previous studies have reported how the viral genes of PIV5 are 
transcribed in a sequential manner and, therefore, it was expected to 
measure decreasing levels of the genes located closer to the 5’ end. 
However, the levels of M were consistently lower compared to HN mRNA 
in untreated cells despite having a more proximal position in the genome 
than the HN gene (Figs. 3.7; 3.11; and 3.15).  When the cells were treated 
with IFN 8 hours post-infection the viral transcription pattern changed and 
M mRNA levels were increased substantially, resulting in higher levels of 
M mRNA compared to HN mRNA. The reason for this is still unclear. 
However, the lower levels of M and/or higher levels of HN may be due to a 
difference in stability of the two mRNAs. HN may be more stable than M 
and turned over less quickly, which might explain the high expression of 
HN. Given that IFN treatment results in an increase in all viral mRNAs 
except for HN may suggest that IFN affects the stability of viral mRNAs. 
However, HN would appear to be less affected by IFN, as the levels are 
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similar between untreated and post-treated cells. Another possibility that 
would explain the under represenation of M versus over representation of 
HN would be the presence of a second reinitiation site for the polymerase 
near HN, thus explaining why the levels of HN are higher than M. 
However, this is unlikely given what is known about paramyxovirus 
transcription. 
 
ISG56 is a protein encoded by the IFIT1 gene (Chebath et al., 1983) and 
has been identified as an important antiviral protein which is characterised 
by multiple tetratricopeptide repeat motifs that mediate protein-protein 
interactions (D'Andrea & Regan, 2003). Viral PAMPs can induce ISG56 
independently of IFN via the activation of IRFs, most importantly IRF3, 
which recognise the ISRE in the promoter region and initiate ISG56 
transcription (Bandyopadhyay et al., 1995; Fensterl & Sen, 2011; Sarkar et 
al., 2004; Terenzi et al., 2006).  
As ISG56 seems to specifically target the translation of viral mRNAs this 
posed the question how can ISG56 distinguish between viral mRNAs and 
cellular mRNAs. A recent paper suggested that the antiviral mechanism of 
ISG56 may be connected to the viral cap structure (Daffis et al., 2010; 
Zust et al., 2011). The caps of most eukaryotic cells are methylated at the 
N-7 position and at the 2’-O site (Fig. 1.11). Viruses that replicate in the 
cytoplasm cannot use the host cell machinery for capping, instead they 
have developed the means to facilitate N-7 and 2’-O capping by 
methyltransferases, or cap “snatching” from host cell mRNAs (Decroly et 
al., 2012). The function of N-7 methylation is important for RNA stability 
and translation but the function of 2’-O methylation has remained unclear. 
Studies with artificial virus mutants lacking the 2’-O methyltransferases 
have recently proposed that ISG56 recognises this unmethylated site and 
that this is how ISG56 distinguishes self from non-self RNA (Daffis et al., 
2010; Zust et al., 2011). Other members of our laboratory have 
investigated a possible binding of ISG56 to the cap structure of PIV5 but 
no such connection could be found (Andrejeva et al., 2012).  
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One surprising finding that also emerged from these studies was that the 
ratio of genome to antigenome was approximately 1:1 which is not 
consistent with what can be found in the literature where the ratio of 
genome to antigenome for paramyxoviruses has been described as 
approximately 10:1 (Le Mercier et al., 2002). These findings were 
investigated further by examining the levels of genome to antigenome in 
RNA from purified RNPs of CPI- infected Vero cells. Surprisingly, this also 
showed a ratio of 1:1. Further work is needed to examine this, for example 
by quantitative Northern blot analysis or by strand-specific RNA 
sequencing, which is a method that is increasingly becoming a useful tool 
to measure sense and anti-sense RNA. Briefly, with this technique the 
sequence coverage rate is calculated and from this, it is possible to 
calculate the gene score (gene score = reads per nucleotide/length of 
gene). This results in two gene scores per gene: one score for sense RNA 
and one for anti-sense RNA (Passalacqua et al., 2012).
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4 Minireplicon studies of PIV5 intergenic 
regions 
 
Introduction 
The development of reverse genetics has greatly increased our knowledge 
of the biology of RNA viruses as it has enabled the generation of infectious 
viruses from cloned cDNA, thus allowing the manipulation of viral 
genomes. Reverse genetics systems are now available for the recovery of 
many RNA viruses, including paramyxoviruses such as SeV, MeV and 
PIV5 (Garcin et al., 1995; He et al., 1997; Murphy & Parks, 1997; Radecke 
et al., 1995; Rassa & Parks, 1998). Minireplicon studies of PIV5 have 
shown that there is sequence diversity in the different intergenic regions, 
and it has been suggested that viral transcription is controlled not only by 
the location of the gene relative to the 3’ end but also by the intergenic 
regions (Rassa & Parks, 1998). 
Studies on the intergenic regions of PIV5 have demonstrated that when 
the M-F intergenic region was substituted with a nonviral sequence it 
resulted in elevated levels of M-F readthrough transcription compared to 
the other intergenic regions. This substitution also resulted in a global 
decrease in levels of viral mRNA from genes upstream and downstream of 
the M-F intergenic region. Overall viral protein synthesis was also 
reduced. It was proposed that the attenuation of this recombinant virus 
resulted from increased accessibility of the polymerase at the 5’ end of the 
template, resulting in over-expression of the L protein (Parks et al., 2001). 
It has also been shown that the length of the U tract plays a role in 
transcription termination and reinitiation (Rassa & Parks, 1999). 
 
The data presented in Chapter 3 raised the question as to why IFN 
treatment causes alterations of the PIV5 transcriptional gradient. The 
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intergenic regions of members of the respiroviruses, such as SeV, hPIV1 
and hPIV3, are highly conserved (Kolakofsky et al., 1998). In contrast, the 
regions of pneumoviruses and rubulaviruses, including PIV5, are variable 
both in sequence and in length (Hardy et al., 1998; Kuo et al., 1997; Lamb 
& Parks, 2006). We have reported that the transcription gradient of PIV5, 
where the genes closest to the 3’ end are transcribed in higher amounts 
than the more distal genes, is due to the polymerase disengaging from the 
template although the reason for this disengagement is not known. One 
might speculate that the intergenic regions contain specific motifs that 
would cause the polymerase to disengage from the template more easily. 
In addition, our finding that IFN alters the pattern of the viral transcription 
gradient may also suggest that IFN affects the polymerase complex. 
The strategy to elucidate the role of the intergenic regions involved the 
design of a minireplicon consisting of two reporter genes flanking each 
gene junction of PIV5. Transcription activity could then be measured 
before and after the intergenic region by comparing the luciferase activity 
of the first reporter gene to the second.  
 
The engineering of a T7 RNA polymerase expressing 
Hep2/BVDV/Npro cell line 
The six intergenic regions of PIV5 range from a single nucleotide to 22 
nucleotides, with the M-F junction being the longest and the NP-P and SH-
HN junctions consisting of only one nucleotide (Table 4.1).  
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Intergenic region Sequence (3’ to 5’) 
NP-P A 
P-M GCUAAUUGCUAUUUA 
M-F GUUUAGUAUAAUUCUGAUAGGA 
F-SH GCUA 
SH-HN A 
HN-L GGUUCUCUUGUUA 
L-trailer (gene end) AAUCAAAUUCU6 
 
Table 4.1: Nucleotide sequences of the gene junctions of PIV5. Adapted from Rassa 
and Parks, 1998. 
 
The sequences in Table 4.1 only depict what is considered to be the true 
intergenic region, not the entire sequence between the end of the 
upstream gene and the start of next downstream gene. The sequence 
surrounding the intergenic region consists of the signal directing 
transcription termination, a stretch of uridine residues that serve as 
template for polyadenylation and a signal for transcription reinitiation of the 
next gene.  
The engineering of six different minireplicons was a strategy to further 
investigate the role of the intergenic regions in virus transcription and to 
determine whether IFN affects the polymerase processivity in these 
regions. The early reverse genetics systems for nonsegmented viruses 
commonly used antigenomic positive sense RNA as the template for 
replication. The plus sense RNA was then either transcribed by the T7 
RNA polymerase expressed by a recombinant vaccinia virus (Collins et al., 
1995; Garcin et al., 1995; Schnell et al., 1994; Whelan et al., 1995) or by 
cells that constitutively expressed T7 RNA polymerase (Radecke et al., 
1995). However, it was later determined that infectious virus particles 
could be generated regardless of RNA polarity but that the efficiency of the 
virus rescue was lower with positive sense RNA than with negative sense 
RNA (Kato et al., 1996).  
Most reverse genetics systems previously used vaccinia as a helper virus 
to provide T7 RNA polymerase for transcription of RNA but it was then 
necessary to separate vaccinia virus from the virus of interest (Neumann 
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et al., 1999b). Buchholz et al. (1999) described the generation of a baby 
hamster kidney (BHK) derived cell line with T7 RNA polymerase 
constitutively expressed, thus enabling a vaccinia virus-free rescue 
system. These cells, termed BSRT7/5, are exceptionally suitable for the 
recovery of infectious virus. However, since we wanted to study the PIV5 
intergenic regions in the presence of human IFN, it was preferable to use 
a human cell line. Hep2/BVDV/Npro cells were chosen since they express 
the Npro protein of BVDV and are able to respond to IFN but cannot 
produce it. A T7-based reverse genetics system was chosen for this study 
and therefore Hep2/BVDV/Npro cells were infected with a T7 RNA 
polymerase-expressing lentivirus, kindly provided by Prof. Richard Elliott 
(University of St Andrews, UK), to create a constitutively expressed cell-
line. Cells were washed with serum-free DMEM, prior to infection with 1 ml 
of lentivirus in serum-free medium and 8 µg/ml of polybrene. Four hours 
post-infection, the inoculum was supplemented with 2 ml of DMEM/10% 
FCS and the infected cells were then incubated at 37°C. Two days post-
infection, the medium was aspirated and the cells were subjected to 
antibiotic selection. Expression of T7 RNA polymerase was tested by co-
transfection of a plasmid expressing firefly luciferase under the control of a 
T7 RNA polymerase promoter (pTM1-FFLuc), as well as a plasmid 
expressing Renilla luciferase under a CMV promoter (phRL-CMV) to 
control for transfection efficiency. Equal amounts (50 ng) of each plasmid 
were transfected into Hep2/BVDV/Npro/T7, Hep2/BVDV/Npro and BSRT7 
cells. Twenty-four hours post-infection, the cells were lysed and the 
luciferase activity was measured using the Dual Luciferase Assay system 
(Promega). The results were plotted as the levels of T7 RNA polymerase 
expression in the Hep2/BVDV/Npro/T7 and Hep2/BVDV/Npro cells 
normalised against BSRT7/5 cells (Fig. 4.1). The results demonstrated 
that T7 RNA polymerase was expressed in the Hep2/BVDV/Npro/T7 cells 
compared to the control Hep2/BVDV/Npro cells that do not express a T7 
RNA polymerase (Fig. 4.1).  
 
                                         4  Minireplicon studies of PIV5 intergenic regions                                
                                       
 
 109 
  
 
Figure 4.1: Functional analysis of the Hep2/BVDV/Npro/T7 cell line. 
Hep2/BVDV/Npro cells and Hep2/BVDV/Npro/T7 cells were transfected with one plasmid 
containing firefly luciferase under the T7 RNA polymerase promoter and one plasmid 
containing Renilla luciferase under the CMV promoter, which served as transfection 
control. RLU = relative light unit. 
 
Cloning strategy of the PIV5 minireplicon 
The transcription plasmid TVT7R(0,0) was chosen as the backbone of our 
minireplicon since it contains a T7 RNA polymerase promoter, a hepatitis 
delta virus ribozyme and a T7 RNA polymerase terminator sequence 
(Johnson et al., 2000). The ribozyme creates a perfect 3’ end terminus by 
self-cleavage. Figure 4.2 shows the sequence of the promoter and the 
cleavage site. By using the BbsI restriction enzyme it is possible to excise 
the existing open reading frame (ORF) and create overhanging ends, thus 
facilitating cloning of the PIV5 minireplicon sequence. Digestion with BbsI 
would create a 5’ overhang of ATAT and a 3’ overhang of GGGT (Fig. 
4.2).  
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Figure 4.2: Schematic figure of TVT7R(0,0) plasmid. Sequence of the region 
containing the T7 RNA polymerase promoter (underlined), transcription start site and 
cleavage site (arrowheads). The recognition site of BbsI is shown in italics and the 
remaining nucleotides following BbsI excision is shown in bold. Rz denotes the hepatitis 
delta virus ribozyme and T7 term. denotes T7 termination site. Adapted from Johnson et 
al. (2000).  
 
Most minireplicons only use one reporter gene, such as CAT, GFP or 
luciferase. The PIV5 minireplicon construct was planned to contain two 
different luciferase genes: a Renilla luciferase gene upstream of the entire 
region between the coding regions (which from now on will be referred to 
as intergenic region) and a firefly luciferase gene downstream of the gene 
junction. By doing so, it would be possible to monitor the transcription 
activity before and after transcribing the intergenic regions by comparing 
luciferase activities and to determine whether IFN has an effect on the 
polymerase complex. There are a number of points to consider with this 
cloning strategy. Firstly, because we are interested in looking at six 
different intergenic regions and therefore require six different 
minireplicons, it was necessary to make it straightforward to swap the 
regions without needing to change much of the plasmid structure. 
Secondly, the nucleocapsid protein of paramyxoviruses is associated with 
six nucleotides (Egelman et al., 1989) and PIV5 only replicates efficiently 
when its genome is a multiple of six, according to a concept termed the 
“rule of six” (Calain & Roux, 1993; Kolakofsky et al., 1998; Murphy & 
Parks, 1997). The different regions between the coding sequences of PIV5 
                                         4  Minireplicon studies of PIV5 intergenic regions                                
                                       
 
 111 
genes range from 114 bases to 255, but each minireplicon needs to be 
divisible by six. Fortunately, three of the six intergenic regions were 
already a multiple of six; however, for the other three regions it was 
necessary to add three or four nucleotides to the minireplicon (Table 4.2).  
 
Intergenic region Number of 
nucleotides 
Rule of six 
NP-P 168 , 
P-M 114 , 
M-F 255  (+ 3 nt) 
F-SH 183  (+ 3 nt) 
SH-HN 146  (+ 4 nt) 
HN-L 132 , 
 
Table 4.2: Schematic table of the number of nucleotides in each gene junction of 
PIV5. Three of the regions (NP-P; P-M; HN-L) were divisible by six, but the regions for M-
F, F-SH and SH-HN did not follow the rule of six. Three or four nucleotides would need to 
be added to the minireplicon for efficient replication.  
 
The chosen cloning strategy was to construct a minireplicon containing the 
PIV5 leader sequence, firefly and Renilla luciferase genes flanking the NP-
P intergenic region, as well as the PIV5 trailer sequence in a negative 
sense polarity. Immediately after the ATG initiation codon of the Renilla 
luciferase gene, six extra nucleotides were inserted which created the 
recognition site for NdeI. Before the TAA termination codon of the firefly 
luciferase gene, the recognition sequence for NotI was inserted. A T7 RNA 
polymerase promoter and a hepatitis delta virus ribozyme would then flank 
the minireplicon, and digestion with NdeI and NotI restriction enzymes 
would enable easy substitution of the intergenic regions (Fig. 4.3). 
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Figure 4.3: Schematic representation of the PIV5 minireplicon with the nucleotide 
sequence of leader and trailer regions in genomic sense. The arrows indicate the 
sites of NdeI and NotI recognition sequences, just after the ATG of Renilla luciferase 
(Ren) and before the TAA of firefly luciferase (Luc). This strategy allows substitution of 
the intergenic regions by digestion of NdeI and NotI.  
 
This cloning strategy would solve the problem of exchanging the different 
intergenic regions; however, the problem of where to insert the extra 
nucleotides to make the sequence a multiple of six still remained.  
 
Cloning of the PIV5 minireplicon 
Figure 4.2 showed the coding region of the transcription plasmid 
TVT7R(0,0), which contained recognition sites for the remote cutting 
enzyme BbsI. Using this restriction enzyme to clone the minireplicon 
sequence allowed for the creation of a 5’ ATAT overhang, thereby creating 
a TATA before the transcription start site (Fig. 4.4A). Thus, if the PIV5 
minireplicon sequence was designed containing recognition sites for the 
remote cutting enzyme SfaNI at both ends, it would be possible to create a 
5’ TATA overhang followed by three extra G residues for enhanced 
transcription, and a 3’ GGGT overhang that would ligate into the 
pTVT7R(0,0) vector (Fig. 4.4B). The resulting sequence would then 
contain a TATA element, three G residues, followed by the PIV5 
minireplicon with the NP-P intergenic region. The two luciferase genes 
would contain recognition sites for NdeI or NotI to enable the substitution 
of each intergenic region as a cassette without needing to make changes 
to the backbone structure of the minireplicon (Fig. 4.4C). The red arrow in 
Figure 4.4C indicates where the extra nucleotides would be inserted in the 
firefly luciferase coding region to make the genome divisible by six. The 
sequences containing the other intergenic regions and the extra 
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nucleotides would be made by conventional PCR in a standard vector 
before digestion and ligation into the TVT7R(0,0) vector.   
 
 
   A) 
 
 
 
B) 
 
 
 
C) 
 
Figure 4.4: Cloning strategy of the PIV5 minireplicon. BbsI restriction enzyme was 
used to excise the coding region of the TVT7R(0,0) vector. T7 promoter region is 
underlined and arrow heads indicate transcription start site and cleavage site of the 
hepatitis delta virus ribozyme (A); the sequence of the PIV5 minireplicon was designed 
with ends containing recognition sites for SfaNI, that would generate suitable overhangs 
for ligation with the TVT7R(0,0) vector (B); the final minireplicon structure contained a 
TATA, three extra G residues for increased transcription efficiency, the trailer and leader 
regions of PIV5 and the NP-P intergenic region flanked by the Renilla luciferase and 
firefly luciferase genes with internal recognition sites for NotI and NdeI in negative 
polarity. The red arrow indicates where extra nucleotides would be inserted with the other 
intergenic regions to follow the “rule of six” (C).  
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Transfection of a PIV5 minireplicon termed pMG-RLuc 
While designing the construct of the new PIV5 minireplicon, another PIV5 
minireplicon was kindly supplied by Prof. Biao He (University of Georgia, 
USA). This minireplicon, termed pMG-RLuc, contained a Renilla luciferase 
gene in a negative sense orientation flanked by the leader and trailer 
regions (Lin et al., 2005). As it contained only one reporter gene it could 
therefore not be used for studying the intergenic regions, because the 
regions need to be flanked by a reporter gene. However, it was still 
possible to use this minireplicon for preliminary experiments. pMG-RLuc 
plasmid DNA (220 ng)  together with pCAGGS-NP (170 ng), pCAGGS-P 
(140 ng) and pCAGGS-L (220 ng) plasmids were transfected into 
Hep2/BVDV/Npro/T7 cells and BSRT7/5 cells. The three plasmids 
expressing NP, P and L were in positive sense orientation to allow for 
immediate expression of viral proteins. Furthermore, a BUNV minireplicon, 
kindly given by Prof. Richard Elliott (University of St Andrews, UK) was 
also used as a positive control. In this minireplicon system, two plasmids 
called pTM1-S and pTM1-L expressing the BUNV S and L segment of 
BUNV, respectively, under the control of a T7 RNA polymerase promoter, 
were transfected together with a plasmid with a Renilla luciferase gene 
flanked by the UTRs of the M segment in the negative orientation 
(pT7BUNMRen(-)). A plasmid called pTM1-FFLuc was used as a control 
of the transfection efficiency. The optimal amounts of plasmid DNA were 
as follows: 100 ng of pTM1-S, 250 ng of pTM1-L, 300 ng of 
pT7BUNMRen(-) and 50 ng of pTM1-FFLuc.  
The two minireplicon systems were tested in Hep2/BVDV/Npro/T7 cells 
and BSRT7/5 cells. Samples lacking the polymerase were used as 
controls. The luciferase activity was measured 24h post-transfection. It 
was clear that, for both minireplicon systems, the luciferase activity in the 
Hep2/BVDV/Npro/T7 was poor compared to the BSRT7/5 cells (Fig. 4.5). 
The BUNV minireplicon worked significantly better in BSRT7/5 cells than 
the PIV5 minireplicon, but poorly in the Hep2/BVDV/Npro/T7 cells (Fig. 
4.5B).  
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To further confirm the poor transfection efficiency of the 
Hep2/BVDV/Npro/T7 cell line, cells were transfected with 1 µg of a 
plasmid expressing GFP. Twenty-four hours post-transfection, a count of 
the cells expressing GFP showed that the transfection efficiency of the 
Hep2/BVDV/Npro/T7 cells was approximately 25%. In contrast, the control 
BSRT7/5 cells had an efficiency of as much as 60%, clearly demonstrating 
the unsuitability of the Hep2/BVDB/Npro/T7 cells for these experiments 
(data not shown).  
 
A) 
 
 
B) 
 
Fig. 4.5: Comparison of Renilla activity in BSRT7/5 cells and Hep2/BVDV/Npro/T7 
cells. A PIV5 minireplicon termed pMG-RLuc (A) or a BUNV minireplicon (B) were 
transfected into BSRT7/5 and Hep2/BVDV/Npro/T7 cells, followed by measuring of 
Renilla luciferase activity. RLU = relative light unit. 
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It was evident from this result that it would be difficult to use the 
Hep2/BVDV/Npro/T7 cells in the planned minireplicon system, as the 
activity of the minireplicon was low compared to BSRT7/5 cells. This 
posed a problem since human cells were preferred in this study where the 
effect of IFN would be studied and BSRT7/5 cells are derived from the 
baby hamster kidney (BHK) cell line.  
 
Immunoprecipitation of CPI- infected BSRT7/5 cells 
Figure 4.5 demonstrated the suitability of BSRT7/5 cells for minireplicon 
systems. However, one disadvantage with minireplicon systems based on 
T7 RNA polymerase is that 5’-triphosphorylated transcription products of 
T7 RNA polymerase activate RIG-I and thus induce IFN production 
(Hornung et al., 2006; Kim et al., 2004; Pichlmair et al., 2006). A T7-based 
system is therefore not optimal for certain experiments, such as 
generation of recombinant viruses lacking an IFN antagonist. The ability of 
BHK-derived cell lines to induce IFN is not entirely clear, as some studies 
have reported IFN production (Ferran & Lucas-Lenard, 1997; Stanwick & 
Hallum, 1974), whereas other studies have shown that these cells do not 
produce IFN (Andzhaparidze et al., 1981; MacDonald et al., 2007).  
 
To ascertain whether BSRT7/5 cells are IFN deficient, BSRT7/5 cells were 
infected with CPI- at an MOI of 10 pfu/cell. IFN competent Hep2 cells and 
IFN deficient Hep2/BVDV/Npro cells were used as controls for the IFN 
response, while "-actin was used as a cellular loading control. Twenty 
hours post-infection, cells were metabolically labelled with [35S]-methionine 
for 1 hour, followed by immunoprecipitation of viral proteins with a pool of 
antibodies to PIV5 proteins. Precipitated viral proteins and total cellular 
proteins were separated by SDS-PAGE and visualised by autoradiography 
(Fig. 4.6). In Figure 4.6, the IFN competent Hep2 showed a restricted 
pattern of viral protein synthesis, with reduced levels of L, HN and M 
proteins. In contrast, the levels of viral protein synthesis for BSRT7/5 did 
not show a reduction in viral protein synthesis compared to the Hep2 cells; 
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instead, they showed similar viral protein synthesis levels to the 
Hep2/BVDV/Npro cells, which can not produce IFN. This result suggests 
that BSRT7/5 cells, like Hep2/BVDV/Npro, are IFN deficient.  
 
 
 
Figure 4.6: BSRT7/5 cells are IFN-deficient. Hep2 cells, Hep2/BVDV/Npro cells and 
BSRT7/5 cells were infected with CPI- at an MOI of 10 pfu/cell. Twenty hours post-
infection, the cells were metabolically labelled with [35S]-methionine for 1 hour, followed 
by precipitation of viral proteins with a pool of anti-PIV5 proteins. Precipitated viral 
proteins were separated by SDS-PAGE and visualised by autoradiography. Actin served 
as a loading control, analysed by Western blot. m = mock infected.  
 
One study has demonstrated that BHK cells and BSRT7/5 cells were 
compromised in the RIG-I pathway, although BHK cells displayed some 
antiviral activity. BSRT7/5 cells, on the other hand, were shown to be 
completely deficient in IFN induction mediated by RIG-I activation (Habjan 
et al., 2008). However, it is preferable to use an IFN deficient cell line to 
monitor the effect of IFN on the cells since they do not produce IFN when 
infected. Since BSRT7/5 cells seemed to respond similarly to 
Hep2/BVDV/Npro, it was decided to investigate further whether it was 
possible to use BSRT7/5 cells in the minireplicon system instead of the 
Hep2/BVDV/Npro/T7 cells that were not suitable due to poor transfection 
efficiency.  
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BSRT7/5 cells were treated with 1000 U/ml of universal IFN 6 hours prior 
to transfection, treated 1 hour post-transfection or left untransfected. 
Universal IFN consists of recombinant human IFN and has activity in many 
mammalian cell lines, including hamster cells. The cells were transfected 
with 170 ng of pCAGGS-NP, 140 ng of pCAGGS-P, and 220 ng each of 
pCAGGS-L and pMG-RLuc. A plasmid expressing firefly luciferase (FF-
Luc [pCAGGS-FFLuc]) was co-transfected (100 ng) to control for 
transfection efficiency control. Preliminary data shown in Figure 4.7 
demonstrated that pre-treatment with IFN had a substantial effect on the 
luciferase activity. In contrast, IFN treatment post-transfection showed 
increased activity. However, when examining the luciferase data more 
closely, it was discovered that the transfection efficiency could be affected 
by the presence of IFN. The firefly luciferase measurements from the 
experiment in Figure 4.7, representing the transfection efficiency were 
plotted in Figure 4.8.  
 
 
Figure 4.7: The effect of universal IFN in BSRT7/5 cells. BSRT7/5 cells were 
transfected with the pMG-RLuc minireplicon together with expression plasmids. The cells 
had either been treated with universal IFN for 6 hours prior to transfection (pre-) or 1 hour 
post-transfection (+IFN) or were left untreated (-IFN). Twenty-four hours post-
transfection, the Renilla luciferase activity was measured and normalised against firefly 
luciferase. Error bars denote the standard error of the mean of triplicates. RLU = relative 
light unit. 
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Figure 4.8: IFN treatment affects the transfection efficiency in the minireplicon 
system.  Firefly luciferase activity plotted for PIV5 minireplicon. - IFN = untreated; + IFN 
= IFN treated 1 hour post-transfection; and pre- = IFN treated 6 hours prior to 
transfection. Error bars denote the standard error of the mean of triplicates. RLU = 
relative light unit. 
 
It may be that IFN affects the ability of the polymerase to transcribe the 
firefly luciferase thereby inhibiting expression of the minireplicon system. 
Studies have suggested that IFN affects both Renilla and firefly luciferase 
post-transcriptionally as Renilla luciferase mRNA was not affected by IFN 
treatment (Ghazawi et al., 2005; Shifera & Hardin, 2010). 
 
Discussion 
In this Chapter, the strategy to be used to engineer a minireplicon 
containing the intergenic regions of PIV5 flanked by a Renilla luciferase 
gene and a firefly luciferase gene was described (Fig 4.4). By using two 
different luciferase genes, it would have been possible to compare the 
difference in luciferase activity before and after transcription of the 
intergenic region in the absence and presence of IFN. However, several 
problems were encountered during this project. Firstly, it was preferred to 
use a human cell line that was not only unable to produce IFN but able 
respond to it, as well as a cell line that constitutively expressed the T7 
RNA polymerase. Therefore, a Hep2/BVDV/Npro/T7 cell line was 
engineered as described. However luciferase assays performed in this cell 
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line with either a BUNV minireplicon or a PIV5 minireplicon showed that 
these cells were not suitable due to their poor transfection efficiency (Fig. 
4.5). BSRT7/5 cells, on the other hand, could easily be transfected and 
preliminary data seemed to indicate that BSRT7/5 responded to IFN (Fig. 
4.7), but it was also noted that IFN treatment affected the firefly luciferase 
activity, which was used as a control for transfection efficiency (Fig. 4.8).  
The inhibitory effect of IFN treatment on luciferase activity has been 
reported in recent studies. The activity of both Renilla and firefly luciferase 
was shown to decrease in the presence of IFN by as much as 60% with 
IFN-", however, expression of green fluorescent protein (GFP) was not 
altered by IFN. It was suggested that the inhibition of Renilla luciferase 
occurred on a post-transcriptional level as IFN-!/" did not have an effect 
on Renilla luciferase mRNA (Ghazawi et al., 2005; Shifera & Hardin, 
2010).  
Due to the problem with the transfection efficiency it was decided to 
pursue other aspects of our research.  
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5 Sequence analysis of different PIV5 isolates 
  
Introduction 
As discussed in the Introduction, PIV5 was first isolated from rhesus and 
cynomolgus monkey kidney cells and was named simian virus 5 (SV5) 
(Choppin, 1964; Hull et al., 1956). It was initially believed that monkeys 
were the natural host for SV5, however it was later shown that wild 
monkeys did not have antibodies against SV5, but rather were infected in 
captivity after contact with humans (Atoynatan & Hsiung, 1969; Hsiung, 
1972; Tribe, 1966). After evidence that SV5 naturally infected humans 
(Goswami et al., 1984; Hsiung, 1972), and antigenic cross-reactivity 
between SV5 and human parainfluenza virus type 2 was reported (Randall 
& Young, 1988; Tsurudome et al., 1989), it was suggested that SV5 
should be re-named PIV5 (Chatziandreou et al., 2004). Further, data from 
numerous PIV5 strains isolated from the bone marrow of human multiple 
sclerosis patients named LN, DEN, MIL, MEL, and RQ suggested that 
there was a link between PIV5 and multiple sclerosis as antibodies to PIV5 
could be detected in patients with multiple sclerosis (Goswami et al., 
1987), however, this theory was later proven to be incorrect (Russell et al., 
1989; Vandvik & Norrby, 1989).  
 
Next generation sequencing has had a huge impact on genomic research 
in the last few years. In traditional Sanger sequencing, the single stranded 
DNA is divided into four reactions, one for each nucleotide. Labelled 
nucleotides, modified so as to terminate DNA elongation, are added to the 
reactions. The terminated DNA extension results in fragments of various 
lengths, thus enabling identification of each nucleotide. Next generation 
sequencing, on the other hand, reads the template randomly along the 
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genome by breaking the genome into small pieces and then ligating them 
to specific adapters during DNA synthesis. This process is sometimes 
called sequencing-by-synthesis. Unlike Sanger sequencing, next 
generation sequencing generates much shorter lengths of continuous 
sequenced nucleotides. Whereas the Sanger method reads approximately 
1000-1200 bases, next generation sequencing only reads 50-500 bases. 
Coverage is therefore extremely important in deep sequencing, and is 
defined as the number of short sequenced fragments that overlap each 
other within a genomic region (Voelkerding et al., 2010).  
There are several next generation sequencing platforms currently 
available, which differ in base read lengths, error rates and error profiles to 
each other. The sequencing data in this chapter was generated on the 
Illumina Genome Analyzer, which is a platform that uses the sequencing-
by-synthesis process where single stranded DNA fragments are added to 
the surface of a flow cell that amplifies each fragment into a cluster. The 
cluster fragments are then denatured and annealed with a sequencing 
primer. One fluorescently labelled nucleotide is incorporated per cycle, 
which is then followed by an imaging step to identify the incorporated 
base. (Fig. 5.1). The Illumina Genome Analyzer generates approximately 
200 giga base pairs of sequence reads per run and has a base-read 
accuracy greater than 99.5% (Voelkerding et al., 2010).  
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Figure 5.1: Next generation sequencing process with Illumina Genome Analyzer 
platform. DNA is cut into pieces and ligated to clusters on a glass surface (also called 
flow cell). Each cluster is amplified on the flow cell surface in the presence of a 
polymerase and fluorescent nucleotides. After each incorporated nucleotide there is an 
imaging step to identify the incorporated base. Modified from Voelkerding et al. 2010.  
 
RNP preparation of different PIV5 strains 
Recently, two different PIV5 strains termed W3vM0 and V)CvM2 were 
analysed by next generation sequencing. The sequencing data covered 
several hundred thousand reads and showed a high degree of 
conservation across the genome. However, the sequenced reads showed 
variation at base 25, with an approximate 50/50 ratio of C/T nucleotides 
(data not shown). This remarkable pattern could be seen in both W3vM0 
and V)CvM2, despite being widely different viruses. Base 25 was mapped 
to the leader region (nucleotides 1-55), and it was suggested that perhaps 
the identity of the base at position 25 (a C or a T) is of importance for the 
viral polymerase in deciding whether to engage in transcription or 
replication. Therefore, RNPs of different strains of PIV5 were prepared for 
next generation sequencing analysis to determine whether base 25 
consisted of a C or a T in other strains as well.  
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Additionally, it was of interest to investigate the relationship of the different 
PIV5 isolates and the evolution of PIV5. 
 
Vero cells were grown in roller bottles and infected with 10 pfu/cell of one 
of eleven strains of PIV5 with different origins (Table 5.1). Two days post-
infection, the infected cells were lysed and subjected to several steps of 
centrifugation and finally spun through a CsCl gradient for approximately 
20 hours (see Chapter 2 for more details). The RNP band was harvested 
with a syringe and the RNA was purified using TRIzol (Invitrogen). The 
RNA samples were then sent to Dr. Derek Gatherer and Dr. Andrew 
Davison at the MRC Unit, University of Glasgow for next generation 
sequencing.  
 
The strains CPI+ and CPI- were isolated from German dogs and have 
been described previously in Chapter 3 (Baumgärtner et al., 1981; 1982; 
Evermann et al., 1980). In addition to CPI- and CPI+, two canine strains 
(H221 and 78524) isolated from Scottish dogs (obtained from O. Jarrett, 
University of Glasgow, UK), one porcine isolate (SER) (Heinen et al., 
1998), five human strains (DEN, MEL, MIL, LN, RQ) isolated from multiple 
sclerosis patients (Goswami et al., 1984) and the prototypic monkey strain 
W3 (also called W3A) (Choppin, 1964) were sent for deep sequencing 
(Table 5.1). 
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Table  5.1: Strains of PIV5 and their origins that were sent for deep sequencing. 
 
Sequence variations of the different isolates of PIV5 
Mapping the areas of single nucleotide polymorphisms 
One of the aims of performing next generation sequencing on the eleven 
PIV5 strains was to investigate whether base 25 showed the same 
variation as observed for W3vM0 and V)CvM2. As the sequenced reads 
in both the W3vM0 and V)CvM2 strains showed approximately a 50/50 
distribution of C or T nucleotides, it was suggested that the identity of base 
25, a C or a T, was of specific importance for the switch between virus 
transcription and replication.  
However, the next generation sequencing data disproved this theory, as 
the various PIV5 isolates did not show the same distribution of 
Strain Origin  
CPI- Canine Baumgärtner et al. 1987 
CPI+ Canine Evermann et al. 1980 
H221 Canine Obtained from O. 
Jarrett, University of 
Glasgow 
78524 Canine Obtained from O. 
Jarrett, University of 
Glasgow 
SER Porcine Heinen et al. 1998 
W3 Monkey Choppin et al. 1964 
DEN Human Goswami et al. 1984 
LN Human Goswami et al. 1984 
MIL Human Goswami et al. 1984 
MEL Human Goswami et al. 1984 
RQ Human Goswami et al. 1984 
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approximately 50% each of C and T nucleotides at base 25 (data not 
shown).  
Another aim was to map potential areas of high levels of single nucleotide 
polymorphisms (SNPs). Analysing polymorphisms can give a better 
understanding of the evolution of a virus and determine sequences that 
are significant for the function of the virus. The levels of SNPs were 
analysed with the DnaSP software that calculates the average number of 
nucleotide variation per site between two DNA sequences chosen 
randomly from a sample population, defined as Pi (Nei & Li, 1979). 
Nucleotide polymorphism was plotted on a graph with each point 
representing 100 bp (Fig. 5.2). Three areas of high variation were 
identified, marked with an asterisk in Figure 5.2, as well as a fourth weaker 
area.  
 
 
Figure 5.2: Graph representing areas of polymorphism in the genome. Each point 
represents an area of 100 nucleotides. Pi = the number of nucleotide substitutions per 
site/length of the genome. Three areas of substitutions were identified and marked with 
an asterisk. A fourth, but weaker area around 8000 bp was also mapped.  
 
The first of these areas was mapped to bases 1676-1775 which is just at 
the end of the NP coding sequence and extends into the NP-V/P 
intergenic region just one base after the NP transcription termination site 
(nt 1774) (Fig. 5.3A). The second weaker area of SNPs was located to 
bases 4250-4400, which is at the end of the M gene and the M-HN 
intergenic region (Fig. 5.3B), and the third and also the strongest area of 
SNPs was mapped to nucleotides 6300 to 6500, which includes the entire 
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SH gene (Fig. 5.3C). A fourth, weak area of variation was identified in the 
region between 8300-8400, corresponding to the region between the 
coding sequences of HN and L (Fig. 5.3D).  
  A) 
 
 
B) 
   
 
 
   
C) 
 
 
D)  
 
Figure 5.3. Areas of high nucleotide variation in the coding region of PIV5 genes. 
Black arrows denote the start and end of the genomic coding sequences and red arrows 
denote the start and end of the hotspots. The first area was located at the end of the NP 
gene (A), the second area at the end of the M gene (B), the third was located in the SH 
gene (C), and the last one was mapped to the transcription termination site of the HN 
gene (D). Figure not drawn in scale. 
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Figure 5.4 shows the aligned genome sequence of the identified areas of 
nucleotide variation. The conserved regions are depicted in dark blue, light 
blue shows areas where the identity of the base cannot be decided upon, 
and bases shown in white are true substitutions. The nucleotide 
substitutions showed similarities between the different strains. The two 
strains CPI- and CPI+ isolated from German dogs had the same 
nucleotide substitutions, and the strains from Scottish dogs 78524 and 
H221 shared variations with each other. Additionally, the human isolates 
DEN, LN, RQ, MEL and MIL shared the same variations. In the SH gene, 
the porcine strain SER seemed to share a certain amount of sequence 
variation with CPI- and CPI+. Of the total twenty substitutions in SER, half 
of them were also found in CPI- and CPI+ (Fig. 5.4C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 5  Sequence analysis of different PIV5 isolates                         
                                          
 
 129 
A) 
 
 
B) 
 
 
C) 
 
 
D) 
 
Figure 5.4: Sequences of the identified areas of nucleotide substitutions. Bases 
1676-1775 (A); 4250-4400 (B); 6300-6500 (C); 8300-8400 (D).  
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Functional analysis of the PIV5 SH gene 
CPI-, CPI+ and SER strains lack an SH gene 
The strongest area of nucleotide variation was mapped to the SH gene 
and when this region was analysed more closely it was discovered that 
three of the strains, CPI-, CPI+ and SER, lacked a start codon for SH 
compared to the wild-type strain W3. The T residue in the SH start codon 
was instead substituted with a C residue in CPI-, CPI+ and SER, thus 
creating a threonine residue instead of a methionine (Fig. 5.5). SER had a 
C residue in the stop codon creating a glutamine, but this CAA may still 
function as a stop codon. CPI- and CPI+, on the other hand, had an 
additional substitution in the glutamine residue (a G instead of an A) thus 
mutating the stop codon. In addition, the hydrophobic domain of SH, as 
shown underlined for W3 (Fig. 5.5), was missing for the two CPI strains 
and SER. As hydrophobic residues are important for correct protein 
folding, this suggests that even with a start codon SH would not have been 
functional.  
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                 start       stop 
                codon    codon 
 
MLPDPEDPESKKATRRAGNLIICFLFIFFLFVTFIVPTLRHLLS- W3 
TLPDPEDPESKKATKRTRNPTI-FLFIFFLSANLTVPTPRHLPSQ CPI- and CPI+ 
TLPDPEDPESKKATRRTGNPIIRLPFIPSLPATFTVPTPRHLLSQ SER 
 
Figure 5.5: Start and stop codons and the amino acid sequence of SH. Due to 
nucleotide substitutions in CPI-, CPI+ and SER, no start codon is present (top panel). In 
addition, the hydrophobic region of SH (underlined) is missing in the three strains 
compared with wt W3 (bottom panel). (-) = stop codon. 
 
CPI-, CPI+ and SER do not express an SH protein 
As genomic analysis revealed that CPI-, CPI+ and SER did not contain a 
start site, Western blot analysis was performed with these strains to 
confirm that they do not express a functional protein. Wild-type W3 was 
used as a positive control and "-actin was used as a cellular loading 
control. Vero cells were infected with 10 pfu/cell of W3, CPI-, CPI+ or 
SER. Sixteen hours post-infection, the cells were lysed and the proteins 
were separated by SDS-PAGE and transferred onto a PVDF membrane 
and then incubated with rabbit anti-SH antibody (kindly provided by Prof. 
Biao He, University of Georgia, USA). As expected, SH was not expressed 
in CPI-, CPI+ or SER, confirming that SH is non-functional in these strains 
(Figure 5.6).  The antiserum used to detect SH was raised against the N 
terminal peptide and would therefore have reacted against CPI and SER 
SH proteins if they had been expressed. However, as a stop codon is 
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present in CPI- and CPI+ after 22 amino acids, it is possible that these 
truncated forms of the SH protein are not visible on the gel due to their 
small size.  
ACG has been known to function as a translation intitiation codon, which is 
the case for Sendai virus (Curran & Kolakofsky, 1988; Mehdi et al., 1990). 
However, currently there are no reports of ACG being able to function as a 
start codon for PIV5. Additionally, these strains lack a TAA stop codon, 
which suggests that SH would be non-functional. Studies have shown that 
mRNAs that lack in-frame stop codons result in stalling of ribosomes and 
subsequent degradation (Ge et al., 2010; Vasudevan et al., 2002).   
 
 
 
 
Figure 5.6: Western blot analysis of SH expression in Vero cells infected with W3, 
CPI-, CPI+ or SER. Cells were infected with 10 pfu/cell and lysed 16 hours p.i. The 
proteins were separated by SDS-PAGE and immunoblotted. Actin served as a cellular 
loading control. m = mock infected.  
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Nucleotide insertions in the SH transcription termination site 
Sequence alignment of the genome also showed a six nucleotide insertion 
in the SH intergenic region of the LN and RQ strains. The SH transcription 
termination site for PIV5, according to the NCBI database, is located 
between bases 6502-6515 with the nucleotide sequence 5’-
TTTTAAAGAAAAAA-3’. The human strains LN and RQ had an extra 
AAAGAA inserted at nucleotide 6505 (Fig. 5.7), and additionally, the last 
residue in the transcription termination sequence was a G instead of an A 
for all strains. 
 
 
 
Figure 5.7: Nucleotide sequence of the SH transcription termination site showing 
the six inserted bases in the LN and RQ strains.  
 
The high degree of variation in the SH gene was located mostly in the 
CPI-, CPI+ and SER strains (34% for CPI- and CPI+, and 27% for SER) 
(Fig. 5.8). In contrast, the other two canine strains, 78524 and H221 from 
Scottish dogs, as well as the human isolates, had a low degree of variation 
with only 4.5% and 2.2% variation, respectively.  
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W3   78524   CPI-   CPI+   DEN   H221   LN   MEL   MIL   RQ   SER      aa 
M                    T        T                                                                    T         1 
A                                            T                  T       T       T       T                 13 
R                    K        K                                                                              15 
A          T        T        T                     T                                                        17 
G                    R        R                                                                              18 
L                     P        P                                                                    P        20 
I                      T        T                                                                               21 
C                  Stop   Stop                                                                  R       23 
F                                                                                                      L        24 
L                                                                                                      P        25 
F                                                                                                      P        28 
F                                                                                                      S        29 
F         L          S        S                     L                                             P        31 
V                     A        A                                                                    A        32 
T                     N        N                                                                              33 
F                     L         L                                                                              34 
I                      T         T                                                                    T        35 
L                     P         P                                                                   P        39 
L                     P         P                                                                             43 
Stop               Q        Q                                                                   Q        44 
 
Figure 5.8: Representation of amino acid variations in the SH gene. W3 represents 
wild-type PIV5, as from the published sequence.  
 
Amino acid variation in the HN gene 
As Figure 5.2 showed, there was no high degree of variation overall in the 
PIV5 genome except for the areas identified (Fig. 5.3). However, as one of 
the areas of variation was mapped to the HN gene and because more 
variation would be expected in the glycoproteins due to the pressure of 
immune selection, the HN gene was chosen for closer analysis.  
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The amino acid sequences of the various PIV5 isolates were compared to 
the wild-type W3. Comparison of the isolates revealed seven residue 
substitutions that were conserved in all isolates: A10G, S114G, M148I, F209S, 
G312D, R368Q, T491A (Figure 5.9). In addition, there were residue 
substitutions that were unique for a specific species, such as T460K for the 
canine strains 78524, H221, CPI- and CPI+. The canine isolates also had 
the G57R and A254T substitutions in common with the porcine strain SER. 
The human isolates shared the two substitutions I22L and A49S, and 
shared N318S with SER. Porcine SER also had several unique 
substitutions, such as Q48H, N288T, T445A and G524S. As expected, the two 
German canine isolates (CPI- and CPI+) appeared to be closely related to 
each other, and the next closest related virus appeared to be the two 
Scottish canine isolates 78524 and H221.  
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W3  78524   CPI-   CPI+   DEN   H221   LN   MEL   MIL   RQ   SER        aa  
A        G         G       G         G        G       G      G       G       G      G          10 
I                                           L                   L       L       L        L                   22  
Q                                                                                                   H          48 
A                                          S                  S       S      S        S                   49 
S                    F       F                                                                                 56 
G        R         R      R                     R                                             R          57 
S        G         G      G           G       G       G       G      G       G       G       114 
D                                                                                                    N       120 
M        I           I        I             I        I         I         I        I         I        I        148 
P                                                              L                            L                149 
E                                                    K                                                        159 
F       S          S       S           S       S        S       S       S        S      S        209 
F                    L       L                                                                               252 
A       T          T       T                     T                                              T        254 
N                                                                                                    T        288 
I                     T       T                                                                               305 
G       D          D      D           D       D       D       D       D        D      D        312 
N                                          S                 S       S        S        S      S       318 
L        F                                                                                                    332 
R       Q         Q       Q           Q       Q       Q       Q       Q        Q     Q       368 
V                    I         I                                                                               377 
T                                                                                                     A      445 
D       N                                           N                                                       447 
T        K         K        K                     K                                              K      460 
T        A         A        A         A          A       A        A       A        A      A      491 
G                                                                                                     S      524 
M        I                                T          I        T        T        T        T              536 
 
Figure 5.9: Representation of amino acid variations in the HN gene. W3 represents 
wild-type PIV5, as from the published sequence (accession number NC_006430).  
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Phylogenetic study of PIV5 strains 
Generation of a phylogenetic tree 
The phylogenetic tree was generated using the MEGA software (Tamura 
et al., 2011), which selected the general time reversible gamma model as 
the most likely substitution model. General time reversible models allow 
for different substitution rates between nucleotides but require that the rate 
of substitution is the same in both directions. A time reversible model is 
preferred when the sequence comes from present-day species and the 
ancestral species is unknown, while gamma gives the distribution 
probability of substitution. Figure 5.10 shows the obtained phylogenetic 
tree, which is similar to a previous tree by Chatziandreou et al. (2004). 
With the exception of DEN and MEL, which differed from the previously 
published tree, most branches show the maximum credibility values 
(shown as percent). The maximum credibility values were calculated using 
the bootstrap model, which measures how many times a clade occurs in 
subsamples of the data used to generate the tree. Usually 100-1000 
bootstrap trees are estimated to calculate the final tree. Bootstrap is often 
used to describe accuracy, but several studies have shown that it 
underestimates clade reliability (Hillis & Bull, 1993; Suzuki et al., 2002), 
i.e. the clades in the estimated model are more likely to exist in the real 
tree than what is indicated by the bootstrap model. One option to further 
investigate the relationships of DEN, MEL and MIL would be to increase 
the number of bootstrap trees for the estimation of maximum credibility. In 
this experiment, 500 bootstrap trees were calculated to generate the 
phylogenetic tree, but maybe 1000 would have generated a higher 
percentage for the DEN, MEL and MIL branch (Figure 5.10).   
This tree correlates with the analysis of the nucleotide and amino acid 
sequence, with for example the German canine strains CPI- and CPI+ 
sharing many substitutions with the Scottish dog isolates H221 and 78524, 
and the human isolates sharing substitutions with each other. SER 
appeared to be related to both Scottish and German dogs, and the 
monkey isolate W3 formed a separate clade alone.  
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Figure 5.10: Phylogenetic tree based on deep sequencing data. The PIV5 genome of 
15,246 nucleotides of eleven different PIV5 virus isolates were analysed using the 
program MEGA. Credibility values (%) are indicated for each branch.  
 
Discussion 
One of the aims for this study was to ascertain whether there were areas 
of variation in the genome of eleven different isolates of PIV5 and to 
establish the relationships between these isolates.  
Sequence alignment revealed four areas of high level single nucleotide 
polymorphism (Figure 5.2 and 5.4) that were mapped to the area between 
the coding regions of NP and V/P, M and F, HN and L, and the entire SH 
gene (Figure 5.3). All of these areas of high nucleotide polymorphism 
(except for the one located in the SH gene) were located either just before 
or in the middle of the transcription termination site of the upstream gene. 
Many of the nucleotide substitutions appeared in all isolates, however, a 
certain degree of species specificity was also observed, as some 
substitutions could be found in only human or canine isolates. On the 
basis of the nucleotide sequence there was a difference in relationships 
between the four canine isolates. The two isolates from Germany (CPI- 
and CPI+) were more closely related to each other, as were the two 
isolates from Scotland (78524 and H221) (Figure 5.4). With regard to the 
human isolates, they shared many of the changes. There were, however, 
a few changes that were unique for LN and RQ, such as the six 
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nucleotides inserted in the transcription termination site of SH (Figure 5.7) 
and the amino acid change P149L in the HN gene (Figure 5.9). 
Phylogenetic analysis also placed RQ and LN on the same branch, 
indicating a closer relationship of those two isolates compared to the other 
human isolates (Figure 5.10). Overall, the interpretation of the 
phylogenetic tree generated from sequence data of the eleven virus 
isolates generally supports the tree published by Chatziandreou et al. 
(2004). However, there was one major discrepancy between the new tree 
and the 2004 tree, namely that the credibility values of the branch 
containing DEN, MEL and MIL only reached 49% (for DEN) and 70% (for 
MEL and MIL). These percentages may have increased if the number of 
bootstrap trees used for the estimation had been higher. It is also worth 
noting that the bootstrap model may show an underestimate if it is used to 
interpret whether the generated tree is correct and that a probability of 
70% may correspond to a probability of as high as 95% (Hillis & Bull, 
1993). The bootstrap model is still preferred for assessing reliability of a 
phylogenetic tree because conclusions are usually drawn only from 
statistical data without experimental data as support. The bootstrap model 
also shows a low level of false-positives compared to other models (Hillis 
& Bull, 1993; Suzuki et al., 2002).  
 
One of the most surprising findings was that three of the virus isolates, 
namely CPI+, CPI- and SER did not encode an SH protein (Figure 5.6). 
Analysis of the sequence revealed that these isolates lacked a start codon 
and furthermore, CPI- and CPI+ lacked a stop codon. Additionally, there 
was a high level of variation in the hydrophobic domain of the gene and 
when analysed by the Phobius software, which recognises hydrophobic 
regions, no such domain was recognised. The function of SH has for a 
long time been unclear, but recent studies have reported that SH inhibits 
TNF-!-induced apoptosis (He et al., 2001; Li et al., 2011; Lin et al., 2003). 
In certain cell types, such as bovine kidney MDBK cells PIV5 causes little 
CPE, but it has been shown that when MDBK cells were infected with a 
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recombinant PIV5 lacking the SH gene, increased CPE was observed (He 
et al., 2001). This result indicates that the SH gene was lost a 
considerable time ago, as CPI+, CPI- and SER were isolated in the 1970s 
and 1990s. SH appears to be dispensable for virus growth, and the lack of 
SH in these three isolates would suggest that German dogs and pigs are 
not the natural host for PIV5.  
  
The HN gene was chosen for closer analysis for two reasons: firstly, 
because one of the areas of high variation was mapped to the HN gene, 
and secondly, because it was of interest to investigate if there were 
substitutions of amino acids involved in recognition by neutralising 
antibodies.  
The following changes were unique for all eleven isolates: A10G, S114G, 
M148I, F209S, G312D, R368Q, T491A (Figure 5.9). SER had the unique 
changes Q48H, N288T, T445A and G524S, but also had two residue 
substitutions in common with the canine isolates (G57R and A254T) and one 
with the human isolates (N318S).  
Positions 342, 437 and 457 have been linked to giving resistance to 
neutralising antibodies (Baty & Randall, 1993), but variation in these 
amino acids was not observed in the various isolates (Fig. 5.10). This 
indicates that perhaps PIV5 is less sensitive to the pressure of immune 
selection. 
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6 Conclusions 
 
Thirty years ago it was reported that mRNAs of many non-segmented 
negative-stranded viruses are not transcribed in equal amounts resulting 
in a gradient (Villarreal et al., 1976). Pennica et al. (1979) also showed 
that the half-life of VSV mRNAs was indistinguishable, reflecting different 
mRNA synthesis rather than different turnover (Pennica et al., 1979). In 
addition, it was demonstrated that UV radiation of RNA results in the 
formation of covalent uracil dimers that prevents the polymerase from 
progressing. By measuring the UV sensitivity it was revealed that the size 
of the gene corresponded to the sum of its size and the size of each gene 
that preceded it, thus proving the theory of a single entry site for the 
polymerase of non-segmented negative-stranded viruses (Whelan et al., 
2004). Reports on PIV5 and MeV have also shown that alterations of the 
transcription gradient often are dependent on the immune system of the 
host (Carlos et al., 2005; Cattaneo et al., 1987a). The study on PIV5 by 
Carlos et al. (2005) showed by Northern blot analysis that the effect of IFN 
treatment altered the steepness of the gradient. To shed further light on 
how IFN affects virus transcription, the aim of Chapter 3 was to compare 
viral mRNA levels in the absence and presence of IFN by real-time 
quantitative PCR. We were able to show that PIV5 mRNAs were 
transcribed in higher amounts closer to the 3’ end of the genome, thus 
demonstrating the presence of a transcription gradient due to the viral 
polymerase disengaging from the template and having to re-attach at the 
3’ end according to the single entry site theory. Recently, it was reported 
that the VSV strain S2 had an altered transcription gradient compared to 
wild-type VSV and the authors hypothesised that the viral polymerase 
contained a mutation that decreased the ability to reinititate at each 
intergenic region (Hodges et al., 2012). Here, we suggest that the 
increased levels of viral mRNAs observed when cells had been treated 
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with IFN post-infection were because IFN somehow affected the 
polymerase complex, perhaps by increasing its stability. 
 
Treatment with IFNs is currently the standard antiviral therapy to treat 
virus infections such as chronic HCV, HBV and also co-infections with 
HCV and HIV-1 (Naggie & Sulkowski, 2012). Treatment with IFN alone 
generally induces a so-called sustained virological response of 5-20%, i.e. 
the absence of detectable HCV in blood serum six months after end of the 
treatment but treatment with IFN together with ribavirin induces a 
sustained virological response of 40-50%. However, IFN treatment has 
many side effects, such as headache, fatigue, joint pain and also more 
serious side effects like severe depression and apathy have been 
reported. Patients with these symptoms are often treated with 
antidepressants as well to reduce the IFN-induced depression (Manns, 
2006). Attempts have been made to prevent these side effects, for 
example by using IFN-$ instead of IFN-!. Since IFNARs are expressed in 
many tissues and cell types, IFN-! elicits a strong biological response not 
only in the primary target tissue but also in other organs, resulting in 
severe adverse effects. In contrast, IFN-$ receptors are mainly restricted 
to epithelial cells; therefore IFN-$ is less likely to cause severe side 
effects. Despite the more limited amount of IFN-$ receptors compared to 
IFN-!, the effect of IFN-$ is comparable to the effect seen with IFN-! 
treatment, but with fewer side effects (Donnelly & Kotenko, 2010).  
As severe side effects are such a problem new methods to try and reduce 
them are constantly underway. If one could identify and isolate specific 
ISGs that are important for certain viruses and treat these infections only 
with these ISGs the side effects for the patient may be minimised. 
Therefore, in Chapter 3, we set out to identify and characterise various 
ISGs important for inhibiting PIV5 replication. Of the different ISGs that 
were tested, ISG56 was shown to be primarily responsible for the effect of 
IFN on PIV5 replication.  However, although ISG56 is the major ISG that 
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inhibits PIV5 it was also shown that other ISGs contribute to the antiviral 
effect (Andrejeva et al., 2012).  
From the perspective of the host it would seem disadvantageous to induce 
only one, albeit very potent ISG. Inducing one powerful ISG would 
increase the risk of toxicity in the cell. Instead, it may be preferable for the 
host to induce a broad range of weak ISGs to reduce the risk of toxicity. 
Additionally, the antiviral effect is usually greater when two or more ISGs 
are expressed together rather than either ISG alone (Schoggins & Rice, 
2011).  
 
The development of next generation sequencing technologies has meant 
that it is now possible to efficiently sequence large viral genomes in a 
short period of time. Not only can virus families be compared and novel 
orphan viruses classified, but also emerging viruses and those that mutate 
rapidly can quickly be examined in order to better understand the disease 
and to develop control measures to prevent a possible outbreak (Radford 
et al., 2012). Next generation sequencing is also an important tool for 
investigating the evolutionary rate of viruses and existing quasispecies, i.e. 
groups of viruses with a similar mutation that exist in a population (Lauring 
& Andino, 2010). Quasispecies are of great concern, as populations of 
minor resistance mutations can be selected for and ultimately may lead to 
the failure of antiviral treatments. Studies have shown that next generation 
sequencing is more sensitive than traditional methods in detecting 
mutations and can detect variants present in only 1-2% of the sequence 
reads (Margeridon Thermet et al., 2009). In addition, next generation 
sequencing has been used to study the difference between resistance 
acquired by transmission and resistance which has evolved within the 
patient (Varghese et al., 2009).  
Recently, it was reported that paramyxoviruses have been isolated in bats 
worldwide (Drexler et al., 2012; Kurth et al., 2012). Studies also showed 
an antigenic relatedness between a mumps-related bat virus and human 
mumps virus. This is alarming as it may cause concerns for prospective 
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eradication programs since eradication is only possible if there are no 
animal hosts. Understanding virus evolution allows for better prediction of 
future threats and causes of disease outbreaks (Longdon et al., 2011). 
The aim of Chapter 5 was therefore to examine the evolutionary 
relationship of different PIV5 isolates.  
The sequencing data of the eleven PIV5 strains demonstrated an 
evolutionary relationship between CPI-, CPI+ and SER. Although they are 
from two different species (dog and pig), neither strain expressed the SH 
protein. The three strains were isolated decades apart: CPI- and CPI+ in 
the early 1980s and SER in the 1990s but they were all isolated in the 
same geographical area of Germany. On the other hand, SH was present 
in the Scottish canine strains, suggesting that the disappearance of SH is 
site specific rather than species specific. The fact that SH has disappeared 
from two canine strains would suggest that dog is not the natural host for 
PIV5. These results are surprising, as PIV5 often is considered a canine 
virus. Knowledge of the natural host is important for understanding the 
emergence of viruses. Species closely related to the natural host are more 
susceptible to be chosen by the pathogen as a new host than distally 
related species (Longdon et al., 2011). The question of which is the 
natural host of PIV5 remains to be determined.  
 
The main aim of Chapter 3 was to identify ISGs that are involved in 
inhibiting PIV5 replication. Although ISG56 was confirmed to be the 
primary ISG responsible for the IFN-induced inhibition of PIV5, we were 
unable to determine the mechanism by which ISG56 distinguishes 
between viral and cellular mRNA. One possibility is that the cap of PIV5 
lacked a 2’-O methylation, which was then recognised by ISG56. This has 
been seen in previous studies that reported that viruses that had 
unmethylated 2’-O positions lead to recognition by ISG56 (Daffis et al., 
2010). However, PIV5 is anticipated to have 2’-O methyltransferase 
activity (Ferron et al., 2002), making it unlikely that ISG56 would 
specifically target PIV5 mRNA. To confirm this, collaborators to us 
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performed an in vitro ribose 2’-O-methylation assay, which suggested that 
the mRNA from CPI- infected cells was indeed 2’-O methylated (Andrejeva 
et al., 2012). However, it may still be worth pursuing the hypothesis that 
ISG56 recognises the mRNA cap of PIV5. PIV5 and several other 
paramyxoviruses, such as NDV, PIV2, MuV and SV41 have an alanine 
instead of a glycine residue at position 1804 in a glycine-rich motif of 
domain VI of Sendai virus L gene (Murphy et al., 2010). This mutation was 
shown to affect cap methylation. It is therefore possible that the reason for 
ISG56 specifically inhibiting PIV5 mRNAs but not cellular mRNAs is due to 
this alanine mutation. One way to further examine this would be to 
generate a recombinant CPI- virus containing either the alanine mutation 
or a glycine residue and use this strain to infect ISG56 knockdown and 
control cells (i.e. cells where ISG56 is expressed). If the glycine is 
important for efficient cap methylation, ISG56 would not be able to 
distinguish between viral and cellular mRNAs, thus the specific inhibition 
of virus translation of mRNAs would be prevented.  
 
Virus infections are of great concern as they have a serious impact on 
society. Research on the mechanisms behind virus infections and on new 
treatments is therefore very important. Although a lot of research has been 
done on PIV5 and IFN signalling there are still many unanswered 
questions. Further insight into the mechanisms of paramyxoviruses is 
needed to hopefully lead to improved antiviral therapies.  
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Appendix 
 
Published manuscript 
ISG56/IFIT1 is primarily responsible for IFN-induced changes in patterns 
of PIV5 transcription and protein synthesis. 
Andrejeva, J., H. Norsted, M. Habjan, F. Thiel, S. Goodbourn and R.E. 
Randall. (2012) J Gen Virol.; 94, 59-68.  
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